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Abstract 
Voltage-gated sodium channels (NaV) are integral membrane proteins that are responsible for the 
increase in sodium permeability that initiates and propagates the rising phase of action potentials, 
carrying electrical signals along nerve fibers and through excitable cells. NaV channels play a diverse 
role in neurophysiology and neurotransmission, as well as serving as molecular targets for several 
groups of neurotoxins that bind to different receptor sites and alter voltage-dependent activation, 
inactivation and conductance. There are nine NaV channel isoforms so far discovered, each of which 
display distinct functional profiles and tissue-specific expression patterns. The modulation of specific 
isoforms for therapeutic purposes has become an important research objective for the treatment of 
conductance diseases exhibiting phenotypes of chronic pain, epilepsy, myotonia, seizure, and cardiac 
arrhythmia. However, because of the high sequence similarity and structural homology between NaV 
channel isoforms, many current therapeutics that target NaV channels – the vast majority of which are 
small molecules – lack specificity between isoforms, or even other voltage-gated ion channels. The 
current push for greater selectivity while maintaining a relevant degree of potency has led the focus 
away from small molecules and towards the discovery and development of peptidic ligands for 
therapeutic use. Venom derived peptides have proven to be naturally potent and selective bioactive 
molecules, exhibiting inherent secondary structures that add stability through the formation of disulfide 
bonds. Organisms such as cone snails and spiders have evolved venom for the purpose of prey capture 
and defense, therefore many of the components exhibit paralytic qualities and specifically target NaV 
channels. Much of the discovery process has focused on screening crude venoms for a particular 
function and then isolating the molecule responsible for that function using assay guided purification. 
 
The first section of this thesis describes the development of a cell-based, high-throughput functional 
assay for the detection of NaV modulating venom peptides in crude venom. This assay was successfully 
implemented and resulted in the isolation and sequencing of MVIA from Conus magus. Initial results 
and sequence similarity placed MVIA into the δ-conotoxin family, a poorly described class of peptides 
that inhibits fast inactivation. However, multiple solid-phase synthesis and bacterial recombinant 
expression methods were unsuccessful in producing enough of the extremely hydrophobic δ-MVIA for 
further characterization. As no more C. magus crude venom was available, this project was left until 
optimized methods of production for highly hydrophobic peptides could be developed. 
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An optimized method of bacterial recombinant expression was successful in producing large yields of 
another venom peptide, β/δ-TRTX-Pre1a, isolated from the spider Psalmopoeus reduncus. The same 
recombinant expression method was also used to produce uniformly labeled 13C/15N-peptide for 
determination of a heteronuclear NMR solution structure. Pre1a was revealed to be a sub-micromolar 
inhibitor of both NaV1.2 and NaV1.7 peak currents, yet demonstrated potent inhibition of fast 
inactivation of NaV1.3. This dual mode of action on different NaV isoforms had not yet been reported 
for any known venom peptide. Further, Pre1a exhibited structural heterogeneity as determined by 
analysis of rpHPLC and NMR 15N-HSQC, which was traced to the contribution of residues making up 
the all aromatic, hydrophobic face of the peptide.  
 
The high sequence similarity of Pre1a to previously discovered spider venom peptides allowed 
comparative functional analysis and the identification of key residues contributing to NaV isoform 
selectivity. Mutagenesis focusing on both structural and functional aspects of Pre1a was performed 
incorporating both alanine and non-alanine substitutions. Through a single mutation a residue critical 
for the observed conformational heterogeneity was identified. This mutation served as a model for the 
obtainment of a high-resolution solution structure for comparison with the active Pre1a. Lastly, we 
identified a single residue on the C-terminus critical for NaV channel isoform selectivity. Substitution 
with amino acids exhibiting different properties of charge, polarity, and size could modify selectivity 
and in the process create a highly selective inhibitor of NaV1.2. This study not only revealed a unique 
mode of action for a venom peptide, but also demonstrated novelty as a proof-of-concept for the 
rational design and engineering of venom peptides using available information and non-standard 
methods of selective mutagenesis. 
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Chapter I: Introduction 
 
The use of plant and animal remedies to knowingly cure and treat disease predates written human 
history[1]. Although herbal remedies are arguably the most widely known examples of natural 
medicine throughout ancient history, treatments derived from animal venoms have been in use for 
thousands of years[2]. Venom is a complex mixture of molecular components that is administered via 
bite or sting for the purpose of prey capture and defense. Low molecular mass peptides make up the 
primary bioactive component of venoms. Millions of years of evolutionary selection have honed these 
peptides to maximize effectiveness for prey capture and defense[3]. 
Many venom peptides work together as a cabal to immobilize prey through selectively targeting ion 
channels, either by inhibiting conductance or altering gating kinetics[4]. It is this action that has led 
researchers to explore individual venom components as potential therapeutic leads for the discovery of 
new molecules to treat neurological disorders, such as chronic pain. Two organisms – the marine 
gastropods Conus spp. and spiders – have served as a rich source for the discovery of highly potent, 
selective, neurologically bioactive peptides, and are the focus of this thesis. 
This thesis outlines structure-function relationships of peptides isolated from two venomous organisms, 
the piscivorous Conus magus and a single species of old-world spider in the family Theraphosidae. The 
peptides isolated and characterized within represent molecules that – although from different organisms 
– share a similar structural motif and target mammalian voltage-gated sodium channels, which are ion 
channels associated with nerve signal transmission. 
 
1 Voltage-gated sodium channels 
 
Voltage-gated sodium (NaV) channels are integral membrane proteins which form gated pores that 
conduct Na+ ions passively across the cell membrane, via an electrochemical gradient[5]. This 
electrochemical gradient is maintained through the active transport by Na+/K+-ATPases as well as 
various potassium channels, imparting a negative resting potential – or resting state – of around -70 to -
90 mV for most neurons[6]. NaV are activated through cell membrane depolarization events  –  which 
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is a positive shift in the membrane 
potential past threshold – triggered by a 
variety of external stimuli, typically 
involving ligand-gated, mechano- or 
chemo-receptors[6].  
 
NaV channel depolarization is responsible 
for the initiation and propagation of the 
rising phase (or positive shift) of action 
potentials, which carry electro-chemical 
signals through nerve fibers and excitable 
cells (Figure 1). However, NaV channels 
are found on the surface of a wide range of 
cell types, both excitable and non-
excitable[7]. Because of their ubiquitous 
role in driving signal conduction 
throughout the entire nervous system, NaV 
channels make excellent therapeutic 
targets for a variety of neuropathic disorders. 
 
1.1 The mammalian NaV family 
Mammalian NaV channels are part of the superfamily of voltage-gated ion channels, which is the 
largest subgroup of ion channels[6]. Other members of this superfamily include voltage-gated calcium 
channels (CaV) and voltage-gated potassium channels (KV). Several other ion channel families share 
structural and functional homology to these primary members of the voltage-gated ion channels, 
however they lack the strong cation selectivity of their cousins. The cyclic nucleotide-gated (CNG) ion 
channels and some members of the transient receptor potential (TRP) family ion channels are weakly 
voltage dependent and retain voltage sensor domains with a few positive charges[8, 9]. The CNG 
channels have been showed to be involved with vertebrate phototransduction, olfaction[8], and smooth 
muscle contraction[10]. The TRP family has diverse functions, including invertebrate 
phototransduction[11] as well as vertebrate thermal-, mechano- and somatosensation[9]. 
 
Figure 1: An “ideal” action potential. 
NaV channels contribute to the “upward” 
depolarization – or a shift to more positive potential – 
of the cell membrane after a threshold is reached. 
Potassium channels are activated in response to 
depolarization and help to “reset” the resting 
membrane potential through repolarization. 
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Members of the voltage-gated ion channel superfamily share a tertiary structural homology composed 
of four homologous domains (DI-DIV). Each domain is composed of six transmembrane segments (S1-
S6)[6, 12], which fold into a voltage sensing region (S1-S4) and a pore forming region (S5-S6)[13]. 
The quaternary structure of these proteins is typically functionally expressed in association with a 
variety of auxiliary subunits that modify function and expression, such as the β-subunits in association 
with NaV channels. 
 
1.2 Evolution of mammalian NaV channels 
Mammalian NaV channels have evolutionary roots dating back to the earliest metazoans, with ancestral 
NaV genes detected in eukaryotic organisms without a nervous system, including a placazoan and a 
single-celled choanoflagellate[6, 14]. Human voltage-gated channels are believed to have derived from 
whole-gene duplication events that occurred early in the vertebrate lineage. The 2R hypothesis suggests 
two early whole genome duplication events in vertebrates led to four ancestral NaV genes in teleosts, 
which further evolved into the current set of mammalian channels[15-17]. Using electrophysiological 
recording, biochemical purification, and molecular cloning techniques, nine mammalian NaV α-
subunits – officially designated NaV1.1-1.9 – have been identified and functionally characterized 
(Table 1). Further reference to NaV channels will be in regards to mammalian isoforms, unless 
otherwise specified. The gene sequence homology between the nine NaV α-subunits – encoded by the 
SCNA genes – are all greater than 50% in the transmembrane and extracellular regions, enough that all 
nine isoforms are classed in the same NaV family[18]. By comparison, members of the CaV and KV 
channels can be grouped into distinct subfamilies with greater than 50% gene variation between each 
other, but a much higher relative sequence similarity within the subfamilies[19]. 
 
Differentiating between mammalian NaV isoforms has been aided with the discovery of subtype 
selective neurotoxins such as tetrodotoxin (TTX), a key natural product that helped early researchers 
divide NaV channels into either TTX-sensitive (TTXs) or TTX-resistant (TTXr) classes[20] (Table 1). 
Studies of NaV isoform expression have shown unique patterns of temporal and spatial expression 
throughout different tissues, with some localized to specific regions such as cardiac (NaV1.5) or 
skeletal muscle (NaV1.4) tissue. Many of the neuronal isoforms exhibit differential regulation after 
mechanical[21] or inflammatory[22] stress, as well as preferential expression to pre-natal versus post-
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natal tissue[23]. Further, splice variants of multiple isoforms have recently been discovered, expanding 
the potential for therapeutic targeting[24]. 
 
 
Table 1: Mammalian NaV channel family. 
Red indicates NaV channels contributing to pain transmission[18]. 
 
 
 
Channel	Name Gene TTX	sensitivity Preferential	Expression Attributes
NaV1.1 SCN1A TTXs	(10	nM) CNS,	cardiac KO	perinatal	lethal
NaV1.2 SCN2A TTXs	(10	nM) CNS,	peripheral Defects	implicated	w/	seizure
and	epilepsy
NaV1.3 SCN3A TTXs	(1.8‐4	nM) Embryonic	CNS Rapid	repriming
DRG,	sympathetic	 Amplifies	depolarizing	inputs
neurons ↑regulation	after	injury
Cardiac	myocyte LoF	attenuates	pain
NaV1.4 SCN4A TTXs	(5	nM) Skeletal	muscle Skeletal	muscle	function
NaV1.5 SCN5A TTXr	(1.8	μM) Cardiac	myocyte,	CNS Cardiac	pacemaker
NaV1.6 SCN8A TTXs	(1	nM) Nodes	of	Ranvier Ubiquitous.	Mutations	lead	to
DRG,		dendrites muscular,	neuro,	and	nocicepti
Synapses,	glia dysfunction
NaV1.7 SCN9A TTXs	(4‐25	nM) DRG,	sympathetic Slow	repriming,	amplifies
neurons,	dorsal	horn GoF	results	in	IEM,	PEPD
Sciatic	nerve LoF	results	in	CIPD
Schwann	cells ↑reg	postinϐlammation
NaV1.8 SCN10A TTXr	(40‐60	μM) DRG Rapid	repriming,	supports	
repetitive	firing
↑reg	after	injury,	inϐlammation
NaV1.9 SCN11A TTXr	(40	μM) Small	diameter	DRG Slow	activation,	Ultra‐slow
inactivation,	amplifies
Hyperpolarized	voltage‐
dependance	of	activation
Voltage‐gated	sodium	channel	family
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Although there has been some variation in the determination of NaV phylogeny in mammals, the most 
recent research supports a general consensus in agreement with the 2R hypothesis[25]. The entire NaV 
channel family is thought to be a product of pre-mammalian whole genome duplication events, with 
recent evidence suggesting evolution predating the development of the nervous system (Figure 2)[26, 
27]. This relatively high homology between members of the ion channel superfamily contributes to 
making the search for selective modulators quite difficult. 
 
 
Figure 2: Evolutionary relationships among key members of the ion channel superfamily.  
The top of the figure shows the structures of the channels. Moving from left to right: a linear leak K+ 
channel that is composed of two membrane-spanning helices and a pore (blue); a 6 transmembrane 
(TM) channel with a single voltage sensor (red); and 4 domain x 6TM channels with four voltage 
sensors. There is uncertainty about the origin of the 4x6TM family, which more likely evolved in 
eukaryotes than prokaryotes, as indicated in this figure. Figure used without permission from Zakon 
H.H. PNAS 2012[27] 
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The latest phylogenetic tree for the human Nav family used a method of maximum parsimony to 
compared aligned sequences for relatedness by measuring the number of nucleotide changes required 
for the change in codon at each position[19]. By this method NaV1.1, NaV1.2, NaV1.3, and NaV1.7 have 
been determined to be the most genetically related, with all four encoding genes occurring on human 
chromosome 2q23-24. All four channels are also strongly TTX-sensitive and widely expressed in 
neurons[15]. NaV1.5, NaV1.8, and NaV1.9 also have close phylogenic homology, with encoding genes 
found on human chromosome 3p21-24. These sodium channels are TTXr to varying degrees due to 
changes in amino acid sequence at a single position on the pore forming region[28]. NaV1.4 and NaV1.6 
are the most phylogenetically distinct TTXs subtypes, occurring on human chromosomes 17q23-25 and 
12q13, respectively. 
 
1.3 NaV channel structure 
The voltage sensitivity and Na+ ion selectivity of the NaV -subunit allows these membrane proteins to 
play an essential role in initiation and propagation of action potentials in neurons and other excitable 
cells[6]. NaV channels are defined by their activation through membrane depolarization events, 
allowing Na+ ions to flow passively along a gradient[6]. However, channel state and kinetics can be 
affected by various ligands – including toxins – as well as membrane potential, which will be discussed 
later. Understanding the structure of the NaV channel and how ligands can interact with different 
regions is fundamental to developing better regulatory therapeutics. 
 
1.3.1 The NaV -subunit 
The α-subunit of the Nav channel is arranged from four homologous domains (DI-DIV), each 
containing six highly conserved, hydrophobic, α-helical transmembrane segments (S1-S6) that form a 
protein approximately 260 kDa in size[29-32]. The transmembrane regions are connected by intra- and 
extracellular loops (Figure 3). The outer vestibule and ion selectivity filter of the NaV channel is 
formed by an extracellular “P-loop” on each domain that re-enters the membrane between S5 and S6, 
making up the pore forming region[33]. S4 is traditionally referenced at the voltage sensor, although 
the entire S1-S4 region has been referred to as the voltage sensor domain[34]. Co-expression with a β-
subunit is usually required for the -subunit to exhibit the endogenous kinetics and voltage-dependence 
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of native NaV channels, as well as regulating channel expression[35]. However, the α-subunit is fully 
functional as a voltage-mediated ion pore on its own. 
 
The predicted structure of the outer vestibule and selectivity filter were both discerned using the 
guanidinium toxins TTX and saxitoxin (STX). These small molecule toxins have similar structural 
properties, overlapping binding sites, and are highly selective for NaV channels. A number of 
interaction sites between the toxins and the NaV channel were determined through point mutation 
studies of the channel[36-39], then spatially arranged by Lipkind and Fozzard to produce a working 
model of the extracellular pore region[33]. An unexpected outcome of the model was the visualization 
of a narrowing in the pore caused by four conserved caboxylate amino acids – DEKA – that form an 
inner ring necessary for conveying Na+ ion selectivity to the P-loop. This precise region was initially 
proposed by Heinemann et al[40] to be a candidate for the selectivity filter after mutations to the 
DEKA amino acids were observed to cause a pronounced alteration of ion selectivity. Later studies 
demonstrated the importance of an additional outer ring composed of the carboxylate amino acids 
EE(M/D)D[39, 41, 42].  
 
These studies succeeded in linking critical toxin binding sites along the outer vestibule to residues 
controlling ion permeation that help define the first pharmacologically relevant site on the NaV channel, 
“Site 1”. An updated structural model for the NaV channel TTX-binding region within the outer 
vestibule has since been published, taking into account an additional 15 years of work and using the 
crystal structure of the bacterial KcsA channel as a template[43]. A structural model for the 
anticonvulsant binding site within the inner pore has also been published[44]. While these models have 
limitations as they are based on relatively low homology templates and a rigid conformation for ligand 
interactions, they remain useful for visualizing NaV channel residues important for drug interactions.  
 
Recently, a groundbreaking accomplishment was made utilizing a bacterial NaV channel from 
Arcobacter butzleri (NaVAb) to elucidate the first full crystal structure of a NaV channel[46]. This was 
quickly followed up with structures in potentially two inactivated states[45]. These detailed snapshots 
into the conformational changes of the NaV structure have great potential for understanding the 
complexities of how ligands bind and interact with the NaV channel, which is critical for the 
development of selective therapeutics. 
 
8 
 
 
Figure 3: NaV channel structure.  
A) Flat cartoon of general NaV structure based off crystal structure arrangement. Individual segments 
are numbered (1-6). Domains are labeled (I-IV). The S4 voltage sensor is labeled with (+) and the 
inactivation gate is labeled with IFM. The pore forming region is highlighted in green. B) Folded 
conformation of NaV channel based off crystal structure of NaVAb[45]. Green = voltage sensing 
region. Purple = pore forming region, boxed region = selectivity filter. Red = linker regions 
connecting the activation gate. 
 
1.3.2 NaV physiological states 
Electrophysiological experiments conducted over the past four decades have demonstrated three 
primary physiological states directly related to observed Na+ permeability, which can be further broken 
down mathematically into eight kinetic states[6]. The three primary states include: activated (open 
state), inactivated (closed state), and resting (primed closed state). These physiological states are 
dictated by conformational changes occurring within the NaV α-subunit. It wasn’t until 2005 when the 
first structural template of the mammalian KV1.2 (Shaker) channel was elucidated in an “activated-
open state” by X-ray crystallography[47]. This allowed the development of molecular dynamics 
simulations of the lipid membrane embedded KV1.2 receptor to characterize structural details[48-50], 
which later led to a series of more defined models detailing the “resting-closed state) as well as 
A) 
B) 
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transitional states [51-53]. This data culminated in a mechanistic model of voltage-dependant gating for 
the entire voltage gated cation channel superfamily[54].  
 
In 2011, the elucidation of a bacterial NaV α-subunit X-ray crystal structure from Arcobacter butzleri, 
NaVAb, was resolved at 2.7 Å[46]. This structure featured a closed PD and the four VSDs seemingly 
activated. The latter was interpreted as representative of the pre-open state of the channel or, in other 
words, a metastable (intermediate) structure along the pathway connecting the resting-closed state to 
the activated-open state. Consistently, recent MD simulations of the channel embedded in a lipid 
membrane have shown structural stability on timescales of ∼100 ns[55]. Importantly, the NaVAb 
structure provides a high-resolution template for enhancing our knowledge on Na+ and related 
Ca2+ channels, for which much less is known. However, there remains a pressing need to relate the 
reported NaVAb X-ray structure to specific functional states of the channel. Given the significant 
degree of structural similarity shared by members of the VGCC family, more extensive studies on KV 
channels are a resource for providing insight into this issue. 
 
The details of how the NaV channel conforms to each state is critical to understanding how ligands 
interact, as the different physiological states are able to preferentially bind small molecule and peptide 
ligands in what is known as “state-dependence”. The information gathered through molecular dynamics 
simulations and, more importantly, X-ray crystal structures, is instrumental in forming a unified model 
of voltage-dependant gating through a complete cycle. What is known will be summarize 
 
When in the resting state the NaV channel is closed and non-conducting, but primed for activation. 
Activation of the NaV channel occurs when membrane depolarization causes a conformation change of 
the voltage sensor region - specifically with the S4 helices - opening the outer pore to allow Na+ ions to 
flow down an electrical gradient. After activation of the NaV channel, an inward flow of Na+ ions (INa) 
occurs within milliseconds, immediately followed by decay in INa during the depolarization phase. This 
decay is due to inactivation of the channel by an intracellular gating motif and is a closed conformation 
state that is distinct from the resting state. The physiological role of the inactivated state is to stop ion 
conductance during prolonged depolarization, allowing the channel to reset to a fully closed (resting) 
conformational state. NaV channel inactivation is typically described as either fast or slow, with slow 
inactivation encompassing both ultraslow and intermediate modes[56]. 
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The primary role for fast inactivation is to aid in repolarization of the cell after firing of an action 
potential. In mammalian NaV channels, fast inactivation is well described and has been attributed to a 
highly conserved intracellular linker region between DIII-DIV of the α-subunit (Figure 3). Deletion of 
the linker[57] followed by targeted inactivation of the region using antibodies[58] provided the first 
experimental results pinpointing this region as the inactivation gate. Further point mutations of the 
DIII-DIV linker identified a cluster of three highly conserved hydrophobic amino acids – labeled the 
IFM motif – that is critical for inactivation[59]. To confirm the role of the IFM motif in inactivation, 
introduction of the peptide KIFMK via intracellular expression was shown to recover the function of 
inactivation on channels with deleted IFM motifs through open-state dependent block[60]. The first hi-
resolution NMR solution structure of the inactivation gate was published a year later[61], revealing an 
α-helical core with a flexible hinge-like N-terminal turn, which includes the IFM motif. This linker 
region was shown to be stabilized in the inactivated state through interactions with the C-terminal 
section of the NaV channel, which will be discussed in more detail below[62]. The IFM motif 
demonstrates precedence for the potential of intracellular NaV pore block. 
 
Slow inactivation has been shown to be a distinct process from fast inactivation, differing spatially, 
structurally, and pharmacologically - although the process is still not completely understood[63, 64]. 
Slow inactivation is a critical component of recovery from depolarization, controlling membrane 
excitability, firing properties, and spike frequency[65]. Abnormalities in slow inactivation have been 
linked to the neuromuscular disorders hyperkalemic periodic paralysis and myotonia[66], epilepsy[67], 
as well as several cardiac arrhythmia disorders such as Brugada syndrome[68], atrioventricular 
conduction block[69], and long-QT syndrome[70]. These associations underscore the physiological 
importance of this process. Slow inactivation is common to all mammalian NaV channels, although not 
as pronounced in the cardiac NaV1.5 isoform compared to nerve and skeletal muscle isoforms[71].  
 
This functional difference between NaV1.5 and skeletal NaV1.4 was exploited in attempts to isolate the 
structural components of slow inactivation[72]. A comprehensive study utilizing chimeras of hNaV1.4 
and hNaV1.5, as well as differential expression of an associated β1-subunit, resulted in two important 
observations involving the regulation of slow inactivation: (i) that P-loops are structural determinants 
of slow inactivation and (ii) that the β1-subunit modulates this process in hNaV1.4 but not hNaV1.5 
through a possible interaction with the P-loops[73]. P-loop association was further confirmed with 
mutational and modeling studies directed at the outer selectivity ring EEDD motif, which was shown to 
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play a crucial role in modulating slow inactivation[74]. This information was pieced together using a 
model of the TTX-bound channel to give the most comprehensive ionic model of slow inactivation to 
date, and in the process elucidated the binding of many state-dependant drugs that modulate slow 
inactivation[75]. This model suggested that slow inactivation involves disordering of the outer pore 
region rather than direct plugging, which may explain the different kinetic states of slow inactivation. 
However, there is much that remains unanswered, including the suggested involvement of the S4 
voltage sensor. The recent availability of a NaV crystal structure will help to address many of these 
questions. 
 
1.3.3 Voltage sensor 
The mechanism of voltage dependent gating is directly linked to changes in the membrane potential of 
the cell. A candidate for the voltage sensor, the S4 transmembrane helix, had already been suggested at 
the time of the first NaV channel cloning due its location within the membrane electric field and strong 
inherent positively charged residues[76]. This positive charge is due a polybasic region composed of 
arginine and lysine at every third position of the S4 helix. The S4 regions of each domain have 
subsequently been shown to be critical for voltage dependence through site-directed mutagenesis 
studies that targeted these key charged residues[57]. However, the voltage sensors in DI-DIII have been 
shown to be critical for channel gating, while the DIV voltage sensor is more closely associated with 
fast inactivation[77, 78]. This association has been demonstrated further with the use of gating modifier 
toxins, which interact directly with the voltage sensor region of S1-S4[79, 80]. 
 
The classical voltage sensor model suggests that in response to a change in the membrane’s electric 
field due to an influx of positive charge, the voltage sensors will undergo a conformational change, 
moving towards the extracellular space and opening the pore[81, 82]. Continuing research on the 
voltage sensor is revealing that voltage dependant gating is a much more intricate process, involving 
ion pair interactions between multiple segments after physical movement of the voltage sensor during 
depolarization of the membrane[83]. These interactions include a process described as “disulfide 
locking” of the S4 after activation, which is shown to contribute to slow inactivation[84, 85] and 
demonstrates that activation and inactivation are not completely independent processes[86]. 
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1.4 β-subunits 
The four known mammalian NaV channel β-subunits, β1-β4, are between 33-36 kDa in size and 
encoded by the genes SCN1B-SCN4B[87, 88]. SCN1B has been shown to produce species-specific 
splice variants, with humans expressing the variant β1B[89]. All four β-subunits share a similar 
structure, composed of an N-terminal extracellular immunoglobulin (Ig) domain, an alpha-helical 
transmembrane segment, and a short intracellular C-terminal region. All of the β-subunits belong to the 
Ig superfamily of cell adhesion molecules (CAMs)[90]. The NaV β-subunits are known to co-localize 
with NaV α-subunits, with β1 and β3 forming non-covalent bonds while β2 and β4 are covalently linked 
through disulfide bonding, although the residues responsible have not yet been identified[30, 91-93]. 
These interactions with NaV α-subunits have been shown to be multifunctional, affecting not only 
receptor excitability, but also cell adhesion, neuronal migration[94], neurite outgrowth[95], 
transcriptional regulation, and metastatic activity in cancer[96]. Through their interactions with NaV α-
subunits, β-subunits canact as regulators of both temporal and spatial expression of the α-subunits 
through the formation of macromolecular complexes [89].  
 
Because of their association with and regulation of NaV α-subunits, β-subunits have the potential to 
make useful therapeutic targets. However, their multifunctional role as CAMs may be a complication 
as well as a benefit. Using domains of the subunits to elicit a physiologic effect has already been 
demonstrated in vitro. For example, the Ig domain of β1 can promote neurite outgrowth on its own[95], 
which opens up the potential for designing peptide drugs based off of active regions of these subunits. 
Monitoring mutations of β-subunits can be a useful diagnostic tool to help identify the most appropriate 
treatments for variety of ailments such as cardiac arrhythmias[97], multiple forms of epilepsy[98, 99], 
and potentially even some cancers. Manipulating the expression or interaction with α-subunits has the 
potential to lead to multiple downstream signaling effects in vivo and has been shown to play an 
important role in affecting channel kinetics in vitro [90, 100]. However, the in vivo spatio-temporal 
relationships between β-subunits and associated α-subunits are yet to be fully understood. 
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2. Therapeutic relevance of NaV channels: Role in pain pathophysiology 
 
NaV channels play a diverse physiological role and function in many aspects of neurotransmission, 
such as nociception, as well as participating in the modulation of various cellular processes. Deleterious 
genetic defects can occur in domains that affect expression or function, such as the voltage sensor, N- 
and C-terminal domains, or loop regions that act to bind regulatory proteins. Amino acid substitutions, 
deletions, or additions also occur in regions of the channel responsible for voltage sensing, inactivation 
and ion selectivity, resulting in a wide array of conductance diseases, some of which will be discussed 
in detail. NaV isoforms are each expressed selectively in multiple tissues and cell types throughout the 
body, including both excitable and non-excitable cells, immune cells, myocytes, and nerve tissue. 
Therefore, defects among members of this family of voltage conducting channels can be attributed to 
numerous disease states involving electrical conductance throughout the body, including pain and 
inflammation pathways[101], neurodegeneration[102], cardiology[103], neurology[104], and even 
cancer[105]. This ability of NaV channels to contribute to a wide range of physiologic roles supports 
the advance of greater isoform selective targeting for therapeutic development, which has been lacking 
to date. This thesis primarily focuses on targeting the TTXs NaV1.3 and NaV1.7 channels, which are 
known to be involved in pain transmission and nociception. However, since selectivity is of the utmost 
importance for research and therapeutic purposes, all available NaV isoforms will be screened for 
activity. Of these, a few key selections will be discussed for their therapeutic relevance. 
 
2.1 Pain and inflammation 
Primary afferent nociceptors of the peripheral nervous system are responsible for detecting high 
threshold environmental input from thermal, mechanical, or chemical sources, and converting this 
stimulus into electrochemical signals [106].  These peripheral nerves can be divided based on 
morphology and function into three classes. Large diameter myelinated Aα/β-fibers have a low 
threshold for activation and mainly conduct information about innocuous touch. Both the fast 
conducting, lightly myelinated, medium diameter Aδ-fibers and the small, slow conducting, 
unmyelinated C-fibers contribute to nociception from noxious stimuli [107]. Because of their different 
conductance, it is thought that Aδ-fibers mediate the first rapid, acute response while C-fibers 
contribute to the second delayed, throbbing pain. 
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At the transition between the peripheral and the central spinal nervous system lie bundles of afferent 
nerve cell bodies (soma) called dorsal root ganglion (DRG). DRGs are located along the vertebral 
column along the spine just outside the CNS, where the afferent dendritic fibers interface with the soma 
and transition into axon. These ganglia are responsible for transmitting afferent signal from external 
thermo-, mechano-, or chemo-sensory input from the periphery to the spinal cord and on to the brain 
for processing. The channels and receptors responsible for transmission of peripheral nociception are 
expressed in DRGs, including an array of NaV channels that provide the inward current necessary for 
formation and propagation of action potentials[108]. Because of their function and composition, DRG 
neurons have provided researchers with a native cell type to identify the receptors involved in pain 
transmission at the periphery, as well as the mechanisms for neurite outgrowth.  
 
Early electrophysiology studies have demonstrated that after neuronal injury, DRG neurons become 
hyperexcitable, giving rise to the spontaneous action potentials and bursting that contribute to 
neuropathic chronic pain [109-111]. There is substantial evidence linking this hyperexcitability to a 
differential expression of a few key NaV isoforms [112]. In addition, an array of clinical and 
experimental observations using NaV channel inhibitors has demonstrated a link between NaV 
hyperexcitability and the propagation of neuropathic pain [113-115]. The contribution of two TTXs 
NaV channels to neuropathic pain will be discussed.  
 
2.1.1 NaV1.3 
NaV1.3, encoded by the SCN2A gene, is the most questionable in relation to its contribution to 
neuropathic pain. NaV1.3 mediates TTXs, fast-activating and fast-inactivating Na+ current.  It is 
developmentally regulated, with lower expression in adult compared to embryonic rodents[116]. In 
addition, studies using animal models for physical pain from injury – such as sciatic nerve axotomy or 
spinal nerve ligation – have shown marked increases in expression of NaV1.3 around injured nerve 
regions[117-120]. This isoform seems to be the only NaV consistently upregulated after nerve injury 
based on mRNA analysis, RT-PCR and electrophysiology experiments, which determine both 
functional and transcriptional expression[117, 120-122].  
 
This data points to NaV1.3 being an important contributor to the TTXs component apparent in the 
spontaneous, rapid repriming current seen in inflammatory and neuropathic pain. However, more 
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recent data has contradicted this hypothesis. Antisense oligonucleotides to knockdown expression of 
NaV1.3 after peripheral nerve injury reduced NaV1.3 expression by 50% in DRG neurons[123]. Yet this 
reduction failed to yield a therapeutic benefit by attenuating mechanical and thermal allodynia. In 
addition, the upregulation of NaV1.3 was shown to be non-specific to injured DRG. However, this 
study was contrary to previous results, again using oligonucleotides targeting NaV1.3, which showed 
that knockdown of mRNA and protein did attenuate hyperexcitability and allodynia[21]. In a pivotal 
study, normal levels of neuropathic pain were recorded in two conditional NaV1.3 knockout mice 
strains and hyperexcitability seen in neuropathic pain states was unaffected[122]. Thus, despite robust 
upregulation of NaV1.3 after nerve injury, its role in the development of neuropathic pain remains 
unclear[124]. 
 
In recent years, NaV1.3 has also received attention for its putative involvement in epilepsy. Although 
rodent NaV1.3 is down-regulated postnatally, adult human brain expresses significant levels of the 
NaV1.3 isoform, with mutations found in patients with cryptogenic pediatric partial epilepsy[125]. 
These mutations were found to enhance both the persistent and ramp currents of NaV1.3, and increase 
excitability in hippocampal neurons, a finding consistent with upregulation of NaV1.3 in spontaneously 
epileptic rats[126]. However, the precise contribution of NaV1.3 to various forms of epilepsy remains 
to be determined. Similarly, while specific site mutations have not been identified to date, recent data 
from animal models of epilepsy suggest an involvement of NaV1.6 in certain forms of epilepsy, 
including absence seizures. These data suggest that subtype-specific pharmacological modulators might 
emerge as useful treatments for multiple epileptic disease states. 
 
2.1.2 NaV1.7 
NaV1.7 is encoded by the SCN9A gene and preferentially expressed in both nociceptive DRG and 
sympathetic ganglion neurons[127, 128]. This channel also mediates a TTXs fast-activating, fast-
inactivating current, however it is slow to recover from inactivation as compared to other NaV 
channels[129-131]. NaV1.7 also exhibits slow inactivation from the closed-state, which allows the 
channel to generate a current in response to a small, slow ramp depolarization. This action helps set a 
gain by amplifying sub-threshold conductance that contribute to hyperexcitability[132, 133]. The 
ability of this channel to boost sub-threshold stimuli ultimately increases the total probability that a 
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neuron will reach its threshold to fire an action potential. This functional role has been observed in 
recent studies linking NaV1.7 to heat hypersensitivity after burn injury[134]. 
 
Originally detected in somatosensory and sympathetic ganglion neurons, NaV1.7 has since been 
reported in myenteric neurons[135], olfactory sensory neurons[136, 137], visceral sensory 
neurons[138] and vascular myocytes[139]. NaV1.7 expression is also well characterized in both the 
large diameter, myelinated aδ-fibers and small diameter, unmyelinated C-fibers[140]. Expression of 
NaV1.7 within free nerve endings in the epidermis is consistent with its proposed role of amplifying 
weak stimuli[134, 141]. NaV1.7 has also been detected in a variety of non-excitable cells, including 
prostate and breast tumor cells[105, 142], human erythroid progenitor cells[143] and immune 
cells[144]. However, there has been no evidence of CNS expression, except for within the superficial 
lamina of the dorsal horn in the spinal cord [128, 145]. 
 
NaV1.7 potentially represents one of the best validated pain targets for the development of therapeutics. 
The role for NaV1.7 in human acute and chronic neuropathic pain has been demonstrated through 
observations of human familial mutations, which are responsible for three pain syndromes. The two 
gain-of-function disorders, inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder 
(PEPD), are dominantly-inherited mutations causing hyperexcitability and increased pain 
perception[146, 147]. Congenital insensitivity to pain (CIP) is a recessive loss-of-function disorder, 
with mutations inactivating the NaV1.7 channel[148]. CIP patients typically experience a complete loss 
of pain sensation, even after burns, fractures, or puncture wounds. The only other sensory deficit 
observed is a partial or global loss of olfaction. This loss of smell was determined to be the cause of 
prenatal mouse SCN9A-knockout lethality, since blind, prenatal mice require a sense of smell in order 
to feed, with no other deficit in sensory, motor or cognitive functions observed[149]. These mutations 
highlight the distinct role of NaV1.7 in nociception in humans. The reader is directed to a recent 
comprehensive review highlighting all known human mutations of NaV1.7[150]. 
 
Initial studies seeking to confirm the role of NaV1.7 in pain using NaV1.7 knockout animals were 
hampered due to the perinatal lethality of the global NaV1.7 null mutant. While this was originally 
attributed to decreased gut motility due to the presence of NaV1.7 in the gut, a more likely cause has 
been traced to loss of olfactory sensation, as is seen in human loss-of-function mutations, resulting in 
postnatal starvation as a consequence of loss of NaV1.7 in olfactory neurons. Conditional knock-out 
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and knock-down of NaV1.7 in animal models of pain have demonstrated that NaV1.7 plays a significant 
role in the development of acute and inflammatory pain, probably attributed to an upregulation of the 
channel caused by inflammatory cytokines[151, 152]. Thus, NaV1.7 has attracted considerable attention 
as a putative therapeutic target for the treatment of extreme pain conditions [153] with one lead 
compound, CNV1014802, already in Phase II clinical trials with Convergence Pharmaceuticals (a 
spinoff of GSK)[154]. Xenon Pharmaceuticals is currently working on its own lead compound, 
XEN402, which blocks NaV1.7-mediated pain associated with post-herpetic neuralgia [155]. Other 
major pharmaceutical companies contributing research into small molecule NaV1.7 inhibitors include 
Merck[156, 157], Pfizer, Amgen [158], and AstraZeneca[159], to name a few. 
 
2.2 Muscle channelopathies 
The human gene SCN4A encodes NaV1.4, which plays a critical role in affecting skeletal muscle 
excitability and maintaining resting membrane potential. Muscle channelopathies can be characterized 
by their affects on excitability by causing conditions associated with either nondystrophic myotonia 
(hyperexcitability) or periodic paralysis (nonexcitability) through a variety of ion channel mutations. 
Nondystrophic myotonia conditions are characterized by phenotypes of extreme muscle stiffness 
caused by prolonged relaxation of skeletal muscle after voluntary contraction or external mechanical 
stimulation. Periodic paralysis conditions are characterized by episodes of muscle weakness associated 
with variations in serum K+ concentrations and may be also involve symptoms of myotonia[160]. 
 
Missense mutations specifically affecting SCN4A are known to be responsible for a variety of human 
myotonia and periodic paralysis conditions. Hyperkalemic periodic paralysis and paramyotonia 
congenita (Eulenburg’s disease) are conditions resulting from gain-of-function mutations in SCN4A 
that impair inactivation, leading to persistent Na+ current and mild membrane depolarization[160]. 
NaV1.4 blockers are able to correct the associated myotonia, but are not very effective in preventing 
muscle weakness or frequency of attacks in these two conditions[161]. Potassium-aggravated 
myotonias include myotonia fluctuans, myotonia permanens, and acetazolamide-sensitive myotonia, 
are caused by various SCN4A mutations and aggravated by K+ ingestion[162, 163]. Thus, NaV1.4 is a 
promising therapeutic target for a variety of skeletal muscle disorders, although NaV1.4-specific 
antagonists are lacking, with the exception of certain µ-conotoxins. 
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2.3 Cardiac arrhythmias 
The fast-inactivating cardiac-specific NaV1.5 is encoded by the gene SCN5A and is essential for normal 
cardiac function. NaV1.5 directly contributes to phase 1 of the cardiac action potential, which is the 
depolarization phase caused by the rapid influx of Na+ ions (INa) into the cell, initiating and propagating 
Na+ current. NaV1.5 also contributes to setting the resting membrane potential[103]. Multiple disease 
states result from defects in INa conduction, typically resulting from point mutations on the SCN5A 
gene. Since the first identification of a mutation on the gene SCN5A that was attributed to long-QT 
syndrome (LQTS)[164], close to 200 mutations have been identified. NaV1.5 mutations have since 
been implicated in Brugada syndrome, progressive cardiac conduction defect, dilated cardiomyopathy, 
atrial fibrillation, and sick sinus node syndrome[103]. The numerous mutations implicated in the 
multiple cardiac rhythm disease states can aid the clinical diagnosis and help determine both latent risk 
factors and clinical severity. 
 
Reduced NaV availability due to diminished peak INa amplitude or negative shift in the inactivation 
profile is associated with loss-of-function phenotypes such as Brugada and sick sinus node 
syndrome[165, 166]. The impairment of conduction can act through different mechanisms, such as 
reduced membrane channel density, a voltage-dependant shift in the steady-state inactivation and 
activation profiles, or an increased onset of inactivation. These phenotypes are not pharmacologically 
treated by NaV channel blockers, although increasing NaV1.5 activity through subtype selective 
activators could be a potential treatment strategy. 
 
In contrast, mutations that cause increased late INa augment the depolarizing impact on cardiac 
myocytes and thereby prolong the action potential duration, as seen in LQTS[167]. This latter type of 
arrhythmias can be treated with Class I NaV channel blockers[168, 169]. Current antiarrhythmic drugs 
have low target specificity and potential for serious side effects[170]. Current antiarrhythmic drugs 
were developed at a time when the underlying molecular mechanisms of the pathology were little 
understood, so molecular target selectivity was not a factor. That said, there are currently no selective 
NaV1.5 drugs available on the market.  
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2.4 Epilepsy 
As one of the world’s most prevalent neurological disorders, epilepsy encompasses a group of diseases 
with a wide range of clinical features and causes, all sharing the similar phenotype of seizure. 
Monogenetically inherited epileptic syndromes are typically associated with mutations in genes 
encoding for ion channels. In the case of NaV channels, over 300 mutations on the SCN1A gene that 
encodes NaV1.1 have been discovered to date[171, 172]. Gene mutations and functional disturbances 
causally linked to the development of both inherited and acquired epilepsy have also been reported for 
SCN2A/NaV1.2, SCN3A/NaV1.3[125, 173] and SCN8A/NaV1.6[174]. It is interesting to note that 
NaV1.1, NaV1.2 and NaV1.6 are all highly expressed in the adult mammalian brain and their genes 
SCN1A, SCN2A, and SCN3A are all located on the same chromosomal cluster.  
 
NaV mutations have been correlated with multiple epileptic disease states [175], with NaV1.1 linked 
primarily to severe myoclonic epilepsy of infancy and generalized epilepsy with febrile seizures plus 
syndrome, while NaV1.2 has been linked to benign familial neonatal-infantile seizures. Reduced 
expression and mutations of the β1-, β2-, and β3-subunits have all been shown to contribute to seizure 
activity through modulation of NaV voltage-dependence towards a more increased level of persistent 
current, most likely by affecting expression patterns of associated NaV α-subunits[100, 176]. 
Intriguingly, loss of function mutations in NaV1.1, which intuitively would lead to decreased neuronal 
excitability, are also associated with the development of epilepsy. The majority of SCN1A mutations 
result in localized high-frequency repetitive firing and hyperexcitability through hyperpolarized shifts 
in voltage-dependence, persistent inward current, or inhibition of inactivation. The reason for this 
seeming discrepancy presumably arises from predominant expression of this NaV isoform in inhibitory 
interneurons, whose loss of NaV currents leads to increased excitability overall [177]. Compensatory 
inhibition of NaV1.6 has been suggested to partially correct the neuronal hyperexcitability resulting 
from loss-of-function mutations in NaV1.1[178]. Thus, inhibition of NaV activity remains a possible 
treatment strategy, even for types of epilepsy based on loss-of-function mutations. 
 
In recent years, NaV1.3 has also received attention for its putative involvement in epilepsy. While 
rodent NaV1.3 is downregulated postnatally, human brain expresses significant levels of NaV1.3, and 
mutations in NaV1.3 were found in patients with cryptogenic pediatric partial epilepsy[125]. These 
mutations were found to enhance both the persistent and ramp currents of NaV1.3, and increase 
excitability in hippocampal neurons, a finding consistent with upregulation of NaV1.3 in spontaneously 
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epileptic rats[126]. However, the precise contribution of NaV1.3 to various forms of epilepsy remains 
to be determined. Similarly, while specific site mutations have not been identified to date, recent data 
from animal models of epilepsy suggest an involvement of NaV1.6 in certain forms of epilepsy, 
including absence seizures. These data suggest that subtype-specific pharmacological modulators might 
emerge as useful treatments for multiple epileptic disease states. 
 
The antiepileptic drugs (AEDs) currently in use are not known to be NaV subtype selective[179]. 
However, they do act as use-dependent modulators, blocking the high-frequency repetitive firing that is 
believed to occur during seizures. AEDs preferentially block depolarized channels in a mechanism that 
resembles fast-inactivation. The current AED drugs on the market are all known to bind to a common 
site, the local anesthetic (LA) binding site, located within the pore of the NaV channel[180]. However, 
the slow onset of activity distinguishes AEDs from LAs. This slow binding is important because it 
highlights the requirement of repetitive depolarization events, as seen in epileptic seizures versus 
normal synaptic transmission. There is also evidence that current AEDs can inhibit persistent current, 
which contributes to the initiation and propagation of seizure-like current. NaV1.6 is the most 
abundantly expressed NaV channel in the nervous system and plays a significant role in promoting 
repetitive firing and enhanced excitability seen in persistent current[174, 181]. The specificity of AEDs 
to NaV isoforms including NaV1.1 and NaV1.6 is not yet known, although such experiments may prove 
enlightening.  
 
2.5 Summary 
The contribution of NaV channels to many other pathological conditions have been identified and are 
discussed in greater detail within the book chapter from which this was adapted[182]. This further 
demonstrates the relevance of NaV channel modulators as potential therapeutics. The broad spectrum of 
physiologic conductance roles also highlights the need to develop subtype specific modulators, which 
is something current small molecule therapeutics are lacking. 
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3. NaV channel neurotoxin receptor sites 
 
As a significant member of the ion channel superfamily, NaV channels act as unique molecular targets 
for several groups of naturally derived neurotoxins. Early pharmacological studies identified four 
neurotoxin receptor sites on mammalian NaV channels, primarily affecting ion conductance and 
voltage-dependent gating[183]. Later studies provided evidence for sites 5[184, 185] and 6[186] 
(Figure 4). Binding to these sites can influence gating kinetics by inducing conformational changes to 
the NaV channel or simply act as a plug, blocking the flow of ions and therefore the transmission of 
current.  
 
 
 
Figure 4: NaV channel neurotoxin binding sites.  
Neurotoxin binding sites are color coded where toxins are known to interact with mammalian NaV 
channels and cover broad regions of the extracellular loop domains and transmembrane helical 
regions. The S4 voltage sensor is labeled with (+) and the inactivation gate is labeled with IFM. 
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These sites have been determined primarily through a series of site-directed mutagenesis studies 
focusing on different regions of the NaV channels, used in combination with electrophysiology, 
isotopic ion permeability and radioligand competitive binding assays to assess the regions role in 
activity[187]. Similar neurotoxin binding  sites exist on insect NaV channels, with some venom 
peptides demonstrating activity for both insect and mammalian NaV channels[188-190]. However, 
insect NaV channels will not be discussed in this thesis for the sake of brevity.  
 
Because of their natural high affinity and specificity to individual sites on the NaV channel, several 
groups of neurotoxins have been instrumental tools for structure-function studies[191, 192]. Binding to 
these sites strongly modulate channel function by altering permeation and gating properties. There have 
been three proposed molecular mechanisms of action for neurotoxin modulation of NaV channels; pore 
block, indirect allosteric modulation of gating, and voltage sensor trapping[192]. These mechanisms 
will be explained in greater detail in the next section. 
 
3.1 Site 1 - Pore blockers 
Site 1 one the NaV channel is composed of residues that make up the re-entrant P-loop between S5 and 
S6 on all four domains. Binding to this site results in extracellular pore block and inhibition of INa 
conductance[193]. TTX and STX are both water-soluble heterocyclic guanidines that fall into the first 
class of neurotoxins known to interact with NaV channels[194]. As previously mentioned, these toxins 
have been fundamental tools in studies dissecting NaV channel structure and function[39, 195]. The 
peptidic μ-conotoxins have been isolated from marine cone snails and interact competitively with TTX 
and STX[196, 197] (Figure 4). However, certain mutations of the NaV pore forming region have been 
found to affect TTX affinity without altering μ-conotoxin binding, suggesting these toxins share only a 
partially overlapping binding site[198, 199]. More recent experiments have demonstrated synergistic 
inhibition of INa with both µ-KIIIA and TTX forming a ternary complex with the NaV channel pore 
region[200]. µ-KIIIA alone allows a small but measurable leak of INa, while the addition of TTX results 
in complete inhibition. Although the inhibition effect was more complete when both toxins were 
combined, kinetic effects for both toxins appeared competitive. The presence of prebound TTX 
accelerates the off rate of µ-KIIIA after subsequent addition, while the presence of prebound µ-KIIIA 
slows the on rate of TTX after subsequent addition. However, it was noted that the same ternary 
complex forms regardless of the order of ligand addition. TTX also appears to reduce the Kon of µ-
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KIIIA The authors explained these effects as being caused by differential binding on site-1 
“microsites”, dependent on the order of ligand binding. As µ-KIIIA binds closer to the vestibule, it 
would slow the Kon of TTX through partial physical occlusion of the inner binding site. Likewise, the 
presence of TTX would limit the affinity of subsequent µ-KIIIA binding. These results give hints 
towards the development of a peptide that could either i) act as a stronger inhibitor of NaV channels 
through the addition of guanidine side chains, or ii) bind strongly to the outer pore in a way to limit 
TTX binding while still allowing enough leak current to maintain a functional channel. This latter 
method could be developed as an effective treatment for paralytic shellfish poisoning. 
 
3.2 Site 2 
Toxins that bind to the transmembrane site 2 on the NaV channel are lipid soluble, small molecule, 
allosteric modulators, causing persistent activation as either full or partial agonists[192, 201-203] 
(Figure 4). However, these toxins are derived from a variety of organisms and are diverse in structure. 
Plant derived toxins include the diterpene grayanotoxins from the Ericaceae family[204], and the 
alkaloids aconotine from Aconitum[205] and veratridine from the Lilaceae family[206]. The alkaloidal 
steroid batrachotoxin (BTX) is found in frog, bird, and insect species and has served as a primary tool 
for determining site 2 functional roles in NaV channels[207]. Antillatoxin and hoiamide are two 
structurally unique NaV agonists isolated from marine cyanobacteria[208, 209]. Both molecules were 
found to partially displace [3H]BTX, but the precise site of binding remains undefined. 
 
Site 2 toxins share the characteristic of preferential binding to open-state NaV channels and are able to 
modulate several functional NaV properties. BTX has been used as a primary tool to study many 
functional roles of site 2 modulation as well as map residues composing the site 2 region. Site 2 
modulation results in a hyperpolarizing shift in the voltage-dependence of activation, resulting in 
activation at resting potential[210]; slowed or inhibited inactivation, resulting in sustained, non-
inactivating currents137; reduced INa conductance[211]; and modification of the selectivity filter, 
resulting in reduced selectivity for permeating ion[212]. 
 
Photoreactive BTX was initially used to determine an interaction site at DIS6[213]. Site-directed 
mutagenesis studies of NaV1.4 confirmed residues along DIS6 were necessary for toxin binding as well 
as demonstrating overlapping regions in DIVS6 that were common to both BTX and grayanotoxin[207, 
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214]. Accumulating evidence from computer modeling and molecular docking experiments suggests 
that BTX and veratridine – as well as potentially other site 2 agonists – interact with all four S6 
segments near the DEKA selectivity filter in a way that stabilizes the open-state of the NaV channel, as 
well as limiting fast inactivation through S6 interactions[212, 215, 216]. BTX has been shown to bind 
towards the cytosolic end of the pore region in an open-state dependent, irreversible manner[217]. 
Grayanotoxin has been shown to bind an overlapping but not identical region in the pore in a reversible 
manner[207]. The close interactions with the selectivity filter region helps explain observed changes to 
ion permeability. The modeling experiments demonstrating pore binding also helps explain the 
decrease in peak current, as well as the observation that close analogues to some site 2 agonists are able 
to act as NaV inhibitors[218, 219]. 
 
The mode of binding has been less studied for veratridine, although classical electrophysiology studies 
measuring whole tissue currents have been completed. Veratridine is known to have a reversible effect 
on NaV1.1-NaV1.7 and exhibits similar functional alterations of NaV channels[18, 220]. An interesting 
functional quality of veratridine is a lack of state-dependent binding in nerve tissue[221] while 
exhibiting state-dependence in muscle tissue[222-224]. Interestingly, in many of these same studies 
veratridine was also shown to have differential effects on peak amplitude in a tissue specific manner. 
Differences between cardiac myocytes, smooth muscle, and nerve tissue hint that the effect is most 
likely dependant on the NaV isoforms preferentially expressed in corresponding tissue. A more recent 
study on NaV1.6 in mouse vas deferens myocytes demonstrated a bell-shaped curve for peak amplitude 
in relation to veratridine concentration. Peak amplitude was enhanced until a concentration of 10 µM 
was reached, whereas higher concentrations reduced INa[225]. No change in ion selectivity was noted. 
The effect is likely due to partial pore obstruction caused by toxin binding. 
 
3.3 Site 3 and Site 4 
Toxins that bind to both site 3 and site 4 are gating modifier toxins that have evolved voltage sensor 
trapping mechanisms. They typically exhibit hydrophilic properties and therefore likely do not interact 
directly with the transmembrane segments, but instead exert their actions on the S4 voltage sensor 
through binding to extracellular loop domains[192]. Site 3 and site 4 were described for the first time as 
two distinct sites on rat brain synaptosomes while assessing competitive binding of the scorpion toxins 
AaH II (Androctonus australis Hector) and Css II (Centruroides suffusus suffusus) [226, 227]. The lack 
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of competition between these two toxins, which bound to distinct sites and exhibit different 
pharmacological profiles, led to the classification of α- and β-scorpion toxins, of which AaH II and Css 
II belong respectively[226, 227].  
 
Several classes of peptide toxins have been found to interact with site 3 through electrophysiological 
and competitive binding experiments, including α-scorpion toxins, sea anemone toxins, and the spider 
toxin families 2, 4, and 12[228-230]. This group of toxins work by preventing the outward movement 
of the DIVS4 transmembrane segment, thereby inhibiting conformational changes necessary for fast 
inactivation[231]. An important feature of these toxins is their voltage-dependent binding, which 
decreases in affinity as prolonged depolarization forces the outward movement of the S4 region, even 
causing voltage-dependant displacement of the ligand[229, 232]. Initial antibody mapping using 
photoaffinity labeling with α-scorpion and sea anemone toxins suggested the extracellular 
transmembrane segments S5-S6 in both DI and DIV, as well as part of the DIS5-S6 P-loop, comprised 
at least part of the site 3 binding domain[233, 234]. Experiments suggested that these extracellular 
loops are in close proximity and form a single binding space when the NaV channel is viewed in its 
tertiary structure. Further experiments revealed the additional contribution to α-scorpion toxin binding 
of the S3-S4 extracellular loop in DIV[231]. Research into NaV isoform selectivity using chimeras of 
DIVS3-S4 demonstrated only a few residues were critical for α-scorpion toxin binding and selectivity, 
demonstrating regions of importance that can be exploited when attempting to design specific ligands 
to NaV subtypes[235]. 
 
Site 3 neurotoxins function through the mechanism of voltage sensor trapping, where binding to the 
extracellular DIVS3-S4 loop is thought to slow or inhibit inactivation by preventing the normal 
outward movement of the DIVS4 transmembrane segment during channel gating. Site-specific 
fluorescent labeling of the S4 segment of NaV1.4 demonstrated the effect of stabilizing S4 of DI and 
DIV through α-scorpion toxin binding[236]. Both sea anemone and α-scorpion toxins have been shown 
to enhance the recovery of inactivation[232, 237]. As the S4 region is responsible for voltage-
dependant gating, toxins that interact with this region are referred to as gating modifier toxins. 
 
Venom peptides from two organisms have been instrumental in studying the mammalian NaV 
neurotoxin site 4: the β-scorpion toxins and spider NaV toxin families 1, 3, 5, and 7[226, 227, 238, 
239]. Unlike site 3 neurotoxins that inhibit inactivation, site 4 neurotoxins enhance activation by 
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trapping the voltage sensor region in its resting state, subsequently shifting the voltage-dependence of 
activation to a more hyperpolarized potential, as well as reducing peak current[240-242]. Site 4 
neurotoxins bind preferentially to resting state channels in a concentration-dependent manner. 
However, some more recently discovered spider venom peptides have redefined the original role for 
site 4 modulation, which will be discussed later[243-246]. 
 
In order to initially determine the site 4 region of interaction and learn more about voltage sensor 
function, the β-scorpion toxin TiTxγ (Tityus serrulatus) was tested against chimeras of NaV1.4 
(skeletal) and NaV1.5 (cardiac) domains. This research determined TiTxγ interacts preferentially with 
the NaV1.4 isoform at DII, which was necessary for the negative shift in the voltage-dependence of 
activation to occur[247]. A more detailed chimeric study using domains of NaV1.5 and the CNS 
expressed NaV1.2 with the highly potent β-scorpion toxin Css4 (Centruroides suffusus suffusus) 
confirmed DII, localized to the extracellular loops between DIIS1-S2 and DIIS3-S4. It was proposed 
that as the DIIS4 moves outward during depolarization, toxins will bind to newly accessible residues on 
the DIIS3-S4 loop, subsequently trapping the voltage sensor (S4) in an outward, activated position 
[248, 249]. The study also demonstrated that a single residue change of G845N is primarily responsible 
for the lack of affinity of NaV1.5 as compared to NaV1.2, giving further insight into the potential 
precision with which toxins interact with their receptors[242]. The β-scorpion toxin Tz1 (Tityus 
zulianus) helped resolve an additional interaction site on the NaV channel as well as determine 
specificity for different mammalian NaV isoforms[250]. Tz1 had the highest affinity for NaV1.4, 
followed by the neuronal NaV1.2 and NaV1.6, while NaV1.5 and NaV1.7 had little to no effect. Through 
chimeric studies with NaV1.2 and NaV1.4, the additional site 4 binding region of DIII was narrowed 
down to three residues on the C-terminal pore loop. The DIII region is critical for the observed NaV 
subtype specificity, which may be of interest when attempting to design specific NaV channel 
modulators[250]. 
 
Four NaV modulating spider toxin families are known to interact with mammalian neurotoxin site 4 
(Figure 4), all of which conform to an inhibitory cysteine knot (ICK) secondary structure and are 
thought to act as gating modifiers[251, 252]. Mg1a (Magi-5), isolated from Macrothele gigas, was the 
first spider venom to show affinity towards the mammalian site 4 through displacement of the β-
scorpion toxin, CssIV (Centruroides suffusus suffusus), using rat brain synaptosomes[188]. The 
electrophysiological properties of site 4 neurotoxins as defined by the β-scorpion toxins and Mg1a 
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exhibit a shift in the voltage-dependence of activation to a hyperpolarized potential, resulting in 
hyperexcitability through activation at sub-threshold potentials[188, 253, 254].  
 
Multiple other spider venom peptides have since been discovered with critical binding domains located 
on the site 4 DIIS3-S4 loop[239](Figure 4), as determined by either mutagenesis of key residues on this 
region of the NaV channel[243, 245, 255] or competitive assay with β-scorpion toxins[244]. However, 
many of these spider venom peptides exhibit a distinct functional profile to the β-scorpion toxins, 
whereby the peptide traps the DIIS4 voltage sensor in the closed state resulting in an inhibition of peak 
current [245, 255, 256]. Although a few of the jingzhaotoxins (Chilobrachys jingzhao) so far 
discovered have been shown to inhibit NaV current by acting as gating modifiers[244, 257-259], only 
one – β/κ-TRTX-Cj1a (jingzhaotoxin-III) – has so far demonstrated direct binding to the site 4 DIIS3-
S4 loop[245]. Two other spider venom peptides that have been shown to bind the DIIS3-S4 linker 
through mutational analysis include µ-TRTX-Hh2a (huwentoxin-IV isolated from Ornithoctonus 
huwena)[243] and µ-TRTX-Hhn2a (hainantoxin-III isolated from Ornithoctonus hainana)[255]. Both 
of these toxins also inhibit NaV current by interacting with the DIIS3-S4 linker and trapping the voltage 
sensor in the closed conformation. These NaV inhibitory spider venom peptides acting as gating 
modulators conform to a similar ICK secondary structure but exhibit highly variable NaV isoform 
selectivity profiles and promiscuous activity, affecting both CaV and KV channels[257, 259, 260]. This 
promiscuity across members of the voltage-gated ion channel superfamily could be attributed to partial 
binding in the vicinity of the highly conserved voltage sensor domain (S4) as many of these venom 
peptides have been shown to bind to S3-S4 linkers of the highly homologous voltage-gated ion channel 
family[261]. This should be taken into consideration when assessing the selectivity profiles of similar 
venom peptides. 
 
In addition to the spider venom peptides just mentioned, a single family of conotoxins, labeled µO, 
have been found to bind to a similar, overlapping region of site 4, also resulting in inhibition of current. 
Through NaV channel chimeric studies using NaV1.2 and NaV1.4, the µO-conotoxin MrVIA has been 
reported to interact with the C-terminal pore loop in DIII to inhibit activation[262]. Further, 
neutralization of the charged residues on the S4 segments of each domain demonstrated affinity to 
DII[263]. This same study also demonstrated functional competition between MrVIA and the β-
scorpion toxin Ts1a (Tityus serrulatus), suggesting µO conotoxins are site 4 modulators[263]. The 
inhibitory effects of these toxins can be reversed by strong, long-lasting positive voltage pulses, which 
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drive the voltage sensor back into its activated conformation[246]. Only five µO-conotoxins have been 
isolated to date, most varying only slightly in sequence homology[263-266]. 
 
The discovery of structurally related peptides that can exhibit two modes of voltage sensor trapping on 
the same receptor site demonstrates the unique ability of venom combinatorial libraries to exploit 
potential modulatory niches with only slight modifications in amino acid sequence. These small 
changes can be exploited to identify the functional necessity of charge, hydrophobicity, or chemical 
space for optimal interaction with the receptor. It also highlights the importance of continuing research 
into the discovery of venom peptides that might yet determine new functional roles or regulatory 
domains of the NaV channel. 
 
3.4 Site 5 
Marine dinoflagellates produce two classes of highly lipophilic, cyclic polyether compounds that 
interact with NaV neurotoxin site 5: brevetoxins (PbTX), produced by Karenia brevis and ciguatoxins 
(CTX), produced by Gambierdiscus toxicus[185, 267, 268]. Both classes of toxins bind preferentially 
to open-state, activated channels and result in a negative, hyperpolarized shift in the voltage-
dependence of activation, with some derivatives producing inhibition of fast inactivation[192]. 
Competitive NaV channel binding experiments demonstrated both toxins allosterically enhance 
[3H]batrachotoxin activation while they compete against each other for a unique binding site, 
subsequently labeled neurotoxin receptor site 5[269]. Photoaffinity labeling experiments using PbTX 
identified critical residues along DIS6 and DIVS5 that may form a binding pocket, as they would be 
located in close proximity in the native folded NaV channel[270] . 
 
To date, thirteen natural derivatives of PbTX and twenty-nine natural derivatives of Pacific (P)-CTX 
have been identified[271, 272]. However, most research has focused on synthetic studies of these 
molecules and has neglected a more in-depth look into NaV channel pharmacology, such as selectivity 
profiles or defined site 5 residues. 
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3.5 Site 6 
Site 6 on the NaV channel was originally identified through characterization of δ-conotoxin TxVIA, 
isolated from the cone snail C. textile[186, 273]. However, the first group of δ-conotoxins discovered 
was mollusk-specific and, although able to bind, had no effect on mammalian NaV channels. The 
isolation of δ-AM2766 from C. amadis was the first δ-conotoxin discovered to modulate mammalian 
NaV channels[274]. This discovery was quickly followed up by δ-EVIA from C. ermineus, which was 
found to be the first conotoxin selective for neuronal NaV isoforms – although activity was very low – 
with no effect on NaV1.4 or NaV1.5[275]. NMR solution structures for both toxins confirmed a 
common ICK motif for this class of peptide as well as visualizing the large hydrophobic surface area 
also common for the δ-conotoxins[276, 277].  
 
The δ-conotoxins have been shown to interact with NaV channels in a state-dependent manner, trapping 
the voltage sensor in the outward, activated position and resulting in an inhibition of fast inactivation, 
with sustained depolarization leading to toxin dissociation. Although the mechanism is extremely 
similar to site 3 modulation, δ-conotoxins so far discovered do not seem to exhibit voltage-
dependence[273, 275, 278]. The most in depth work to date on δ-conotoxins used δ-SVIE from C. 
striatus as a tool to discern the molecular mechanisms of interaction with NaV channel site 3, using two 
representative α-Lqh scorpion toxins in conjunction[279]. Mutagenesis of the NaV1.4 channel site 3 
DIVS3-S4 loop resolved a highly conserved triad of residues (Y1433-F1434-V1435) critical for δ-SVIE 
activity. Mutation of these residues also affected the function of α-Lqh-2 while doing nothing to α-Lqh-
3. This result was used to demonstrate functional competition with α-Lqh-2 and synergistic cooperative 
binding with α-Lqh-3 through mutual stabilization [279]. This work helped further define site 6, while 
maintaining strong overlapping effects between site 3 and site. However, site 6 still remains largely 
undefined and could simply be a natural extension of site 3, or could include residues completely 
unique to site 6. The discovery of novel δ-conotoxins is needed to further elucidate the structural 
interactions and functional roles this class has with NaV channels. 
 
3.6 Regarding toxin “sites” 
The classical nomenclature of neurotoxin sites has been essential in defining and classifying molecular 
interactions with the NaV channel. With the elucidation of a NaV channel crystal structure, more insight 
into how ligands interact with the various regions of the NaV channels can be explored in 3-
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dimensional space[45]. Computer aided modeling and co-crystallization studies can compliment 
traditional functional studies, which typically involve mutagenesis of key residues on either the ligand, 
receptor, or both. Macromolecular polypeptides most likely form complex interactions with multiple 
interaction sites across the NaV channel, such as what has been observed with sites 3, site 4, and site 6 
modulators. There still remains great potential for stronger definitions of binding regions. The classical 
definition of neurotoxin receptor sites as viewed on a planar map will likely shift to a more 3-
dimensional perspective as more ligands are discovered and receptor binding surfaces materialize. 
Furthermore, multiple regulatory roles for existing sites – such as in the dual modes of voltage sensor 
trapping apparent at site 4 – may yet to be determined. This is promising for structural bioengineering 
of ligands with greater selectivity profiles, among other functional properties. 
 
4. Conus and spider venom peptides targeting NaV channels 
 
Venoms represent a virtually untapped resource of novel pharmacologically active molecules[280]. In 
addition to potent drug leads, these highly specific peptides are also important tools to probe the 
structure and function of their receptor and ion channel targets[3]. Each venom producing species 
yields its own distinct natural combinatorial library of target selective molecules to be explored[281, 
282]. Of all the venom producing organisms, spiders and cone snails are of particular interest in the 
search for NaV channel modulators[283]. The majority of active peptides from these organisms are 
relatively small and contain multiple disulfide bonds, imparting a stable secondary structure[284].  
 
The genes encoding venom peptides are under intense selective pressure and have been shown to 
undergo rapid hypermutation, imparting target selectivity to individual peptides in a continual, 
generational predator-prey arms race[285]. These hypermutation events from ancestral genes have 
created venom peptide families with high sequence similarity as well as similar genetic precursors[239, 
285]. As sequencing technology becomes more accessible, this information can be used in the search 
for novel venom peptides at the transcribed gene level. This is accomplished through mRNA 
sequencing of venom producing tissue in a quickly arising offshoot of transcriptomics, dubbed 
venomics[286, 287]. 
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Further, as the number of new gene sequences and novel isolations from crude venom increases, 
methods for producing these toxins in a complimentary manner to solid phase peptide synthesis (SPPS) 
need to be developed. Recombinant expression has the ability to compliment SPPS and can be 
adaptable to both eukaryotic (yeast) and prokaryotic (bacterial) systems[288, 289]. By current 
measures, bacterial recombinant expression is by far the most cost-effective and straightforward means 
to express peptides and proteins. Issues such as solubility, folding, and purification can usually be 
overcome through the addition of a fusion protein, co-expression with chaperones, or the addition of 
molecular tags for directed expression or affinity chromatography. High-resolution structural 
elucidation has been improved through utilizing 15N/13C-labeling of peptides in combination with 
improved automated multidimensional NMR methods, requiring a fraction of the time of previously 
used methods, including crystallography[290]. Recombinant expression allows the fast labeling of 
peptides through simple media changes, at a fraction of the cost of SPPS[291]. 
 
4.1 Peptides as therapeutics 
Compared to small molecules, which can be developed and produced at low cost, orally bioactive, 
membrane-permeable, and generally stable, peptides are at a disadvantage[292, 293]. Nevertheless, 
venom peptides have become a source of novel ligands with potential therapeutic value. The rich 
diversity of venom peptides is a result of remarkable genetic hypervariability and accompanying post-
translational modifications (PTMs) which in turn generates species specific libraries of hundreds to 
thousands of primary structures[294-296]. Their high natural selectivity and potency towards key 
receptors, channels, transporters or enzymes of crucial biochemical signalling pathways involved in 
organism homeostasis make venom peptides an unrivalled and unexplored source of leads for the 
development of molecules with therapeutic potential. 
 
Many properties of venom peptides set them apart from the traditional limitations of peptides as 
therapeutics. Despite their variable size, averaging between 10–90 amino acids, most venom peptides 
have a high cysteine content which enables them to form specific disulfide bonds that provide them 
with a high level of thermodynamic stability as well as resistance to proteases. Conserved cysteine 
patterns and disulfide-bond connectivities with defined folds are found among the venom peptides of 
several thousands of different venomous animal species and in many cases are examples of either 
convergent or divergent evolution[296-298]. Coupled with secondary structure, many synthetic 
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methods are being developed to improve oral bioavailability and plasma/thermostability of 
peptides[299]. Some of these include cyclization[300, 301], substitution of cysteine with 
selenium[302], and the creation of peptidemimetics[303, 304]. 
 
Although peptide therapeutics are not historically well represented in the market compared to small 
molecules, the number of NCEs for peptide based drugs has grown by 27% at the turn of the century 
compared to the 1980s[305]. Methods of production and synthesis have increased in efficiency and 
ability, leading to a sharp increase in the number of new chemical entities. Six peptide drugs were 
approved in 2013 alone, with only one of those administered intravenously[306]. The clinical pipeline 
as of 2013 is composed of 128 peptide therapeutics under evaluation for a wide variety of ailments, 
with 40 in Phase I studies and 74 that have advanced to Phase I/II or Phase II studies[306]. The current 
increase in peptides approved for therapeutic use is a promising sign of future developments in the 
search for new drug entities.  
 
4.2 The inhibitory cysteine knot 
Despite the apparent sequence diversity among individual species, venom peptides appear to have 
evolved from a relatively small number of structural frameworks that are particularly well suited to 
addressing the crucial issues of potency, selectivity, and stability[280]. One of these structural motifs – 
the inhibitory cysteine knot (ICK) – is present in peptides and proteins from a variety of species, 
including both spider and cone snails[307]. The ICK motif is comprised of a two distinct structural 
features: i) a triple-banded antiparallel β-sheet and ii) a ring formed by two disulfide bonds and their 
connecting backbone segments, which is threaded by a third disulfide bond forming a “knot”[308] 
(Figure 5). Many ICK spider peptides lack a third β-strand, exhibiting a double-banded antiparallel β-
sheet[309]. 
 
It was previously suggested that the three-disulfide ICK motif is an elaboration of a simpler, ancestral 
two-disulfide fold coined the disulfide-directed β-hairpin (DDH)[310]. The discovery of DDH folded 
peptides in the venoms of both spiders (HWTX-II/Hh1a) and scorpions (Lw1a) lend support for the 
hypothesis that the DDH motif is an evolutionary precursor of the ICK[311]. 
 
33 
 
The most important aspect of ICK peptides is 
their inherent structural stability imparted by 
the knot motif. The term “knot” is actually a 
misnomer, as the ICK motif does not actually 
fold a true knot in the mathematical sense of 
the word, unlike its closed-loop cyclotide 
relative the cyclotide cysteine knot 
(CCK)[312, 313]. The ICK structure can be 
unfolded without the need for breaking any 
bonds whereas the CCK cannot[314]. 
Regardless of this discrepancy, ICK peptides 
still maintain a relatively high level of 
structural, thermal and biological stability, 
lending themselves as well-defined molecular 
scaffolds for drug design[315]. As ICK 
peptides do not require cyclization, they can 
be recombinantly expressed in single-celled 
organisms such as bacteria and yeast, which 
lack the enzymes necessary to catalyze such a 
reaction[289]. ICK peptides can also be 
converted to CCK peptides through chemical 
synthesis, which has been shown to increase 
gastric stability, leading to an orally active 
peptide[316]. 
 
4.3 Conotoxins 
Cone snails are marine venomous predators of the genus Conus. Conus is the largest known genus of 
marine invertebrates, with over 700 extant species described[317]. Cone snails are found in tropical 
marine environments and are particularly prominent around coral reefs and other shallow-water tropical 
marine habitats[318, 319]. They are prey specialists that include vermivorous, molluscivorous, and 
piscivorous species. The piscivorous species are expected to produce the most pharmacologically 
 
Figure 5: Inhibitory cysteine knot (ICK). 
A common structural motif adopted by many NaV 
modulating spider and cone snail peptides. 
Cysteines are labeled 1-6 and follow a 
connectivity pattern of I-IV; II-V; III-VI. Arrows 
represent β-strands. The 5 possible loops are 
variable regions of the peptide sequence, with n 
equating to the range of amino acids known to 
occur in different peptides. 
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interesting peptides to human health, since they have evolved to target chordates[320, 321]. The 
molecular diversity and enhanced target selectivity of individual peptides across each Conus spp. 
venom is thought to arise from the specificity of prey between different species[322]. Selective 
pressures forcing gene duplication events over millions of years of evolution have given rise to a vast 
resource of potent scaffolds, specific for a multitude of ion channel targets. The molecular targets of 
individual conotoxins are functionally diverse yet appear to act simultaneously in what has been termed 
cabals[4].  
 
A relatively rapid radiation of the Conus lineage has resulted in over 500 different species, with the 
venom of individual Conus species estimated to contain a unique compliment of over 200 peptide 
components[323, 324]. However, a more recent mass spectrometry analysis suggests the number of 
conopeptides per species could surpass 1000 unique peptides[325]. The majority of conotoxins so far 
discovered range in size from 12-35 amino acids and contain between 2 to 5 disulfide bonds between 
cysteine residues. Each Conus peptide gene encodes a precursor that typically has an N-terminal signal 
sequence of about 25 amino acids, an intervening “pro” region of 20-40 amino acids and a mature toxin 
sequence at the C-terminal end[326, 327]. The correlation between the conservation of both the 
disulfide framework and the “pre-pro” signal regions has allowed a definition of superfamilies based on 
both the pre-pro region and disulfide framework[4, 328]. Genome mining using these highly conserved 
signal sequences has allowed the discovery of new members belonging to defined superfamilies, as 
well as the discovery of completely novel superfamilies[329-332]. It is of interest to note the extremely 
high conservation of signal sequences is in direct conflict with the hypermutational variability of the 
mature toxin region, which is responsible for the amazing biodiversity of conotoxins[328]. These 
superfamilies were further subdivided into families based on molecular targets – represented by Greek 
nomenclature – with four of these families targeting NaV channels[322, 333].  
 
The ι-conotoxins are the most recently discovered family of NaV modulating peptides isolated from 
cone snails and have helped to define the I-superfamily[334, 335]. Eighteen paralogs were found within 
a single genome of C. radiatus, five of which demonstrated excitatory neuronal activity[334]. One 
interesting aspect of this class of peptides is the appearance of a D-epimerized amino acid at the C-
terminus, such as the D-Phe at position 44 of ι-RXIA[336]. To assess the functional role of ι-
conotoxins, ι-RXIA was used as a tool[335]. Results demonstrated ι-RXIA shifted the voltage-
dependence of activation to a more hyperpolarized potential, with some parallels made with the 
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mechanism of action to β-scorpion toxins. Some selectivity between NaV channel isoforms was 
observed. However, unlike β-scorpion toxins there were minimal effects on the voltage-dependence of 
inactivation or the kinetics of INa currents. The L-analog of ι-RXIA[L-Phe44] demonstrated severely 
decreased affinity and efficacy[335]. No binding site has been determined for this family of 
conopeptides. 
 
The µ-conotoxin family was previously mentioned for its ability to inhibit NaV current through site 1 
pore block in a manner complimentary to small molecule guanidinium toxins, like TTX. The µ-
conotoxins belong to the M-superfamily of conotoxins. They are small peptides ranging in size from 
16-30 amino acids, three disulfide bonds, and a highly conserved C-terminal helical region[337]. 
Recurring features include an Arg crucial for activity on the loop 2 region of the peptide, C-terminal 
amidation, and a hydroxylated Pro that seems to aid proper folding but is not always present[338]. 
 
The first µ-conotoxin isolated and characterized was µ-GIIIA from C. geographus. µ-GIIIA was shown 
to be a potent and selective inhibitor of the skeletal muscle NaV1.4, setting a precedence for the ability 
of conotoxins to possess inherent selectivity[339, 340]. Another NaV1.4 selective conotoxin, µ-PIIIA 
from C. purpurascens, demonstrated similar preference for NaV1.4, yet also affected some neuronal 
NaV isoforms, just with much lower potency[341]. Since those first discoveries, numerous µ-
conotoxins have been discovered through genomic analysis or activity-guided isolation from crude 
venom and have demonstrated a wide range of activity and selectivity profiles for NaV channels[342-
344]. Solution structures and mutagenesis studies of a few select µ-conotoxins have begun to reveal 
key residues, loop regions, and even backbone lengths necessary to impart selectivity between different 
NaV channel isoforms[337, 338, 342, 345]. The µ-conotoxins have been a focus for the development of 
novel analgesics targeting single-target NaV isoforms that contribute to nociception. Both µ-KIIIA (C. 
kinoshitai) and µ-SIIIA (C. striatus) have been shown to have analgesic properties in mouse 
inflammatory pain assays[338, 346]. The µ-conotoxins small size, high affinity and diverse selectivity 
of inhibition for TTXs and TTXr NaV channels make them strong prospective therapeutic agents. 
 
The NaV channel selective µO- and δ-conotoxins both belong to the O-superfamily and have been 
discussed in great detail in an earlier section regarding their interactions to NaV neurotoxin sites. Both 
are unusually hydrophobic peptides with the same disulfide scaffold that imparts an inhibitory cysteine 
knot (ICK) secondary structure, which is discussed in detail later[4]. This ICK fold mirrors that of the 
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spider toxins and imparts very high structural rigidity to these peptide classes. The µO-conotoxins 
inhibit activation of NaV current through voltage sensor trapping of the NaV channel in its resting 
state[263]. Peptides of this class can block both TTXs current and the NaV1.8 TTXr current by binding 
to the C-terminal section of the pore loop in DIII in a mechanism different to TTX[262]. Although the 
δ-conotoxins also act as gating modifiers, they exhibit a much different pharmacologic profile through 
trapping the voltage sensor in the activated state, resulting in inhibition of inactivation and channel 
hyperexcitability[279, 347]. The mechanism of action is very similar to α-scorpion toxins, with both 
toxin classes trapping the DIVS4 voltage sensor in an inward, more depolarized position. Research into 
this mechanism of action has demonstrated that δ-conotoxins bind to a region slightly overlapping from 
site 3 on the S3-S4 loop of DIV, which has been defined as the NaV neurotoxin receptor site 6[279]. An 
interesting feature of the δ-conotoxins that has not yet been addressed or explored is the reoccurrence 
of hydroxyprolines, an Arg on or around position 14, and C-terminal amidation; all of which are 
structural features seen repeated in the µ-conotoxin family of NaV channel inhibitors. These close 
structural characteristics could help predict binding regions of the δ-conotoxins or could simply be a 
vestigial feature evolutionary divergence. These questions remain to be answered and could serve as 
critical pieces of information for ligand design. 
 
To date, one conotoxin – the N-type calcium channel blocker MVIIA isolated from C. magus – has 
been approved in the US as an antinociceptive, marketed by Elan Pharmaceuticals under the name 
Prialt[328]. There are a handful of other conopeptides currently undergoing pre-clinical or clinical trials 
for treatment of various neuropathic disorders but presently these don’t include any NaV channel 
inhibitors[285, 348].  
 
4.4 Spider venom 
There are over 43,000 spider species within 110 families currently catalogued, with many more 
expected to be discovered[349]. Mass spectrometry analysis of the composition of different spider 
venoms determined the presence of between 500 and 1000 peptide components per sample, suggesting 
a potentially enormous total pool of bioactive peptides to be explored[350, 351]. Recently, in an 
attempt to categorize the ever increasing number of new peptides discovered, groups of known NaV-
active spider venom peptides (NaSpTx) have been assigned to twelve families based solely on 
sequence homology[239]. Those NaSpTxs specifically affecting mammalian NaV channels average 
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between 31 to 41 amino acids in length and are cross-linked with 3 or 4 disulfide bonds, which impart a 
secondary structure commonly exhibiting an ICK motif[352].  Rational nomenclature for spider 
venoms has also been adopted – loosely based on the conventions of conotoxin naming – where a 
Greek symbol denotes activity and is followed by a letter/number code describing the source organism 
and relation to similar toxins[353]. This nomenclature is extensively used throughout this thesis. 
 
Although many of these spider venom toxins demonstrate activity across ion channel targets, with a 
significant portion purely selective for insect receptors, only those active on mammalian NaV channels 
are of concern to this thesis. These families of toxins have already been discussed in detail regarding 
their classification and how they relate to NaV channel function through neurotoxin site-specific 
binding and the mechanism of voltage sensor trapping. 
 
5. Project summary 
Modulation of NaV channels has been applied as a therapeutic strategy for many years towards roles in 
local anesthesia, cardiac arrhythmia and epilepsy. Clinically available NaV channel modulators have 
also increasingly found applications in conditions ranging from neuropathic pain, migraine, bipolar 
disorder and Alzheimer’s disease to myotonia[354, 355]. In addition, new off-label applications for 
NaV channel modulators are being investigated for neurodegenerative disorders such as Parkinson’s 
disease and multiple sclerosis, neuropsychiatric disorders such as bulimia nervosa and obsessive 
compulsive disorder, and cancers[354-357].  
 
The usefulness of the limited number of clinically available small molecule compounds in such a 
diverse range of therapeutic areas most likely arises from their relatively poor ion channel and subtype 
selectivity, giving these molecules functional diversity. However, this same lack of selectivity 
contributes to the significant toxicity and side-effect profiles seen for these compounds, as well as their 
often narrow therapeutic index. The poor subtype selectivity of many these compounds is offset at least 
partially by their state-dependence, or preferential binding to either the open- or inactivated-state of its 
target receptor[358]. Thus, even poorly subtype-selective NaV channel inhibitors are able to somewhat 
selectively modulate excitability in hyperexcitable states and tissues.  
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As our understanding of the biology of NaV channels and their affiliations with disease states expands, 
so does their therapeutic potential for treating these various diseases through the development of 
selective NaV modulators. The identification of novel, subtype-selective NaV modulators would 
represent significant therapeutic advance in this regard. Unfortunately, little progress has been made 
towards this goal in recent years. This can be partially attributed to the high sequence homology of the 
different NaV subtypes, particularly in the region constituting the local anesthetic binding site in the 
channel pore. For the last few decades, the focus of drug research has been primarily focused on small 
molecules, which tend to occupy a smaller chemical space and lend themselves to receptor cross-
talk[359]. However, an increasing number of subtype-selective peptidic NaV modulators are being 
isolated and characterized from natural venom sources[239, 348]. 
 
This thesis attempts to describe research into the design and development of new methods to identify 
NaV modulators from venom peptides using whole-cell high-throughput technology and 
electrophysiology. Then, using information available from known peptides of related class, attempt to 
study variations of structure of a single peptide through mutagenesis to determine how it relates to 
function. This will benefit towards gaining a better understanding of NaV channel modulation by 
peptidic ligands, as well as potentially improve upon a natural ligand through guided mutagensis.  
 
 
The primary aims of the thesis were as follows: 
 
1) Develop a high throughput, cell-based assay for the screening of crude venoms for the purpose of 
isolating NaV channel modulators. 
 
2) Develop recombinant methods of production for venom peptides. 
 
2) Characterize the function and structure of TRTX-Pre1a, a NaV channel modulator isolated from 
spider venom with a unique pharmacologic profile. 
 
3) Develop mutants of Pre1a, targeting specific residues determined as important through comparative 
sequence homology to known, related peptides. 
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4) Test the function of these mutants to determine if they enhance NaV isoform selectivity or function, 
then solve the solution structure of a single mutant to compare physical attributes with functional 
changes. 
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Chapter II: Development of whole-cell microtiter plate assays to discover 
NaV modulating venom peptides 
 
1. Introduction 
As mentioned previously, voltage-gated sodium (NaV) channels are integral membrane proteins that 
play an essential role in the initiation and propagation of action potentials in excitable cells, making 
them excellent therapeutic targets for a variety of neuropathies involving conductance[6]. The study of 
NaV channel structure and function has been aided by using peptide components isolated from paralytic 
venoms from a variety of organisms, including cone snails and spiders. The individual venom peptides 
possess unique selectivity and affinity profiles that allow researchers to explore novel ligand binding 
domains and different modes of modulation, such as voltage sensor trapping. Less than 0.1% of 
naturally produced venom peptides are thought to have been discovered over the past few decades[3]. 
This estimate doesn’t even take into account the venomous organisms yet to be discovered or studied. 
 
A number of discovery techniques have evolved over the years to keep up with the ever-growing 
number of naturally produced bioactive compounds. One of those techniques heavily employed is 
assay-guided fractionation, which is the systematic isolation and characterization of bioactives from the 
mixture of peptides, proteins, small molecules, and salts present in venoms. The basic requirements of 
a functional assay include high sensitivity, accuracy, and reproducibility. This is especially important 
when dealing with unknown mixtures of crude venoms or partially purified fractions. A growing range 
of potential methods for functional assay are becoming more widely available. However, effective 
initial screens are still needed that are general enough discover an activity of interest (e.g., modulation 
of excitability) yet specific enough to discern a functional target (e.g., NaV channels). 
 
The purpose of this chapter was to develop a cell-based assay to search for NaV channel modulators, 
capable of meeting all the basic requirements of a functional assay, including having enough capacity 
and throughput to handle large volumes of crude or fractionated venoms over short time scales. The 
first aim was to identify potential cell lines demonstrating expression of neuronal NaV isoforms. After 
choosing three cell lines, they were carried forward for testing with two functional platforms using 
either absorbance or fluorescence detection, each measuring a different end-point demonstrating NaV 
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channel function. Each assay shared a common theme of requiring an agonist control to elicit a NaV 
response, which in turn could either be potentiated or inhibited upon addition to an unknown NaV 
modulator within crude venom. The absorbance assay was based on an end-point of cell survival 
measured with the color changing metabolite, MTT. Reversal of induced cell death through inhibition 
of INa resulted in “rescuing” or reversal of Na+ toxicity. The fluorescence based assays incorporated 
two fluorescent dyes: Fluo4 measured ICa as a product of NaV depolarization while the other measured 
direct changed to membrane depolarization. The details of all assays are discussed at the end of the 
chapter. 
 
Using assay methods developed herein, a previously unisolated δ-conotoxin was discovered, purified 
and sequenced.  
 
2. Methods 
 
2.1 Reagents 
Veratridine was obtained from Ascent Scientific (Bristol, UK), tetrodotoxin (TTX) was from Enzo Life 
Sciences (Farmingdale, NY, USA). P-CTX-1 (Pacific ciguatoxin 1) was isolated and purified by 
members of the Lewis laboratory[360]. All other reagents including MTT, unless otherwise stated, 
were obtained from Sigma–Aldrich (Castle Hill, NSW, Australia). MTT stock solutions were made by 
dissolving the powder in PBS to 5 mg/ml. TTX, veratridine, deltamethrin, P-CTX-1, and all peptide 
toxins were routinely diluted in 0.3–0.5% bovine serum albumin (BSA) solution to avoid adsorption to 
plastic surfaces. 
 
Dulbecco’s Modified Eagle Medium (DMEM), RPMI Medium, Ham’s F12 Medium, phosphate 
buffered saline (PBS), sodium pyruvate, and 0.25% trypsin/EDTA were obtained from Invitrogen 
(Australia). Fetal Bovine Serum (FBS) was obtained from Invivo Medical (NSW, Aus). 
 
42 
 
2.2 Cell culture 
SH-SY5Y human neuroblastoma cells were a kind gift from Victor Diaz (Max Planck Institute for 
Experimental Medicine, Goettingen, Germany). Cells were routinely maintained in RPMI medium 
(Invitrogen, 22400) supplemented with 15% FBS and L-glutamine.  
 
The Neuro2a rat neuroblastoma (ATCC-CCL131), F11 hybridoma of mouse neuroblastoma (N18TG-
2) with embryonic rat DRG (ATCC-HB11761), NG108 hybridoma of a mouse neuroblastoma with a 
rat glioma (HB12317), and PC12 rat pheochromocytoma (ATCC-CRL1721) cell lines  were obtained 
from the American Type Culture Collection (USA). Neuro2a and Ng108 cells were maintained in 
DMEM (Invitrogen, 11995) supplemented with 10% FBS. PC12 cells were maintained in Ham’s F12 
(Invitrogen, 11765) supplemented with 15% horse serum, 2.5% FBS, and 20 mM HEPES. F11 cells 
were maintained in Ham’s F12 supplemented with 10% FBS and HAT.  
 
The 50B11 rat immortalized DRG was a kind gift from Dr. Ahmet Höke (School of Medicine, Johns 
Hopkins University, MD, USA). Cell were routinely maintained in DMEM/F12 medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% FBS, 0.5 mM L-Glutamine and 1x B-27 supplement 
(Invitrogen).  
 
The ND7/23 hybridoma of mouse neuroblastoma (N18TG-2) with rat DRG and the ND7/23-rNaV1.8 
stably transfected cell line were kindly donated by Dr. Tony Priestley (Department of Chemical 
Research, Schering-Plough Research Institute, NJ, USA) [361]. Cells were routinely maintained in 
DMEM medium supplemented with 10% FBS. ND7/23-rNaV1.8 cells were additionally cultured with 
200 µg/mL Geneticin-G418 to maintain selection (Invitrogen).  
 
All mammalian cell lines were passaged every 3-5 days at between 70-90% confluency using 0.25% 
trypsin/EDTA. Cells were incubated in a temperature, humidity, and CO2 controlled incubator set to 
37°C with 5% CO2. 
 
2.3 Semi-quantitative PCR methods 
Primer pairs were designed with PrimerX (http://www.bioinformatics.org) using NaV sequences 
acquired through BLAST (http://blast.ncbi.nlm.nih.gov) (Table 2). Oligos were ordered through Sigma 
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(Australia). Cells were cultured as previously described. Total RNA was isolated from cells using the 
Qiagen RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions with on-column 
DNA digestion. The Omniscript Reverse Transcription Kit (Qiagen) was used to reverse transcribe 1 
μg of RNA, as determined by spectrophotometric absorbance at 260 nm, and 20 ng of the resulting 
cDNA was amplified using the Platinum® Pfx kit (Invitrogen). PCR reactions additionally contained 
final concentrations of 2× amplification buffer, 0.3 mM dNTP, 1 mM MgCl2, 0.4 μM primers and 1 U 
Pfx polymerase in a volume of 50 μl and were amplified under the following conditions: 94°C for 5 
min, 30 cycles of 94 for 15 s, 60-64 for 30 s, 68 for 1 min and a final extension at 68 for 10 min. 
Rodent NaV primers were designed using Primer BLAST (Table 2). 100 ng of plasmid encoding for 
each NaV1.1-1.8 verified amplification of the correct products for each subtype. All reaction products 
were analyzed on 2% agarose gels. 
 
Table 2: Primer sets for murine NaV channels 
 
Target Accession 
number
Primer pair sequence Tm ° GC% PCR 
product (bp)
Location 
(bp)
5'-TCCTCAGAAGGAAGCACAGT-3' 52.35 50.00%
5'-TCTGCACACAGCCTTCAGTG-3' 54.75 55.00%
5'-GCCTGATTTGGGACTGTTGT-3' 52.54 50.00%
5'-CCAAGCCGAGTTCCATTAAA-3' 50.26 45.00%
5'-GATTCGCGGGACGTCAAACT-3' 55.33 55.00%
5'-GCAGAAACTCCCCAGTGAAG-3' 52.7 55.00%
5'-GCCTGAGGATATCAAGAAGC-3' 49.96 50.00%
5'-TCAGAGTAGCCCAGCCAGTT-3' 54.57 55.00%
5'-ACAGGAATCCCAAGTTGTGT-3' 51.02 45.00%
5'-ATCAGGAAGTCCAGCCAGCA-3' 55.22 55.00%
5'-GGAGTGTCACCCCTACTGGA-3' 54.29 60.00%
5'-TCAGAAGCAAGGCCAGGAAT-3' 53.34 50.00%
5'-CAACGCACTCATAGGAGCAA-3' 52.55 50.00%
5'-GAATGTTGCAACTTGAAGCA-3' 49.71 40.00%
5'-CTGGCTGGACTTCAGTGTCA-3' 53.77 55.00%
5'-GGAACACACTGCCGTGGCTA-3' 56.91 60.00%
NaV1.8 NM_017247.1 944 605-1548
NaV1.6 NM_019266.2 734 2361-3094
NaV1.7 NM_133289.1 283 3927-4209
NaV1.4 NM_013178.1 525 3266-3790
NaV1.5 NM_013125.2 606 3431- 4036
NaV1.2 NM_012647.1 315 2261-2575
NaV1.3 NM_013119.1 442 4548-4989
NaV1.1 NM_030875.1 112 3702- 3813
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2.4 Specimen collection 
Conus spp. were collected from various locations throughout the Great Barrier Reef on the East coast 
of Australia and on the New Ireland Island group, Papua New Guinea [319]. C. magus was collected 
from intertidal zones on Lizard Island, Australia. 
 
Specimens were transported to the lab either on ice to be frozen whole at -80°C for dissection or kept 
alive in seawater for milking and genomic analysis. 
 
2.5 Venom extraction 
Two separate rounds of venom extraction were each performed on single species of C. magus. Crude 
venom duct contents were extracted with 30% acetonitrile/water acidified with 0.1% trifluoroacetic 
acid and centrifuged at 13,000 rpm for 20 minutes. The pellets were washed several times and re-
centrifuged under identical conditions. Soluble material was lyophilized and stored at -20°C prior to 
use. Crude venom pellets were stored separately at -20°C. After venom was removed from the duct 
sheath manually the remaining duct and bulb were stored at -80°C in RNAlater (Qiagen). 
 
2.6 Reversed phase high-performance liquid chromatography (rpHPLC) 
rpHPLC was performed on 200 μg of a 500 μg crude C. magus venom sample using a Dionex Ultimate 
3000 instrument and fitted with a Vydac C18 column (218TP54; 4.6 × 250 mm; 5 μm particle 
diameter; 300 Å pore size) with automated fraction collection. Peptides were eluted with a flow rate of 
0.7 mL/min using a 1.5% B/min linear gradient buffer exchange over 60 min using buffers A (H20, 
0.1% FA) and B (90% ACN, 10% H20, 0.1% FA). Further peptide purification was carried out by 
second rpHPLC run of fractions under equivalent conditions with slight variations to the gradient. 
rpHPLC fractions were collected at 1 min intervals by a 96-well autosampler. After purification, all 
samples were lyophilized and resuspended in 30% acetonitrile/water for storage at -20°C and further 
analysis. 
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2.7 Mass and sequence determination 
Toxin masses were confirmed by matrix-assisted laser desorption ionization–time-of-flight mass 
spectrometry (MALDI-TOF MS) using a model 4700 Proteomics Bioanalyser (Applied Biosystems, 
Foster City, CA). rpHPLC fractions were mixed [1:1 (v/v)] with α-cyano-4-hydroxy-cinnamic acid 
matrix (7.5 mg/ml in 70/30 acetonitrile/H2O) and MALDI-TOF spectra were collected in positive 
reflector mode. The mass range was set to m/z 800-8000 with a focus mass of 4500 Da. Shots were 
collected using manual acquisition control and close external calibration. The calculated molecular 
weights were obtained using Data Explorer (Applied Biosystems, CA). All masses given are for the 
monoisotopic M+H+ ions unless otherwise stated.  
 
The sequence of purified peptide was determined by Edman degradation at the Australian Proteome 
Research Facility. In brief, the peptide was dissolved in urea (4 M) in ammonium bicarbonate (50 mM) 
and reduced with dithiothreitol (100 mM) at 56 °C for 1 h under argon. The sample was then alkylated 
using acrylamide (220 mM) for 0.5 h in the dark. The reaction was quenched by the addition of excess 
dithiothreitol. After desalting by rpHPLC, the collected fraction was loaded onto pre-cycled bioprene 
discs and subjected to 35 cycles of Edman N-terminal sequencing using an Applied Biosystems 494 
Procise Protein Sequencing System. 
 
2.8 Na+ induced toxicity and measurement of survival by MTT 
Neuro2a and ND7/23 cells were plated at a density of 30-50 x 103 cells/well on 96-well clear imaging 
plates (Corning) 24 h prior to assay. SH-SY5Y cells were plated at a density of 120 x 103 cells/well on 
96-well black-walled imaging plates (Corning) 48 h prior to assay. All cells plated in 90 µl standard 
growth media in 96-well flat bottom microtiter plates (Corning). Cells were treated after 24 h 
incubation to allow settling, attachment, and the start of normal cell division. Ouabain, veratridine, and 
control toxins were all added at this step with no pre-incubation. Unlike the FLIPR assay, which 
measures fast responses to compound addition, the long compound incubation times inherent to cell 
survival assays meant that pre-incubation of a control agonist/antagonist would not likely influence the 
end point measurement of cell survival in a meaningful way, as the lethal effect of Na+ toxicity takes 
up to 24 h to observe. Ouabain and veratridine were diluted in unsupplemented DMEM to a single 10x 
stock. Samples to be tested, including all positive and negative controls, were diluted to a 5x working 
46 
 
concentration in unsupplemented DMEM. In the absence of control toxins, unsupplemented DMEM 
with appropriate buffer controls was added.  
 
To determine the maximum survival for each experiment, 60 µl of unsupplemented DMEM was added 
to a minimum of 4 wells per plate. To determine a maximal effect of control compounds on 
survivability, 30 µl of unsupplemented DMEM was added along with ouabain and veratridine to a 
minimum of 4 wells per plate. 
 
Treated microtiter plates were incubated with reagents for 48 h at 37°C with 5% CO2. After incubation, 
media was removed from microtiter plates and 60 µl of MTT was added to each well. Prior to addition, 
MTT was diluted 1:6 in unsupplemented DMEM. Plates were then incubated for 30 min at 37°C with 
5% CO2. After 30 min incubation, MTT solution was gently removed from each well and cells were 
solubilized with 60 µl DMSO. Absorbance at 580 nm was measured by the PerkinElmer Envision 2104 
microtiter plate reader. 
 
2.9 Fluorescence measurement of membrane potential changes  
To assess changes in membrane potential, SH-SY5Y cells were loaded with the red membrane 
potential dye (Molecular Devices, Sunnyvale, CA) according to the manufacturer’s instructions. In 
brief, red membrane potential dye (proprietary composition) was reconstituted with a volume of 
physiological salt solution (PSS; composition in mM: NaCl 140, glucose 11.5, KCl 5.9, MgCl2 1.4, 
NaH2PO4 1.2, NaHCO3 5, CaCl2 1.8, HEPES 10) as specified in the manufacturer’s instructions and 
after a wash with PSS, cells were incubated with 100 μl of the membrane potential solution at 37˚C for 
30 min. The cells were then transferred to the FLIPRTETRA fluorescent plate reader and changes in 
fluorescence (excitation 510–545 nm; emission 565–625 nm) in response to addition of agonists was 
measured every second for 300 s. 
 
2.10 Fluorescence measurement of calcium responses  
SH-SY5Y cells were loaded with the fluorescent calcium dye Fluo-4 acetoxymethyl ester (AM) by 
incubating the cells in PSS containing 0.3% bovine serum albumin and 4 mM Fluo-4-AM (Invitrogen) 
for 30 min at 37°C. To remove extracellular dye and facilitate dye hydrolysis, cells were washed with 
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PSS for 5–15 min prior to loading of plates into the FLIPRTETRA+ (Molecular Devices, Sunnyvale, CA) 
fluorescent plate reader. Fluorescence (excitation 470–495 nm; emission 515–575 nm) was measured 
using a cooled charge-coupled device (CCD) camera with camera gain and excitation intensity adjusted 
for each plate to yield an average baseline fluorescence value of 1000 AFU. After 10 baseline reads, 
buffer or control antagonists were added and the fluorescence response was measured every second for 
300 reads, followed by addition of agonists and fluorescence measurements every second for a further 
300 s. Raw fluorescence readings were converted to response over baseline using the analysis tool of 
Screenworks 3.1.1.4 (Molecular Devices) and were expressed relative to the maximum increase in 
fluorescence of control responses. 
2.11 Z’ factor determination of assay robustness 
The Z’ factor, a quantitative representation of assay quality, was determined as previously 
described[362], with 48 replicates of a negative control (PSS) and 48 replicates of positive controls (50 
μM veratridine) per plate. Mean and standard deviation for positive and negative controls were 
determined using GraphPad Prism v4.0 (San Diego, California) and the Z’ factor for each plate 
determined according to the following equation: 
 
Z’ = 1 – ((3SDpositive + 3SDnegative)/(meanpositive – meannegative)) 
 
2.12 Data analysis  
Unless otherwise stated, all data are expressed as the mean ± standard error of the mean (SEM) 
determined from at least n = 3 experimental replicates, with 2-4 replicates per plate. To establish 
concentration-response curves, responses after addition of compounds were plotted against agonist 
concentration and a 4-parameter Hill equation with variable Hill slope or a two-site model was fitted to 
the data using GraphPad Prism v4.0. Potency of agonists and antagonists are reported as the mean  
SEM of 3-4 separate experiments. Statistical significance was determined using an ANOVA analysis 
with statistical significance defined as p < 0.05 unless otherwise stated. 
 
Unless otherwise stated, all data are expressed as the mean ± standard error of the mean (SEM) 
determined from at least n = 3experimental replicates, with 2-4 replicates per plate. Positive absorbance 
as compared to the treated control is attributed to cell survival, or the ability of a NaV channel inhibitor 
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to reverse the induced toxic effect. The percent recovery from ouabain and veratridine (O/V) treatment 
was calculated by the following equation: 
 
 % Recovery =    (avg. test wells treated with O/V) - (avg. cont. wells treated with O/V) 
         (avg. untreated cont. wells) - (avg. cont. wells treated with O/V) 
 
Additive cell death as compared to the control is indicative of a possible NaV channel agonist and is 
measured by a decrease in absorbance. This was calculated by the following equation: 
 
 % Inhibition = (avg. test wells treated with O/V) - (avg. cont. wells treated with O/V) 
  (avg. cont. wells treated w/ O/V) 
 
All above calculations including standard error from the mean (SEM) were performed using GraphPad 
Prism 4.0. To establish concentration-response curves, responses after addition of compounds were 
plotted against the log of sample concentrations and a least squares fit 4-parameter Hill equation with 
variable Hill slope fit to the data using GraphPad Prism 4.0. Statistical significance was determined 
using an ANOVA analysis with statistical significance defined as p < 0.05 unless otherwise stated. 
 
3. Results 
 
3.1 Expression profiles of commonly used neuronal cell lines 
Seven neuronal derived cell lines were characterized by an initial PCR screen using primers designed 
to specific regions of the rat NaV isoform of interest. SH-SY5Y was also tested along with this pool of 
cells with the knowledge that it is a human derived cell line and would need specific primers 
developed, which was completed and published in a collaborative follow-up project[363]. 
 
PCR results suggested prevalent expression of NaV1.2 in all cell lines tested, with only a slight band 
apparent for 50B11 cells (Figure 6). NaV1.6 and NaV1.7 demonstrated a similar expression profile to 
each other, with bands for both isoforms apparent in the same cell lines. However, there did not seem 
to be correlation between cell line origin and expression pattern. There was a surprising lack of NaV1.8 
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expression, which is found prevalently in 
DRG neurons. The centrally expressed 
NaV1.1, peripherally expressed NaV1.3, and 
skeletal muscle isoform NaV1.4 were also 
absent in all experiments. NaV1.5 appeared 
to be expressed in three cell lines. All results 
were replicated with at least three separate 
experiments. However, the PCR was not 
performed in a quantitative manner, so not 
further conclusions on relative expression or 
receptor density could be made. 
 
3.2 MTT Results for ND7/23-NaV1.8 
The MTT survival assay platform was tested 
on the stably transfected ND7/23-rNaV1.8 
cell line. Veratridine does not affect TTXr 
NaV channels, which includes NaV1.8. 
However, the pyrethroid deltamethrin has 
been shown to inhibit inactivation of NaV1.8, 
causing sustained activation similar to 
veratridine [364, 365]. Therefore, 
deltamethrin was used in place of veratridine 
in the presence of 1 µM TTX, to block the contribution of TTXs sodium channels[366, 367].  
 
Deltamethrin showed no toxicity at concentrations tested up to 30 μM (Figure 7).  The LD50 of 
deltamethrin in the presence of 300 µM ouabain was 4.8 ± 2.8 µM, with a 100-fold drop in potency in 
the presence of 300 nM ouabain, suggesting a Na+ induced toxicity (Figure 7). The addition of 100 nM 
TTX did not affect the results of the deltamethrin induced toxicity in the presence of 300 µM ouabain ( 
Figure 8). This confirms TTXs NaV channels are not contributing to the observed toxic effect. Non-
transfected ND7/23 cells were tested under similar conditions and were unaffected by treatment up to 
 
 
Figure 6: Agarose gel of NaV channel PCR. 
Control lanes use 1 ng of pcDNA3.1 vector 
containing the NaV gene of interest. No NaV1.7 
control vector was available at the time of the 
experiment. 
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30 µM deltamethrin, suggesting that the NaV1.8 channel is playing a significant role in cell death from 
Na+ toxicity (Figure 9). 
 
P-CTX1 was also tested as an agonist in place of deltamethrin on the ND7/23-rNaV1.8 cell line in the 
presence of TTX (Figure 10). Not only was an attempt made to look at different agonist mechanisms on 
cell toxicity, but results suggest P-CTX1 may activate NaV1.8[368]. However, our results suggested 
that toxicity increased with higher levels of ouabain in combination with P-CTX1 without a 
concentration dependant effect of P-CTX1, which suggested a non-NaV induced mechanism of toxicity 
as well as no observable effect for NaV1.8 induced toxicity.   
 
 
Figure 7: Deltamethrin concentration 
response on ND7/23-rNaV1.8 cell line. 
Deltamethrin alone (black) did not induce 
lethality. Deltamethrin in the presence of 300 
µM ouabain (○) induced lethality in a 
concentration dependant manner. Reducing 
ouabain to 300 nM (●) resulted in a 100-fold 
shift to the right in deltamethrin toxicity. 
 
Figure 8: Concentration response of 
deltamethrin on ND7/23-rNaV1.8 with 
TTX. 
300µM ouabain is present. There is a 
lack of contribution to TTXs NaV 
channels to deltamethrin induced 
lethality. 
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In order to test for reversal of induced toxicity, concentrations of 300 µM ouabain and 30 µM 
deltamethrin were chosen. In order to recover the cells from Na+ induced toxicity, two NaV1.8 
inhibitors were used at pharmacologically relevant concentrations. Lidocaine is a use-dependant 
inhibitor of NaV1.8 and works by shifting the steady-state activation toward more depolarized 
potentials[369]. The same ND7/23-rNaV1.8 cell line was previously used to determine the use 
dependence of lidocaine, further justifying its use as a control inhibitor[370]. Additionally, the µO 
conotoxin MrVIB has been shown to inhibit NaV1.8 current with IC50 values of 100 nM[371]. This 
conopeptide represents a major and consistent component of C. marmoreus venom, with a distinctive 
peak that elutes consistently and yields an identifiable mass signature via MALDI MS. MrVIB was 
discovered through use of a bioassay, exhibiting the most potent NaV modulating activity apparent 
within the crude venom of C. marmoreus[372, 373]. Due to the extreme hydrophobicity of MrVIB, up 
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Figure 9: Untransfected ND7/23 cells. 
Tested under equivalent conditions to 
ND7/23-rNaV1.8, these cells demonstrated 
no significant effect on survival, suggesting 
NaV1.8 is the sole NaV contributor to the 
observed lethality. 
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Figure 10: Concentration response of P-
CTX on ND7/23-rNaV1.8 cells. 
P-CTX in combination with ouabain 
resulted in no measurable lethality, 
suggesting this molecule does not affect 
NaV1.8 at the conditions used. Dotted line 
represents the average absorbance of 
untreated controls. 
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to 80% of the expected mass is lost upon purification from crude venom. As no synthetic material and 
only a small amount of crude venom was available at the time of this experiment, it was decided to use 
a known active concentration of the whole venom. Therefore, 5 µg of crude C. marmoreus venom was 
used to test inhibition of NaV1.8 in the presence of 100 nM TTX (Figure 11). 
 
Neither lidocaine nor C. marmoreus crude venom resulted in cell death on their own (Figure 11). As 
lidocaine was incubated for 48 h, it is unlikely that the lack of effect seen was due to slow onset. Use-
dependence could be a factor in limiting activity. However, evidence has demonstrated in a similar 
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Figure 11: Reversal of induced Na+ tox on ND7/23-rNaV1.8 cells. 
Control represents maximum survival for untreated (light) and treated cells (dark). 
The addition of lidocaine at 1 µM and 1 mM  does not affect cell survival when 
added alone (light). However, lidocaine does not result in a reversal of induced Na+ 
toxicity (dark). The addition of 5 µg of C. marmoreus crude venom containing 
MrVIB also does not result in reversal of induced Na+ toxicity. 
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assay that compounds bind to the NaV channel in a manner comparable to the inactivated state, which 
exhibits an open conformation at the pore[374]. As lidocaine preferentially binds to a depolarized NaV 
channel (closer to the open state)[375, 376], then is can be inferred that the use-dependence of 
lidocaine was not a factor in its lack of activity for this assay. 
 
There was also no recovery from induced toxicity by treatment with either lidocaine or MrVIB, both 
known to block NaV1.8 channels (Figure 11). The question remains why there was no recovery from 
agonist induced toxicity by known NaV1.8 blockers. It is possible that deltamethrin binds competitively 
and preferentially versus both lidocaine and MrVIB. The results could also be attributed to off target 
effects, as deltamethrin and lidocaine are non-selective ligands, as will be discussed.  
 
3.3 MTT results for Neuro2a and SH-SY5Y 
The Neuro2a rat neuroblastoma cell line was chosen as a model for this assay due to its successful use 
on a similar assay platform[377]. Basic PCR analysis also suggested expression of NaV1.2, NaV1.6 and 
NaV1.7, of which NaV1.7 is currently a pursued target for the treatment of neuropathic pain.  
 
Methods described previously incorporating both ouabain and veratridine were used to assess viability 
and responsiveness to the drug combination for Neuro2a cells. A concentration dependent lethality was 
observed with veratridine in the presence of ouabain at 100 µM and 300 µM (Figure 12). Although 
both concentrations of ouabain allowed a comparable veratridine IC50, 300 µM ouabain resulted in a 
decrease of cell survival by 50%. This in turn lowers the effective window by an equivalent amount.  
 
Concentrations of 100 µM veratridine and 100 µM ouabain were used to test the effect of the NaV 
channel inhibitor TTX on preventing induced Na+ toxicity. Recovery from induced Na+ toxicity was 
observed with 30 nM concentrations of TTX (Figure 13A). TTXs NaV channels exhibit an IC50 of 
around 10 nM[18]. To observe agonist synergy with control toxins, the concentration of veratridine was 
lowered to 30 µM in order to stimulate a lowered but measurable lethality. The NaV neurotoxin site 5 
agonist brevetoxin (PbTX1) was used as a positive NaV agonist control[378]. PbTX1 was tested on its 
own and induced no lethality up to 1 nM. However, this same concentration induced an apparent 
synergistic lethality when tested in combination with ouabain and veratridine, demonstrating 
synergistic agonist induction of Na+ toxicity (Figure 13B). 
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Figure 12: Concentration response of 
veratridine on Neuro2a cells. 
A concentration response of veratridine was 
tested over both 300 µM and 100 µM ouabain. 
Although both concentrations of ouabain allowed 
a similar IC50, 300 µM ouabain decreased cell 
survival by approximately 50%. 
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Figure 13: Neuro2a MTT assay validation. 
A) The addition of 30 nM TTX inhibits the lethal combination of 100 µM veratridine and 
100 µM ouabain. B) 1 nM PbTX does not affect cell survival on untreated cells. However, 
in combination with 30 µM veratridine and 100 µM ouabain, 1 nM PbTX decreased cell 
survival by an additional 20%, demonstrating a possible synergistic effect. 
Asterisk indicates significance as compared to ouabain and veratridine treated wells 
(p < 0.05). 
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The SH-SY5Y human neuroblastoma cell line was also chosen as a model for this assay because of the 
expression profile of NaV channels relevant to pain transmission as well as this cell lines human origin, 
which is important when screening for human therapeutic relevance. In depth analysis of this cell line 
was performed using human specific PCR primers, functional characterization, and 
immunohistochemistry and results were subsequently published[363].  
 
Assay conditions were described previously. Ouabain induced lethality at concentrations above 100 nM 
(Figure 15). However, lower concentrations of ouabain were not used as the effect on the Na+/K+-
ATPase reverses at low nM concentrations. A concentration dependent lethality was observed with 
veratridine in the presence of 300 nM ouabain (Figure 14).  
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Figure 14: Lethal concentration response 
of veratridine on SH-SY5Y cells. 
Response measure with addition of 300 nM 
ouabain. The LD50 for veratridine over a 
background of 300 nM ouabain was 3 ± 0.4 
µM; n = 3. 
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Figure 15: Lethal concentration response 
of ouabain on SH-SY5Y cells.  
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To test the reversal of the induced toxic effect of ouabain and veratridine, two NaV channel inhibitors 
were used at pharmacologically relevant concentrations (Figure 16). In the presence of 20 µM 
veratridine and 300 nM ouabain, cell survival decreased by approximately 80%. The addition of 10 
mM lidocaine or 1 µM TTX both inhibited the toxic effect by almost 50%, demonstrating the ability of 
this assay to detect NaV channel inhibitors. The MTT based assay using Neuro2a and SH-SY5Y has not 
been used to screen crude venom in a high throughput manner. However, this assay has the potential to 
serve as another screening platform to guide identification of novel peptides. 
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Figure 16: SH-SY5Y recovery from induce Na+ toxicity. 
Control represents maximum survival for untreated SH-SH5Y cells. 200 µM of 
veratridine with 300 nM ouabain resulted in a decrease in survival by approximately 
90% compared to control. The addition of 10 µM lidocaine or 1 µM TTX in combination 
with ouabain and veratridine resulted in inhibition of induced Na+ toxicity. 
Asterisks indicate significant recovery from ouabain/veratridine induced toxicity 
(p < 0.05) 
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3.4 FLIPR assay results and assay validation 
The Neuro2a, ND7/23, and SH-SY5Y immortalized cell lines adapted for the MTT assay format were 
tested for total agonist-induced fluorescent response with two fluorescent dyes: Fluo4 AM (Figure 
17A), which monitors Ca+ flux as an endpoint; and the Molecular Devices Membrane Potential Assay 
Kit (MP-kit) (Figure 17B), which measures ionic changes in a cells resting membrane potential. 1 mM 
veratridine was used as a control agonist for all experiments. Neuro2a cells did not yield a significant 
response upon addition of veratridine when loaded with Fluo4. However, these cells did result in a 
small but measurable response with the MP-kit, which was inhibited in the presence of 100 nM TTX. 
ND7/23 cells loaded both Fluo4 and the MP-kit and elicited a TTXs veratridine response, but with total 
responses lower than the positive response for Neuro2a. SH-SY5Y cells demonstrated an ability to load 
both Fluo4 and the Membrane Potential dye, as well as yield the largest total response of all cells tested 
to veratridine stimulation. The SH-SY5Y fluorescent response for the Membrane Potential dye was 
approximately half that of Fluo4. Overall, it was determined that SH-SY5Y cells yielded the greatest 
overall veratridine induced fluorescence response, which is directly applicable to the observable 
window of efficacy, or Z-score, for determining activity of unknowns. Veratridine was also able to 
elicit a concentration-dependent response from SH-SY5Y cells loaded with Fluo4 (Figure 18). This 
data resulted in SH-SY5Y cells being subjected to further, in depth characterization of NaV α- and β- 
subunits as well as validating this cell line for use in a FLIPR-based Fluo4 assay with a number of 
control compounds[363]. 
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Figure 17: Cell line comparison of veratridine response with two fluorescent dyes.  
Three cell lines were loaded with either A) Fluo4 or B) the Membrane Potential Kit. Maximal response 
was elicited with 1 mM veratridine. The presence of 100 nM TTX demonstrates a NaV mediated 
response. 
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Figure 18: Veratridine concentration response using SH-SY5Y cells loaded with Fluo4.  
Maximal response could be elicited with 1 mM veratridine. 
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3.5 Activity guided isolation of δ-MVIA 
A FLIPR screen of Conus crude venoms tested in duplicate was conducted using SH-SY5Y cells with 
Fluo4. The wells containing C. magus demonstrated both excitation and potentiation of the veratridine 
control response (Figure 19). Initial analysis of C. magus crude venom demonstrated concentration 
dependant agonist activity when tested against SH-SY5Y cells loaded with Fluo4 (Figure 20). 
Potentiation of the fluorescent response for both agonists controls, veratridine and ciguatoxin (P-
CTX1), was also observed. This response was inhibited with the addition of 1 µM TTX, demonstrating 
a NaV channel mediated response. 
 
 
 
 
Figure 19: FLIPR screen of Conus crude venoms. C. magus is outlined in black. 
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Figure 20: Concentration dependence of C. magus crude venom on SH-SY5Y 
cells. 
Measured on the FLIPR with Fluo4. Crude venom was added at the solid red arrow.  
The dotted arrow represents the 2nd addition of agonist control A) veratridine or B) 
P-CTX1.  
B) 
A) 
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The crude venom was subject to analytical rpHPLC with fractions collected by autosampler, 
lyophilized, and resuspended at an equivalent volume of 100 µL. 10% volume of each fraction was 
tested for activity after reconstitution in PSS (composition in mM: NaCl 140, glucose 11.5, KCl 5.9, 
MgCl2 1.4, NaH2PO4 1.2, NaHCO3 5, CaCl2 1.8, HEPES 10). Fractions were added as a primary 
addition to corresponding wells of a 96-well microtiter cell plate containing SH-SY5Y cells. The 
FLIPRTETRA assay was carried out as previously described. Late eluting fractions demonstrated activity 
along consecutive wells corresponding to minute 45-50 (Figure 21). The discrepancy of well number 
and time was caused by a noted 7 minute early startup of the fraction collector plus a standard one 
minute lag due to travel from the detector to the collector. The active fractions from wells 55 and 56 
were pooled, freeze dried, and resuspended in 30% B.  
 
 
Figure 21: Activity guided fractionation of C. magus crude.rpHPLC of C. magus crude venom with 
active peak highlighted. Insert shows FLIPR assay plate with active wells 53-57, corresponding to the 
marked HPLC peak. Bell-shaped response is suggestive of one active constituent across fractions.   
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Approximately 0.05% of the pooled 
active peak from the primary 
fractionation was loaded onto a MALDI 
plate with a 1:1 ratio of 5 mg/mL CHCA 
matrix to yield a single strong M+H+ 
peak of 3536.5, corresponding to a 
molecular weight of 3535.5 Da (Figure 
22). This mass did not match any known 
Conus peptides in public databases, 
including ConoServer[379]. The pooled 
sample was reduced and alkylated before 
being submitted for N-terminal Edman 
degradation (Australian Proteome 
Analysis Facility), which yielded the 
following sequence (Figure 23):  
 
 
 
 
Figure 23: δ-MVIA sequence.  
1) As isolated by cDNA analysis with predicted PTMs[380]. 2) Experimentally determined mass of δ-
MVIA, which matches sequence mass + predicted PTMs. O=hydroxyproline; *=C-terminal amidation 
 
 
The determined peptide sequence was found to be previously discovered through cDNA analysis[380]. 
The methods to isolate the cDNA sequence for δ-MVIA used specific primers to pre/pro-toxin regions 
designed for ω- and δ-conotoxins and named the resulting peptide for which the sequence encodes, δ-
MVIA. C-terminal amidation and a position 14-hydroxyproline were predicted post-translational 
1) DGCYNAGTFCGIRPGLCCSEFCFLWCITFVDS 3526.5
16  = hydroxylation of proline
-6  = 3 disulfide bonds
-1  = C-terminal amidation
2) DGCYNAGTFCGIROGLCCSEFCFLWCITFVDS* 3535.5
 
 
Figure 22: MALDI-TOF analysis of C. magus 
pooled fractions 55 and 56. 
A strong, dominant mass signature of M+H+ of 
3536.5 was detected. 
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modifications (PTMs) due to sequence homology to other known δ-conotoxins. Based on current 
nomenclature convention, the original discovery should have been named “m6a” to represent a gene-
based discovery. This work represents the first known isolation of the δ-MVIA peptide from venom. 
 
The previous discovery helped to explain the observed discrepancy between the molecular mass of the 
determined sequence versus the experimental results. The mass detected experimentally for native δ-
MVIA corresponded to an oxidized peptide sequence containing three disulfide bonds and the original 
prediction of two PTMs: C-terminal amidation and 14P hydroxyproline.  
 
4. Discussion 
 
4.1 Assay development 
In order to quickly and efficiently screen a large number of crude venoms for NaV activity, high-
throughput methods of detection are needed. However, the discovery process has been hindered by a 
lack of effective, high throughput assays sensitive enough to detect active molecules from crude 
venoms, but accessible enough for use outside of the biotech industry[381, 382]. Ideally, assays should 
display high sensitivity and specificity, high-throughput and information content, high robustness and 
flexibility as well as high physiological and ideally pathological relevance, all at a relative low 
cost[383]. The ability of cell based multi-well microtiter detection assays to be developed into high-
throughput methods is well characterized [384, 385]. Many neuronal mammalian cell lines express 
endogenous NaV channels equivalent to the tissue isolated, such as cortex or DRG. Endogenously 
expressed receptors have greater pharmacologic relevance due to their expression in a native system, 
containing necessary auxiliary subunits and expression cofactors/enzymes, as opposed to being 
transfected into a non-neuronal host-cell. A variety of cell-based functional assays have been employed 
to guide the identification and characterization of novel, subtype-selective NaV modulators. Two such 
assay platforms include fluorescence-based and survival endpoint assays and have been commonly 
used for screening a variety of receptor targets, including both voltage-gated and ligand-gated ion 
channels. 
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Fluorescence-based assays are widely used for high-throughput screening[386]. A high-throughput 
assay platform particularly well suited to the primary identification of novel drug leads is the FLIPRTetra 
(Molecular Devices). This sophisticated technology consists of a fluorescence detection platform in 
combination with advanced robotics which enable multiple user-defined compound addition protocols 
and simultaneous fluorescent readings from 96-, 384- or 1536-well plates[387]. The FLIPR was 
designed for high-throughput Ca2+ flux assays and is rightly the industry leader in this application. 
However, this has limited the availability of different excitation and emission wavelengths. Na+ dyes 
with fluorescence spectra similar to calcium dyes, such as CoroNa Green, Sodium Green, or more 
recently Asante NAtrium, are commercially available. However, most of the single wavelength Na+ 
dyes amenable to high throughput FLIPR assays are relatively weakly fluorescent, a problem that is 
further compounded by the relatively shallow Na+ gradient that exists across cell membranes. The 
concentration difference of intracellular versus extracellular Na+ is roughly 10 fold, whereas the 
difference in Ca2+ is over 30 000 fold[388]. This results in a generally poor signal to noise ratio for 
fluorescent measurement of the movement of Na+ ions and makes these Na+ dyes poorly suited for drug 
discovery of NaV modulators.  
 
In contrast, membrane potential dyes measure changes in the electrical potential of the membrane, with 
significantly improved sensitivity to Na+ specific dyes[383, 389, 390]. Although this provides some 
functional and indirect kinetic data, the steady-state changes that are measured are neither specific nor 
precise enough for detecting compounds that modulate state-dependent NaV function[383, 390-392]. 
Experimental evidence has suggested that the MP dye, when used in combination with veratridine as a 
control agonist, correlates well with the inactivated state binding constant, obtained through 
electrophysiological experiments[374]. This suggests that the assay measures a single physiological 
state of NaV channels and potentially would not differentiate the state dependence of a compound. In 
addition, membrane potential dyes are particularly prone to artifacts arising from dye-compound 
interactions as well as non-specific effects of compounds on cell viability and membrane integrity and 
require specialized filter sets[383, 390]. 
 
Another assay platform that has been less widely used is based off a standard colorimetric cytotoxicity 
assay. Sustained, persistent INa leads to sufficiently high intracellular Na+ concentrations and is toxic to 
many cells. This principle is adapted for cytotoxicity assays, which measure cell survival after 
activation of NaV, usually through incorporation of dyes that are metabolically converted to 
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colorimetric end-products, such as the case with MTT or XTT[377, 393]. Exposure of cells to NaV 
activators – such as veratridine – causes increased INa and subsequent cell death, which can be reversed 
through NaV inhibitors[393]. These assays frequently require the need to incorporate ouabain, a potent 
cardiac glycoside that blocks the action of the Na+/K+-ATPase, shutting down the Na+ efflux pathway 
and aiding in accumulating toxic levels of [Na+]i to increase the signal window[393]. Moderate 
throughput can be achieved with these assays. They are also relatively inexpensive, both in regards to 
equipment needed (absorbance UV plate reader) and total reagent costs.  
 
A major drawback to survival endpoint assays is the requirement of both NaV agonists and ouabain for 
effective cell death to occur. The lack of selective agonists limits the use of this assay for primary 
screening, unless a heterologously expressing single-channel cell line is used. Using two control 
compounds may also complicate the interpretation of results, especially when testing crude venoms, as 
the action may be the result of inhibiting either receptor. This assay also provides no information on 
kinetics or state dependence of inhibition as channel activity is not directly measured. If this assay is 
adapted for agonist detection through a synergistic response with the control, false positives would be 
expected frequently, as inhibition of growth or proliferation would yield an equivalent result to 
cytotoxocity. Lastly, general toxicity – even minor – would mask potential reversal of INa induced 
toxicity through NaV inhibition, decreasing potential hits. The major drawback for fluorescence-based 
assays is that NaV channel gating modifiers, such as veratridine, deltamethrin or batrachotoxin, are 
required to elicit NaV responses in absence of electrical stimulation[389]. However, compared to the 
two compounds necessary for the cytotoxicity assay, this is an improvement. Kinetics and state 
dependence are also not available, as the fluorescent measurements are of downstream effects of NaV 
regulation. It has also been suggested that fluorescence-based assays – while providing the highest 
throughput by far – may be biased towards detection of pore blockers and results using these 
technologies will need to be interpreted carefully[394]. However, with these negatives addressed, the 
assays used are for general purpose primary discovery screening of crude venoms and many of these 
issues, once understood, can be addressed[384, 395]. The absolute goal of a cost-effective, reproducible 
assay with a large enough window to discern activity from a crude venom sample remains.  
 
To specifically address the SH-SY5Y MTT assay, although a higher concentration of TTX (1 µM) was 
used, the ability of TTX to fully inhibit the effects of ouabain and veratridine could be due to the 
endogenous expression of the TTXr NaV1.5[363], which has a reported IC50 of around 1 µM[396]. 
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Lidocaine is a known inhibitor of NaV1.5, as well as a range of TTXs NaV channels, although a 
complete inhibitory profile has not been performed [397, 398]. A similar explanation to TTX can be 
given for lidocaine, as the lack of full “recovery” after the addition of 1 µM lidocaine may not fully 
inhibit certain NaV channels expressed in SH-SY5Y cells at the concentration used. Additionally, it is 
apparent when looking at Figs. 14 and 15 that ouabain on its own is able to induce a lethal effect. This 
lethal effect could be influencing cell survival, thereby limiting the maximum amount of “recovery” 
upon addition of a NaV channel inhibitor. The mechanism of lethality of ouabain alone is not known. 
 
For the development of a whole cell, high-throughput, microtiter plate-based assay, much relies on the 
cell line used. Immortalized cell lines have been instrumental in the development of a wide variety of 
detection assays[399]. Immortalized cells are no longer subject to the Hayflick limit, which describes 
the number of times a cell population will divide before senescence, due to telomere shortening[400, 
401]. These cell lines are typically derived from cancerous cells, which already possess mechanisms for 
sustained division. However, immortalized cell lines can also be generated from “normal” cells through 
methods such as insertion of oncogenes[402] or induction of key proteins such as telomerase[403] or 
viral T protein[404]. Aside from their ability to divide for prolonged periods of time, immortalized cell 
lines have an added benefit of expressing endogenous receptors relevant to the tissue derived. 
Therefore, neuronal cell lines would preferentially express key neuronal ion channels and theoretically 
have a similar functional pharmacology to primary tissue as opposed to heterologously expressed 
channels. This has been apparent in previous experiments where a splice variant of NaV1.7 
demonstrated abnormalities when expressed in neurons that were not seen when expressed in non-
neuronal HEK cells[405]. However, the NaV expression profiles of many commercially available 
immortalized cell lines remain to be characterized. The initial investigation of this thesis focused on 
determining NaV α-subunit expression profiles for a select group of these neuronal cell lines, which 
included rat neuroblastomas, rat/mouse hybridomas of neuronally derived cells, and the human 
neuroblastoma SH-SY5Y. The expression of endogenous NaV α-subunits was assessed using PCR or, 
in the case of SH-SY5Y, immunohistochemistry and channel function via electrophysiology. 
 
4.2 Cell line characterization and adaptation for assay 
Seven commercially available neuronal cell lines were used in the development of a NaV channel assay. 
Comprehensive research into the NaV expression of most of these cell lines had not yet been completed 
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or submitted to the public domain. The cells that have been studied serve as controls. The initial goal of 
this project was to determine one or more effective cell lines to be used in a general primary screen for 
NaV channel activity. Optimally, expression of NaV1.3 and NaV1.7 with minimal expression of the 
other channels was desired as these two subunits represent high-interest targets for the treatment of 
pain, as described previously. Each cell line was chosen for its mammalian neuronal origins, having 
been isolated from rat, mouse, or human sources. Most have been extensively used as research models 
for neuronal differentiation and neurite growth, with some cell lines developed for use with various 
assays such as Fluo4 or MTT.  
 
SH-SY5Y is a dopaminergic cell line developed from a human neuroblastoma parental line, SK-N-SH, 
isolated from a metastatic bone tumor biopsy[406]. The parental SK-N-SH cell line was subcloned 
three times; first to SH-SY, then to SH-SY5, and finally to SH-SY5Y, then submitted to the ATCC cell 
bank in 1970 for public use[406]. Various research has demonstrated that undifferentiated SH-SY5Y 
cells express nACHr[407] such as α7[408], Kir2.1, KV1.4, KV2.1, KV4.2, KV7.1, [409], KV3.1 [410], 
CaV2.2[411], CaV1.3[411], various ASICs [412], NaV1.1 [413] and NaV1.7 [409, 414]. Conductance 
changes attributed to both NaV and CaV channels such as increased peak current and slower inactivation 
were observed after differentiation[415] [416]. SH-SY5Y cells have served as hosts for transfecting a 
number of receptors and ion channels, including TRP channels[417] and NaV1.8[367]. Both native and 
transfected cells have been extensively used for a variety of assays measuring neurotoxicity and cell 
survival[418-421] as well as being used with Fluo4 to measure Ca2+ flux triggered by activation of ion 
channels or GPCRs[422, 423]. 
 
Neuro2a is a CNS derived mouse neuroblastoma and has been extensively used to monitor NaV channel 
modulation by paralytic shellfish toxins[377, 424] with measurable NaV channel expression detected in 
a number of experiments[425-427]. A comprehensive study of NaV α- and β-subunits using RT-PCR 
demonstrated the endogenous expression of NaV1.2, NaV1.3, NaV1.4, NaV1.7 and the β1- and β3-
subunits, with the predominant α-subunit being NaV1.7[428]. A number of other receptors and ion 
channels have been detected, including Cl- channels[429], angiotensin II receptor subtypes AT1A, AT1B, 
and AT2[430], purinergic receptors[431, 432], somatostatin receptors[433], and the KV channels KV1.1, 
KV1.4, and KV2.1. Low level CaV expression was observed in cAMP differentiated cells using the Ca2+ 
sensitive dye fura-2[434]. Further, these cells have successfully been adapted for use with MTT[377, 
424]. 
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PC12 is another cell line derived from a CNS, isolated from a pheochromocytoma of rat adrenal 
medulla[435]. Differentiation has been shown to increase the number or responsiveness of several 
kinds of ion channels and receptors, such as nicotinic and muscarinic acetylcholine[436, 437], opiate 
[438], bradykinin[439, 440], 5-HT3[441], and both CaV1.2 and  CaV2.2[442-444].  More recently 
ASICs[445] and O2-sensitive KV channels[446] have been found in undifferentiated PC12 cells. 
Undifferentiated PC12 cells have very low NaV conductance and expression that can be upregulated 
through differentiation with NGF or cAMP [447-449]. Through mRNA hybridization analysis, NaV1.2 
and NaV1.7 were shown to be the primary NaV channels present in undifferentiated PC12 cells[450]. 
 
50B11 is a PNS derived cell line recently created from immortalize rat DRG[451]. The authors 
performed detailed electrophysiological analysis to demonstrate no difference between differentiated 
and undifferentiated cells at resting membrane potentials with no spontaneous activity reported. 
Depolarizing IV-stimulation of undifferentiated cells also did not induce action potentials. However, 
action potentials were observed under depolarizing conditions with differentiated cells, suggesting 
upregulation of NaV expression after neuronal differentiation[451]. Interestingly, real-time RT-PCR 
experiments of undifferentiated 50B11 cells confirmed NaV1.4 and NaV1.7 expression at high levels, 
while NaV1.8 was expressed at low levels. Differentiation in the presence of forskolin and NGF 
upregulated the expression of NaV1.4 and NaV1.8 alone, but differentiation in the presence of GDNF 
and forskolin had no significant effect[451]. This data suggests the presence of mRNA with limited to 
no active protein expression of NaV channels in undifferentiated cells. A comprehensive analysis of 
NaV channels has not been completed.  
 
The last three cell lines described are hybridomas of a mouse neuroblastoma (N18TG2) with either 
embryonic rat DRG for F11, adult rat DRG for ND7/23[452] or an immortalized rat glioma cell line 
(C6-BU-1) for Ng108. All three exhibit many properties of neuronal cells after differentiation, 
including neuronal response to bradykinin, expression of neuropeptides, and extensive neurite-like 
processes characteristic of DRG neurons, but with distinct electrophysiological profiles[452-456].  
 
F11 cells can differentiate in the presence of cAMP into neurons with increased expression of ion 
channels and receptors for bradykinin, opioids[457], volume-sensitive Cl- channels, KCNQ 
channels[458], and CaV channels, showing a similar functionally in many regards to DRG sensory 
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neurons[459-461]. Undifferentiated cells were shown to have only TTXs current[462]. However, no 
comprehensive study on NaV expression has been completed to date. F11 cells have also been validated 
for Fluo3 assay[463]. ND7/23 cells exhibit TTXs current similar to DRGs with no endogenous TTXr 
current and expression of both the β1- and β3-subunits[464]. These cells have been successfully used to 
recombinantly express ion channels, specifically multiple NaV isoforms[465-468]. The NG108 cell line 
was originally named 108CC15[469]. Undifferentiated cells have been found to express β-adrenergic 
receptors [470], 5-HT3[471], delayed rectifier K+ channel[472], KV3.1[473], ERG[474], bradykinin 
receptors[475]. Neuronal differentiation causes upregulation of NaV and CaV current [476] with 
upregulation of NaV current due partially to increase in NaV1.7 expression[477]. However, apparent 
change of NaV current only occurred after 15 days of differentiation[478]. A comprehensive analysis of 
CaV channels was recently completed in by Liu et. al., where the CaV1, CaV2, and CaV3 families of CaV 
channels were all observed. However, it was noted that changes in CaV mRNA, expression, and current 
were all strongly subject to time-dependence of differentiation[479]. 
 
This project did not include differentiated cell lines as terminally differentiated cells do not undergo 
cell division[480], require expensive reagents, and take days to weeks to undergo total differentiation. 
Additionally, the regulation of receptors and ion channels by differentiation is dependent on a variety 
of factors, including reagent used and time of incubation. This would be extremely limiting when 
attempting to develop and maintain reproducible, multi-well, high-throughput, functional assays. An 
initial PCR characterization of seven neuronal cell lines was completed using primers designed for 
specific regions of rat NaV channel isoforms. PCR results suggested prevalent expression of NaV1.2 in 
all cell lines tested, with only a slight band apparent for 50B11 cells. This is not a surprising result, as 
NaV1.2 was previously detected in Neuro2a cells[428] and is the most abundant α-subunit expressed in 
the CNS, contributing up to 70% of total NaV expression in rat brain[481]. All cell lines used, with the 
exception of the immortalized DRG line 50B11, are either fully or partially derived from CNS tissue. 
 
NaV1.6 and NaV1.7 demonstrated a similar expression profile with bands for both isoforms appearing 
in the same cell lines, although there did not seem to be correlation between cell line origin and 
expression pattern. NaV1.6 is the predominant NaV isoform found at the Nodes of Ranvier on small 
diameter, myelinated Aδ-fibers, and is also expressed on dendrites and synapses[482]. NaV1.7 
expression is more widely distributed and appears in the somata of all small diameter neurons as well 
as the central and peripheral terminal processes of small diameter DRG neurons[145]. Both NaV1.7 and 
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NaV1.6 at Nodes of Ranvier in small diameter Aδ-fibers occurring throughout the dorsal root and 
sciatic nerve had a 90% coincident of expression. This observation could help explain the concurrent 
expression seen in the cell lines. However, although all cell lines have been shown to express NaV1.7 in 
the literature, 50B11, Ng108, and PC12 did not in this experiment. Ng108 could be explained by its 
lack of differentiation resulting in decreased expression of the channel [477]. However, the discrepancy 
with PC12 cannot be explained, as previous experiments observed the presence of mRNA for 
undifferentiated cells [450, 451]. The lack of NaV1.3 and NaV1.4 mRNA was also a discrepancy from 
previous published results for Neuro2a [428] and 50B11[451]. In the case of murine derived Neuro2a, 
the primers were designed for rat specificity and may be binding to an area of the NaV channel that is 
not conserved for murine NaV isoforms. Finally, NaV1.8 was not detected in 50B11 or any other DRG 
hybridoma. The discrepancy with 50B11 is apparent as no NaV primers detected mRNA for each 
subunit tested. This was most likely due to an error in RNA extraction and cDNA production for this 
individual cell line. The expression profile for NaV1.7 shown here was very similar to that performed 
with human isoform-specific primers, with the only discrepancy being that of NaV1.3 shown to be 
expressed using human isoform specific primers [363].  
 
It is recognized that a more complete characterization would include a follow-up sequencing of each 
band to conclude with more confidence that each band correlates to the expected gene fragment, 
antibody detection of each α-subunit via Western, and electrophysiological characterization of NaV 
function. At the time, only a superficial characterization was required, as other phenotypic methods of 
determining viability of each cell line were used. Cell lines were judged on their ability to grow without 
treated plates, the time it takes to reach confluency within flasks or plates, and the ability of the cells to 
metabolize MTT efficiently or respond to a given fluorescent dye. Further characterization was 
reserved for the best performing cell lines. 
 
Most of the cell lines were determined to be deficient for assay use in an HTS format required for this 
project. The majority of cell lines tested require the presence of cAMP or growth factor for 
differentiation into a neuronal-type cell. Additional to the prohibitive affects of differentiation 
mentioned previously, without differentiation the cells tested either do not express the necessary NaV or 
CaV channels or express them at significantly reduced levels. Individually, the PC12 cell line is known 
to exhibit loss of proliferation after routine passage, with significant changes to phenotype 
observed[483]. This loss of proliferation and a change in phenotype to favor non-adherence was 
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observed after moderate use (approximately 5 passages). Optimally, a cell line that can withstand 
multiple passages while maintaining an equivalent phenotype is preferred, as changes in phenotype 
could signify changes within the genome that can affect expression profiles and, in turn, results. Both 
PC12 and NG108 cell lines grow optimally on the presence of poly-D-lysine or collagen I[484, 485]. 
Their lack of innate adherence could be overcome with the addition of an extracellular matrix. 
However, all assay formats tested require plate washing steps that can mechanically dissociate loosely 
attached cells. This greatly affects reproducibility and is a limiting factor. F11 cells exhibited slow 
proliferation and a suboptimal expression profile of NaV channels. The phenotypic traits described were 
all considered undesirable for our purposes of developing a cost-efficient, robust, and high-throughput 
primary NaV channel screen. The cell lines that did demonstrate robust growth, adherence to microtiter 
plate plastic, and a reasonable level of expression for a NaV isoforms without differentiation were 
carried through for evaluation with the survival based MTT assay and, finally, a fluorescence based 
assay. These included the Neuro2a, SH-SHY5Y, and ND7/23 cell lines. Once an optimal cell line was 
determined – in this case SH-SY5Y – a combination of semi-quantitative PCR, electrophysiology, and 
immunohistochemistry was used for a more detailed characterization of functional expression before a 
validated assay was finally developed. The methods and results for the validated assay have been 
published[363].  
 
4.3 MTT 
The purpose of the MTT assay platform was to develop a method that can stand alone as a NaV primary 
screen, yet inexpensive, easily accessible, and robust enough to identify new NaV regulators through 
assay-guided fractionation. The ability to adapt the assay for testing agonist activity was also explored. 
The attempt was made to use this assay with both stable and transiently transfected cell lines to probe 
single and pan NaV isoform activity. The stable cell line used was ND7/23-rNaV1.8, kindly donated by 
Dr. Tony Priestly. 
 
The MTT assay is a colorimetric, endpoint survival assay that measures the ability of cytosolic 
enzymes in viable cells to metabolize the yellow, soluble tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) to a deep purple, insoluble formazan dye[486] (Figure 24). 
The reduction of tetrazolium is dependent on NADPH-dependent oxidoreductase enzymes and 
increases with cellular metabolic activity due to elevated NADPH[487]. It is interesting to note that 
74 
 
viable resting cells that are metabolically quiet reduce very little MTT. In contrast, rapidly dividing 
cells exhibit high rates of MTT reduction. Changing assay conditions can alter metabolic activity and 
thus tetrazolium dye reduction without affecting cell viability. 
 
The concept of inducing cell death by forcing an influx of Na+ was originally used to screen STX-like 
paralytic shellfish toxins using MTT to measure a survival endpoint[377, 424]. The method uses a 
combination of two small molecule toxins, the alkaloidal site-2 agonist veratridine and the glycoside 
ouabain, the latter of which inhibits Na+ excretion through deactivation of the Na+/K+-ATPase. The 
synergistic action of these two 
molecules effectively promotes cell 
death through Na+ toxicity. It is 
important to note that the working 
concentration of ouabain is around 100 
µM for inhibition of the Na+/K+-
ATPase[488, 489]. However, low nM 
concentrations of ouabain have been 
shown to reverse the effect and 
stimulate Na+/K+-ATPase activity, as 
well as trigger multiple downstream signaling cascades involving the enhancement of ERK1/2 
phosphorylation and reduction of cellular ATP[490-492]. Further, when testing unknown samples it is 
not known for certain whether the recovery effect was caused by NaV channel block or an off-target 
effect. This could include chelation or disruption of ouabain or veratridine directly, reversal of ATPase 
inhibition, or another mechanism entirely. As this is a primary screen, this information can be assessed 
in greater detail during secondary screening or upon isolation and production of the active component. 
 
In the presence of a NaV channel inhibitor, the influx of Na+ ceases and the cell is saved from 
apoptosis. TTX or other known NaV channel inhibitors can act as a control for NaV cell recovery. 
Theoretically, this assay format should be transferrable to different NaV expressing cell lines - either 
transiently, stably, or endogenously – as long as the cells are able metabolize MTT. This assay format 
has the potential to serve as a primary screen for general NaV inhibitory activity in crude venoms or, in 
the case of single-channel expressing cell lines, could contribute to selectivity screening. Further, this 
assay format can potentially be adapted for discovering NaV channel agonists by adjusting ouabain and 
 
Figure 24: Chemical structure of MTT and its 
metabolized formazan product. 
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veratridine concentrations to elicit a minimally significant (20-30%) decrease in survival as compared 
to untreated controls. The addition of a NaV agonist should theoretically result in an additive decrease 
in survival as compared to control. It is possible to use other NaV channel activators, such as ciguatoxin 
or deltamethrin, as controls in place of veratridine. The time point of 48 h was necessary for two 
complimentary reasons: a) The cells were plated at a density where they were only partially confluent. 
The 48 h allowed cells enough time to grow to confluency; b) The 48 h incubation resulted in an 
exposure time sufficient enough to monitor both cell death and growth inhibition, both of which can 
result from Na+ overload at the cellular level [377, 493, 494]. Limited death from Na+ overload can be 
seen before 24 h. Longer exposure time increases the window (z-score) of apparent cell death. 
 
A variant of the ND7/23 cell line was obtained that expressed the TTXr NaV1.8. This cell line was 
tested in place of ND7/23 for its ability to serve as a potential screen of NaV1.8. The contribution of 
NaV1.8 can be isolated from other NaV channels endogenously expressed in ND7/23 with the addition 
of 1 mM TTX. ND7/23-rNaV1.8 cell line demonstrated the potential to serve as a model to screen for 
NaV1.8 activity with the MTT assay format. Initial results indicated a robust lethal response with a 
combination of ouabain and deltamethrin. This was unaffected with the combined addition of TTX, 
suggesting the response was defined by TTXr NaV channels. However, the lethal response elicited from 
ouabain and deltamethrin was not affected by the addition of the known NaV1.8 inhibitor lidocaine or a 
significant volume of C. marmoreus crude venom containing the potent NaV1.8 inhibitor MrVIB. A 
number of factors could be responsible for this occurrence. Ouabain appeared to have no lethal effect 
with the concentrations used. This was apparent in Figure 10, where the addition of P-CTX resulted in 
no significant change from baseline survival. This suggests that the induced toxicity could have been 
affected by the presence of the deltamethrin.  
 
Deltamethrin is a synthetic pyrethroid, which is a class of small molecules based of the naturally 
occurring pyrethrins from genus Chrysanthemum[495]. Because of their observed selectivity towards 
insect NaV channels and improved UV tolerance, these chemical were first synthesized during the 
1970s for use as commercial insecticides. They modulate NaV channel activity by shifting the voltage-
dependence of activation to a more hyperpolarized potential, resulting in persistent current. However, it 
was quickly demonstrated that pyrethrins cause acute toxicity in rats through a variety of mechanisms. 
Although these molecules bind preferentially to NaV1.3, NaV1.6 and NaV1.8, modulation of CaV, 
voltage-gated chloride channels, GABA, glutamate, and acetylcholine receptors have all been 
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reported[496]. This high receptor promiscuity, often seen with small molecule ion channel modulators, 
is most likely contributing to induced toxicity through other ion channel or ligand gated channel 
mechanism, which was not explored in this thesis. For example, acetylcholine receptors are permeable 
to Na+, therefore activation of this channel with deltamethrin would result in increased INa and cell 
lethality[6, 497]. This would help to explain the inability of both TTX and lidocaine to reverse NaV 
induced toxicity, although more experiments would have to be done in order to prove this theory, 
including characterization of multiple ion channel and ligand-gated receptors present in the ND7/23 
cell line. As the focus of this thesis was NaV channels, the project moved on to more promising cell 
lines. 
 
The Neuro2a and SH-SY5Y cell lines both resulted in MTT assay methods that could be used to screen 
for general NaV channel inhibitors for the endogenous NaV channels expressed in each cell line. 
Further, Neuro2a cells were able to be adapted to screen for NaV channel agonists. Each 96-well 
microtiter plate is able to screen up to 40 crude venoms with replicates. A fluorescence-based assay 
was also developed in parallel to the MTT assay. The ND7/23, Neuro2a, and SH-SY5Y cell lines were 
all attempted in order to determine the best method available for efficiently screening for NaV 
modulators. 
 
4.4 Fluorescence-based assays 
The Fluorometric Imaging Plate Reader Tetra [FLIPRTetra (Molecular Devices)] is a 96- or 384-well 
capable microtiter plate reader capable of simultaneous whole-plate addition of one or two rounds of 
test compound with continuous whole plate reads. This allows detection of inhibitors by pre-incubating 
with unknowns followed by addition of a control agonist. Likewise, agonists can be detected within the 
same assay.  
 
The FLIPRTetra was used to quantitate an induced fluorescent response via two mechanisms. Fluo-
4 acetoxymethyl ester [AM (Invitrogen)] is a small molecule calcium chelator, which is taken up by the 
cell where the acetoxymethyl ester group is cleaved, internalizing the fluorophore. External Fluo-4 is 
removed to enable the monitoring of calcium mobilization into the cell, in our case after a 
depolarization event. Fluo-4 excites at 488 nm upon binding with a Ca2+ ion[498] (Figure 25) and 
requires a moderate to high level of CaV channel expression to elicit a measurable response. The 
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contribution of NaV channels to the observed response can be tested with a follow up experiment in the 
presence of TTX or other known NaV blocking agents. 
 
A proprietary FLIPRTetra Membrane Potential Assay kit (Molecular Devices; R8126) was also used to 
determine NaV channel activity. This kit incorporates a no wash fluorophore in combination with a 
background quencher. Both chemicals bind to the outer lipid membrane of the cell (Figure 26). 
Membrane depolarization causes the fluorophore to dissociate from its quencher in the outer membrane 
by following the flow of cations into the cell. The dissociation results in a relative increase in the 
fluorescence response, which is measured by a fluorescent detector. The actions are similar to a FRET-
based assay. 
 
Initial experiments tested the 
fluorescent response of ND7/23, 
Neuro2a and SH-SY5Y cells with 
both Fluo4 and the MP-kit. All cell 
lines displayed a fluorescence 
response to depolarization invoked 
upon the addition of 1 mM 
veratridine using the MP-kit. This 
response was blocked with TTX, 
signifying a NaV specific response. 
Neuro2a cells did not respond with 
Fluo4, indicating a potential lack 
or limited availability of CaV 
channels to mediate entry of Ca2+ 
after NaV depolarization. ND7/23 
cells yielded an equivalent 
fluorescence response with both 
Fluo4 and the MP-kit. This 
suggests a minimal depolarizing 
 
Figure 25: Diagram of Fluo4 AM mode of action through 
NaV channel signaling. 
NaV activation results in Ca2+ entering the cytoplasm through 
two linked pathways: external entrance via activation of CaV 
channels and release of internal Ca2+ stored through GPCR 
pathways. Cytoplasmic Ca2+ then binds Fluo4, resulting in 
fluorescence. 
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effect from the addition of veratridine as well as potentially a limited availability of CaV channels for 
Fluo4 detection. SH-SY5Y cells demonstrated the largest comparative fluorescent response using both 
Fluo4 and the MP-kit.   
 
After initial experiments comparing cell lines available, the SH-SY5Y cell line was deemed the most 
applicable to the FLIPRTetra assay format. This was due to its robust nature, ability to load multiple 
fluorescent dyes efficiently, and endogenous expression of human CaV and NaV channels necessary for 
detection by fluorescence response[499, 500]. CaV channel expression in SH-SY5Y cells was 
determined separately[422]. Another large determining factor in choosing the SH-SY5Y cell line was 
the apparent endogenous expression of both human isoforms of NaV1.3 and NaV1.7[363].  
 
 
Because of the large fluorescent response, ability to respond using both Fluo4 and the MP-kit, and 
robust nature, human neuroblastoma cell line was adopted for primary use. The need for only one 
control compound coupled with the high-throughput, quick turn-around time and 384-well potential 
resulted in the FLIPRTetra assay platform as the lead choice for primary screening of crude venoms. The 
SH-SY5Y in conjunction with the FLIPRTetra fluorescent assay platform resulted in the most widely 
used cell-based method for in-house primary HTS of crude venoms[266]. Proof-of-concept for this 
assay was demonstrated after a 96-well crude venom screen of Conus venoms yielded multiple active 
 
Figure 26: Diagram of Molecular Devices Membrane Potential dye mode of action. 
Blue circles represent the charged fluorescent dye that moves in response to ionic flow 
across a membrane caused by depolarization events.  
From: http://www.moleculardevices.com 
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hits. One of those hits, from C. magus, resulted in the isolation and sequencing of a previously 
undiscovered δ-conotoxin. 
 
4.5 Discovery of δ-MVIA 
Using the Fluo4 assay format previously described, initial screening of cone snail crude venoms 
revealed multiple active hits. One of the most potent hits was an agonist of the Fluo4 response, which 
also demonstrated veratridine potentiation of the fluorescent control response. The active peptide was 
purified, sequenced, and found to be a previously unisolated member of the δ-conotoxin family. 
However, the sequence of this conotoxin had already been identified through transcriptome analysis 
and named δ-MVIA[380].  
 
The δ-conotoxins represent a poorly classified family of toxins with a unique mode of action. To date, 
only a small handful of mammalian selective δ-conotoxins have been isolated, with two solution 
structures resolved. They embody the only toxins that interact with the neurotoxin receptor site 6 of 
NaV channels. However, the precise site 6 residues of interaction remain to be determined. Molluscan 
selective δ-conotoxins have been shown to act as both competitive inhibitors and synergistic agonists 
with site 3 scorpion toxins, sharing overlapping but not identical binding regions[501]. Also similar to 
site 3 toxins the δ-conotoxins inhibit inactivation. However, δ-conotoxins also shift the voltage-
dependence of activation and steady-state inactivation to more hyperpolarized potentials, resulting in 
hyperexcitability[347]. Because of their unique interaction with NaV channels, δ-conotoxins have a 
high potential for use as tools to discern the site 6 binding region as well as further elucidate 
interactions with site 3 ligands. Further, as gating modifier toxins, it is possible that these peptides can 
be engineered to act as NaV inhibitors, similar to the variation that occurs with site 4 peptides derived 
from spider venom.  
 
The initially observed properties of δ-MVIA were consistent with the δ-family of conotoxins in 
function and structure. Like other δ-conotoxins discovered, δ-MVIA exhibits a cysteine arrangement 
typical of peptides that conform to the ICK structural motif. The ability to elicit depolarization on its 
own as well as act in synergy with both veratridine and P-CTX suggests binding to a different site on 
the NaV channel. However, the very small amount of isolated crude venom with no other source to 
obtain more limited initial experiments. Therefore, a method of production was needed before 
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pharmacologic characterization could be performed. The extremely high hydrophobicity of δ-
conotoxins can result in complications with solid-phase peptide synthesis, as has been seen with the 
similarly hydrophobic µO-conotoxins. This was the case with δ-MVIA as both BOC and FMOC solid-
solid phase synthesis were attempted but failed in yielding a soluble product. Recombinant expression 
methods have been tested in multiple systems and have proven to be successful means of producing 
conotoxins[265, 502]. However, recombinant expression with two fusion constructs failed to produce 
soluble, mature protein. One system for recombinant expression was developed in association with 
work completed in the following chapters utilizing an MBP fusion protein. Results and methods for δ-
MVIA expression can be found in Appendix A. Although expression was possible, the product was 
insoluble as a fusion protein. Methods to resolubilize were unsuccessful. The general methods for 
expressing an MBP fusion construct were successfully used in the following chapters and will be 
explained in depth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Chapter III: Characterization of NaV modulating TRTX-Pre1a: 
Pharmacology and structure 
 
1. Introduction 
 
As previously discussed in the introduction, NaV1.7 has emerged as a leading target for the 
development of pain therapeutics. Studies involving animal pain models, localization, and functional 
excitability in neurons have demonstrated the contribution of NaV1.7 to pain pathophysiology[139, 
503]. However, it was clinical and genetic observations of NaV1.7’s role in familial inherited human 
pain disorders that has solidified this ion channel as a key molecular target for the treatment of pain. 
NaV1.7 is primarily expressed in somatosensory, peripheral nerve fibers. Gain-of-function mutations on 
the NaV1.7 encoding SCN9A gene develop into paroxysmal extreme pain disorder (PEPD) or primary 
erythromelalgia[146, 504]. By contrast, a different series of mutations that result in loss of channel 
function have been shown to contribute to a rare genetic disorder, congenital insensitivity to pain 
(CIP)[148]. Patients with CIP experience a complete loss of all forms of pain with no deficits to motor, 
cognitive, sympathetic and gastrointestinal function, or loss of any other sensory modality with the 
exception of some instances of impaired olfaction, detected in both rats and humans[149, 505]. The 
functional validation of NaV1.7 as a therapeutic target has initiated a huge research effort towards the 
discovery and development of selective and potent modulators. The majority of pharmaceutical 
research has historically been directed towards small molecule discovery platforms[506, 507]. 
However, over the past decade, venom peptides have proven to be a source of novel, selective, and 
potent modulators of ion channels, leading to an increasing interest in these molecules for therapeutic 
development[508]. 
 
Spiders are by far the most successful venomous predators on the planet with over 43,000 species so far 
described[349]. Individual species can produce a unique assemblage of up to 1000 peptide components, 
yielding a total bioactive compound library in the tens of millions, with less than 0.1% so far 
described[350, 509]. Given that the purpose of spider venom is rapid immobilization of prey, it is not 
surprising that one of their dominant pharmacological actions includes the modulation of NaV channels. 
Not only are spider venom peptides able to target NaV channels selectively, they have demonstrated an 
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ability to functionally differentiate between individual isoforms while still maintaining a high level of 
potency[252, 510]. The ability to selectively modulate NaV isoforms is related to these peptides ability 
to exhibit unique modes of modulatory action, interacting with the voltage sensor domain in order to 
trap the channel in different conformational states and shifting the voltage-dependence of gating. 
Unfortunately, much of this functional information has only been acquired over the past decade, with 
many questions regarding both receptor and ligand left unanswered.  
 
Recently, a unique peptide was isolated from the venom of the tarantula, Psalmopoeus reduncus. 
Named TRTX-Pre1a, this peptide demonstrated the ability to functionally regulate multiple NaV 
isoforms with two different mechanisms of action. Further, TRTX-Pre1a demonstrated structural 
heterogeneity, appearing to take on multiple conformational states in solution at room temperature. 
This chapter described the production, functional, and structural aspects of a new peptide isolated from 
spider venom via a NaV1.7 functional screen using two-electrode voltage clamp (TEVC) methods.  
 
The primary aims of this chapter were as follows:  
 
1) Produce correctly folded and isotopically labeled TRTX-Pre1a using a recombinant expression 
system. 
 
2) Characterize the NaV isoform activity through a combination of electrophysiology and cell-based 
assay. 
 
3) Determine the solution structure of TRTX-Pre1a through heteronuclear NMR.  
 
 
 
 
 
 
 
83 
 
2. Methods 
 
2.1 Expression vector design 
A synthetic gene encoding TRTX-Pre1a was codon optimized for expression in E. coli and cloned into 
a variant of the pLIC-MBP expression vector by GeneArt (Germany)[511] (Figure 27). This vector 
encodes a MalE signal sequence for periplasmic export, a His6 affinity tag for purification, a maltose 
binding protein (MBP) fusion tag to aid solubility, and a tobacco etch virus (TEV) protease recognition 
site directly preceding the TRTX-Pre1a sequence. This expression vector produces the native toxin 
with an additional N-terminal serine residue, a vestige of the TEV protease cleavage site. A T7 
promoter with a lac operon allows for inducible expression upon the addition of IPTG (Invitrogen). 
The pLIC vector also encodes for ampicillin resistance (AmpR).  
 
 
 
rPre1a:   SEDCLGWFSRCSPKNDKCCPNYKCSSKDLWCKYKIW 4314.9 
 
Figure 27: Gene encoding recombinant Pre1a. 
A) Gene segment of pLIC expression vector which encodes for the mature fusion protein. B) Sequence 
of recombinant Pre1a with a N-terminal Ser residue that remains after TEV cleavage. 
 
Fragment of pLICC Pre1a
1626 bp (molecule 6536 bp)
lacO
T7 transl en RBS 6xHis
T7 Terminal prime
TEV Cleavage Site
MBP
MalE ss
Toxin
T7 promoter T7 terminator
KpnI (6213)
SacI (6351)
A) 
B) 
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2.2 Bacterial recombinant expression 
The pLIC vector containing the synthesized expression gene was transformed into BL21(ΔE3) 
chemically competent E.coli (Invitrogen, CA) by heat shock (60 s at 42°C) for recombinant toxin 
production. Cultures were started in 100 mL of Luria-Bertani (LB) medium inoculated from a glycerol 
stock. Starter cultures were grown overnight at 37°C with shaking at 200 rpm under ampicillin (Amp) 
selection. For test expressions, 10% of the starter culture was used to inoculate fresh 100 mL batches of 
LB + Amp and grown to an OD600 of 0.7 to 1.0 before induction with a final concentration of 1 mM 
IPTG (Invitrogen). Several incubation conditions were tested varying both temperature and time. 
Expression was terminated by centrifugation for 15 min at 6000 × g, 4°C. Cells were lysed by 
sonication on ice at 4°C. To check for solubility, the whole cell lysate was centrifuged at 18 000 × g for 
30 min at 4°C and the supernatant was collected for analysis on SDS PAGE. 
 
For large scale expression, 50 mL of starter cultures were added to fresh 2 L batches of LB medium 
and grown at 16°C with shaking at 150 rpm under Amp selection. Expression of the toxin gene was 
induced with 1 mM IPTG at an OD600 of 0.7 to 1.0 and expression was allowed to proceed at 37°C or 
16°C with 150 rpm shaking. Expression was terminated 18-20 h (16°C) or 3 h (37°C) later by 
centrifugation for 15 min at 6000 × g at 4°C. For production of uniformly 13C/15N-labeled TRTX-
Pre1a, cultures were grown as previously described in LB medium. Once an OD600 of 0.7 to 1.0 was 
reached in a 2 L culture, the entire culture was centrifuged at 3000 × g and the LB medium was 
removed. The pellet was washed once with unsupplemented minimal medium and then gently 
resuspended in 500 mL complete minimal medium supplemented with 13C6-glucose and 15NH4Cl as the 
sole carbon and nitrogen sources, respectively. Expression was allowed to continue at 16°C as 
previously described. 
 
2.3 Lysis and IMAC purification 
After removal of medium, the bacterial cell pellets were resuspended in 20 mL chilled TN buffer (40 
mM Tris, 400 mM NaCl, pH 8.0) per gram. TN buffer was supplemented with complete protease 
inhibitor cocktail (Roche) and DNaseI (Roche) then the His6-MBP-toxin fusion protein was extracted 
from the bacterial periplasm by continuous flow cell disruption (TS Series Benchtop System, Constant 
Systems Ltd, Northants, UK) at a constant pressure of 30 kPa. The resulting lysate was centrifuged for 
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30 min at 18000 × g at 4°C to collect the soluble protein. Upon confirmation that the fusion protein was 
in the soluble fraction, the insoluble pellet was discarded.  
 
The His6-MBP-toxin fusion protein was captured by passing the whole cell lysate over Ni-NTA 
Superflow resin (QIAGEN, Valencia, CA) followed by washing with 15 mM imidazole in TN buffer to 
remove nonspecific binders. The fusion protein was then eluted with 250 mM imidazole in lysis buffer. 
The buffer was exchanged with pure TN buffer by centrifugal filtration to remove imidazole (Amicon 
Ultra, Millipore). Reduced and oxidized glutathione were added to 3 and 0.3 mM, respectively, to 
activate TEV protease. TEV protease was made recombinantly in-house according to published 
methods[512]. Approximately 50 μg of His6-tagged TEV protease was added per mg of recombinant 
TRTX-Pre1a, and the cleavage reaction was allowed to proceed at 30°C for 3 h.  
 
2.4 Reversed-phase high performance liquid chromatography 
Semi-preparative rpHPLC was performed on a Shimadzu LC-20AT system with a SPD-10A dual 
wavelength UV/VIS detector. For purification of recombinantly expressed TRTX-Pre1a, the instrument 
was equipped with a Vydac C8 column (208TP1022; 50 × 250 mm; 5 μm particle diameter; 300 Å pore 
size) using a flow rate of 10 ml/min and a linear gradient of 15 to 60%. solvent B (0.1% trifluoroacetic 
acid in 90% acetonitrile) in solvent A (0.1% trifluoroacetic acid in water) over 30 min. Secondary 
purification was followed up on a Thermo Hypersil GOLD C18 (10 × 250 mm; 5 μm particle diameter; 
300 Å pore size) using a flow rate of 3 ml/min.  
 
Analytical rpHPLC was performed on a Shimadzu LC-20AT Prominence system equipped with SIL-
20AHT autosampler, SPD-20A dual 214/280 nm UV/VIS detector and CTO-20A column oven. An 
Onyx C18 monolithic column (Phenomenex; 2 × 100 mm; 130 Å pore size) was used for final 
purification (if needed) and analyzing purity of all samples. 
 
2.5 Determination of peptide concentration 
Peptide concentrations were calculated using the molar extinction coefficient and the absorbance at λ = 
280 nm. Absorbance was measured against a buffer blank on a NanoDrop (Thermo) 
86 
 
spectrophotometer. The extinction coefficient was calculated based on the methods of Gill and von 
Hippel[513]  using the following equation:  
 
εpeptide = (nW× εW)+(nY× εY)+(nC× εC)  
Where εW = 5500; εY = 1490; and εC = 125[514] 
 
The absorbance reading at 280 nm was then used to calculate molarity (M) of the peptide in solution 
using the calculated ε-value with a derivation of the Beer-Lambert Law: 
 
Mpeptide = A280/ εpeptide 
 
2.6 MALDI-TOF mass spectrometry  
Toxin masses were confirmed by matrix-assisted laser desorption ionization–time-of-flight mass 
spectrometry (MALDI-TOF MS) using a model 4700 Proteomics Bioanalyser (Applied Biosystems, 
Foster City, CA). rpHPLC fractions were mixed [1:1 (v/v)] with α-cyano-4-hydroxy-cinnamic acid 
matrix (7.5 mg/ml in 70/30 acetonitrile/H2O) were collected in positive reflector mode. The mass range 
was set to m/z 800-8000 with a focus mass of 4500 Da. Shots were collected using manual acquisition 
control and close external calibration. All masses given are for the monoisotopic M+H+ ions unless 
otherwise stated.  
 
2.7 Peptide sequence determination 
Prior to sequencing, approx. 2-3 µg of the peptide was dissolved in 5 µl of 100 mM ammonium acetate 
(pH 4.5) and reduced by adding 10 µl of 100 mM TCEP (1 hour, 37°C). Alkylation was carried out by 
adding 20 µl of 100 mM maleimide (made up in 10 % acetonitrile) and incubating for 1 hour at 37°C. 
The reaction was quenched by adding 100 µl of 0.1% TFA and desalted using rpHPLC (Prosphere C4 
column, 3x150 mm, 15-35% B in 18 mins). The mass of the reduced/alkylated peptide was determined 
using an API2000 mass spectrometer. The sequence of purified, reduced/alkylated peptide was 
determined by Edman degradation at the Australian Proteome Research Facility using an Applied 
Biosystems 494 Procise Protein Sequencing System. 
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2.8 TEVC methods 
Toxin activity was assessed using two-electrode voltage clamp experiments performed on Xenopus 
laevis oocytes expressing rat or human NaV channels. Oocytes were surgically removed from mature X. 
laevis frogs anesthetized by submersion in 0.13% tricaine methanesulfonate (MS-222). Stage V–VI 
oocytes were prepared for injection by dissociation in Ca2+-free solution containing the following: 
96 mM NaCl, 2 mM KCl, 2 mM MgCl2, 5 mM HEPES (pH 7.4), plus 1 mg/ml collagenase (Sigma, 
type I) for 1.5 h at room temperature. Oocytes were maintained in ND96 solution containing 96 mM 
NaCl, 2 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM pyruvate, 50 μg/ml gentamicin 
(pH 7.4) and 2.5% horse serum. cRNA of NaV 1.2 (100 ng/µL), NaV1.3 (660 ng/µL), NaV1.4 (100 
ng/µL), NaV1.5 (100 ng/µL), and NaV1.7 (250 ng/µL) were injected using a precision injector 
(Nanoliter 2000) and incubated at 18°C for 2-4 days. cRNA was made using an Ambion mMessage 
mMachine kit (Invitrogen) with linearized pcDNA3.1 plasmid containing the NaV expression gene of 
interest. 
 
Voltage and current electrodes filled with 3M KCl had a final resistance of 0.5–2.0 MΩ. Stimulation, 
data acquisition, and analysis were performed using pCLAMP 10.0 software (Molecular Devices, CA, 
USA) using an Axoclamp 900A voltage clamp amplifier (Molecular Devices). All experiments were 
performed at room temperature (20–22 °C). Serial dilutions of stock peptide solution (100 μM in H2O) 
were made in ND96 solution containing 0.1% fatty acid free BSA (Sigma) to prevent adsorption to 
tubing. Current-voltage (I-V) relationship curves were evoked by depolarizations to 0 mV in 5 mV 
increments from a holding potential of -80 mV. The amount of toxin-induced block was measured at -
20 mV with the exception of NaV1.5, measured at -30 mV due this channels hyperpolarized shift in 
activation potential. I-V curves were taken both before addition of compound and after reaching 
steady-state activity (see Appendix B for example I-T plots). All toxins were tested on at least n = 3 
individual oocytes. 
 
The linear membrane capacitative and leak currents were subtracted using a -P/4 pulse protocol. 
Membrane currents were sampled at 20 kHz and filtered at 2 kHz. Oocytes showing <15% change in 
peak current amplitude over a 5 min incubation period were used in these studies to avoid effects 
associated with current run down. Perfusion was stopped, and cumulative additions of toxin were added 
to a Perspex chamber (0.1 ml volume) to achieve rapid mixing. Activity of peptide was assessed by 
monitoring the change in either peak current or late current over time, until equilibrium was reached 
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(Appendix B). An I-V protocol was performed before and after addition of peptide by holding the 
membrane potential at -80 mV and depolarizing for 20 ms in 5 or 10 mV steps, from -60 to +40 mV 
(Appendix C). Nonlinear regression and statistics calculations (means ± S.E; n ≥ 3) were performed 
using GraphPad Prism software 5.0 (San Diego, CA).  
 
2.9 Cell culture and FLIPR assay 
CHO-K1-hNaV1.4 cells were purchased from Chantest (USA; CT4005). HEK-rNaV1.6-TTXr and 
HEK-rNaV1.7-TTXr cell lines were a kind gift from Dr. Steven Waxman. All three cell lines were 
maintained in DMEM medium supplemented with 10% fetal bovine serum. All mammalian cell lines 
were passaged every 3-5 days using 0.25% trypsin/ EDTA and incubated in a temperature, humidity, 
and CO2 controlled incubator set to 37°C with 5% CO2. For assay, all three cell lines were plated at a 
density of 120-140 × 103 cells per well in a 96-well, black-walled imaging plate (Corning) 48 h prior to 
assay. 
 
The FLIPR assay was run as previously described in Chapter II, Section 2.8 for the Molecular Devices 
No-Wash Membrane Potential Kit, with the exception of using the above described single-channel 
expressing, stably transfected cell lines in place of SH-SY5Y cells. 
 
2.10 Data analysis 
FLIPR 
Unless otherwise stated, all data are expressed as the mean ± standard error of the mean (SEM) 
determined from at least n = 3 experimental replicates, with 2-4 replicates per plate. To establish 
concentration-response curves, responses after addition of compounds were plotted against agonist 
concentration and a 4-parameter Hill equation with variable Hill slope or a two-site model was fitted to 
the data using GraphPad Prism (Version 4.00, San Diego, California). Potency of agonists and 
antagonists are reported as the mean  SEM of 3-4 separate experiments. Statistical significance was 
determined using an unpaired student’s t-test with statistical significance defined as p < 0.05 unless 
otherwise stated. 
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TEVC 
Data were analyzed using pCLAMP 10.0 (Molecular Devices, CA, USA) and GraphPad Prism 5.0 
software programs. All data points are shown as mean ± S.E. where n is presented as the number of the 
separate experiments.  
	
To establish concentration-response curves, responses after addition of compounds were plotted against 
the log of sample concentrations and a least squares fit 4-parameter Hill equation with variable Hill 
slope fitted to the data using GraphPad Prism 5.0. Statistical significance was determined using an 
unpaired student’s t-test with statistical significance minimally defined as p < 0.05 unless otherwise 
stated. 
 
2.11 NMR methods and homology modeling 
Lyophilized 13C/15N labeled recombinant TRTX-Pre1a was resuspended at a final concentration of 300 
µM in 300 µl 10 mM sodium phosphate buffer, pH 6.0, constituted in 95% H2O / 5% D2O. An 
additional sample was prepared by lyophilizing the above sample and resuspending it into 100% D2O. 
These samples were both added to susceptibility-matched 5-mm outer diameter microtubes (Shigemi 
Inc., Japan). 
 
Data were acquired at 298 K using a 900 MHz NMR spectrometer (Bruker BioSpin GmbH, 
Rheinstetten, Germany) equipped with a cryogenically cooled triple resonance probe. Sequence 
specific backbone resonance assignments were obtained using 3D CBCA(CO)NH, 3D HNCACB, 3D 
HNCO, 3D H(CCCO)NH-TOCSY, 3D (H)CC(CO)NH-TOCSY, and 2D 1H-15N HSQC spectra, which 
were all acquired using non-uniform sampling and transformed using maximum entropy reconstruction 
with the Rowland NMR Toolkit (http://www.rowland.org/rnmrtk/toolkit.html) as described 
previously[515]. HSQC-NOESY (15N in H2O and 13C in D2O) spectra were obtained for assignment of 
disulfide bonds, using a mixing time of 250 ms. Secondary structure elements were predicted using 
TALOS+ chemical shift analysis [516]. NOESY spectra were manually peak picked and integrated 
using Sparky NMR analysis software[517]. The peak lists were then automatically assigned, distance 
restraints extracted, and an ensemble of structures calculated using the torsion angle dynamics package 
CYANA[518]. The tolerances used for CYANA were 0.03 ppm in the direct 1H dimension, 0.01 ppm 
in the indirect 1H dimension, and 0.4 ppm for the heteronucleus (13C/15N). During the automated 
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NOESY assignment/structure calculation process, CYANA assigned 90.1% of all NOESY cross-peaks 
(829of 920). 
 
TRTX-Pre1a was modeled against the solution structure of β-TRTX-Ps1a (phrixotoxin-3) using 
Modeler v9.8[519]. The solution structure data for β-TRTX-Ps1a was obtained from Prof. Glenn King 
and used with permission.  
 
3. Results 
3.1 Discovery background 
Initial analysis of crude venom from P. reduncus – a tarantula from the family Theraphosidae – using 
two-electrode voltage clamp (TEVC) electrophysiology demonstrated that it potently inhibited hNaV1.7 
channels expressed in X. laevis oocytes. The initial separation step showed that fraction 18 contained 
the desired hNaV1.7 inhibitory activity (Figure 28). Two subsequent steps of activity-guided rpHPLC 
purifications resulted in the identification of a major peak exhibiting inhibitory hNaV1.7 activity 
(Figure 28). The pure peptide also interacted with the rat isoform of NaV1.3. However, instead of 
inhibiting current, as was seen with hNaV1.7, TRTX-Pre1a inhibits the fast inactivation of rNaV1.3 as 
evidenced by the increase in late current (Figure 28 insert). Mass analysis via MALDI-TOF MS 
revealed an M+H+ of 4227.5 (or MW of 4226.5 Da). The mass of the fully reduced/alkylated peptide 
was found to be 588 Da (6 × 98, the MW of maleimide) higher than the native peptide, indicating the 
presence of six cysteines, thus the three disulfide bonds. Edman degradation of the reduced/alkylated 
peptide resulted in complete sequence determination and revealed a previously undiscovered spider 
venom peptide, highly similar to NaV modulating spider Family 1 toxins. This novel peptide was found 
to be 35 amino acids in length with six cysteine residues with spacing indicative of an ICK motif, 
commonly observed with spider venom peptides[239]. The peptide was named as TRTX-Pre1a 
according to standard rational nomenclature proposed by King et al. [520]. Table 3 highlights the 
sequence similarity of TRTX-Pre1a with multiple other spider toxin peptides and their known 
molecular targets. 
 
Reverse-phase HPLC analysis of pure TRTX-Pre1a revealed a leading tail and earlier eluting minor 
peak, as shown in the inset of Figure 28 B. The initial assumption that the lack of symmetry of the 
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peptide was due to the presence of an impurity was put into question when these regions revealed the 
presence of an equivalent mass to the major peak, suggesting there is potential structural heterogeneity 
of TRTX-Pre1a. 
 
 
 
Figure 28: rpHPLC purification of P. reduncus crude venom.  
A) Fraction F18 inhibited NaV1.7, as shown in the insert. B) Secondary purification of F18 
demonstrated NaV1.7 inhibition and NaV1.3 inhibition of fast inactivation. Tertiary purification yielded 
a dominant peak with a leading tail, both with a  M+H+ of 4227.5 (B; insert). 
 
 
A) 
B) 
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Table 3: Sequence alignment of TRTX-Pre1a and related Theraphotoxins.  
Numbering and % similarity are relative to TRTX-Pre1a. U = unknown assignment. 
 
 
3.2  Structural heterogeneity of TRTX-Pre1a as studied by rpHPLC 
It was a possibility that the apparent conformers were a result of cis-trans isomerization about the 
amide bonds, typically occurring around Pro residues but apparent in non-proline peptide bonds, as 
well (Figure 29). Cis-trans isomerization of a peptide bond can result in equilibrium between a cis- and 
trans-isomer as seen for the scorpion toxin BmKIT01[521] and BmK M7[522].  
 
The peptide bond has two stabilized resonance forms, which results in a partial double bond character 
and cis-trans isomerization. Normally peptide bonds adopt the energetically favorable trans-
conformation[523]. But in some instances a peptide bond can adopt cis-configuration as seen for the 
peptide bond Asp9-Tyr10 in the α-scorpion toxin BmK-IT01[521]. An Asn-Tyr bond is also present in 
TRTX-Pre1a so it is possible, that cis-trans isomerization around such a non-Pro peptide bond results 
in the two peaks in Figure 30. Isomerization of the peptide bond between Ser or Cys and Pro in TRTX-
Pre1a is also a possibility, as cis-isomers of peptide bonds between a random amino acid and Pro 
occurs at higher frequency than non-Pro peptide bonds[522]. 
 
In order to test whether the leading tail and minor peak seen with purified TRTX-Pre1a was an 
impurity, misfolded protein, or conformational isomer, a simple rpHPLC experiment based on methods 
developed by Swartz and Mackinnon was implemented[524]. Two fractions were collected covering 
93 
 
sections of the dominant peak of 
TRTX-Pre1a (Figure 30). These 
fractions were reinjected and a similar 
chromatographic profile with the minor 
peak and leading tail was evident. This 
experiment was repeated with 
recombinant TRTX-Pre1a with 
equivalent results. If the leading tail was 
an impurity or misfolded protein, it 
should not appear in the major peak. 
Therefore, reinjection of fractions 
collected from only the major peak 
would result in the absence of a minor 
peak and leading tail, yielding a single 
sharp peak. However, if the structure of 
TRTX-Pre1a has properties that lend it 
towards conformational instability, then 
the minor peak could represent a correctly folded conformational isomer. At room temperature, peptide 
isomerization around the amide bond tends to be a slow process[525, 526]. This could help explain the 
leading tail between the two visible peaks as transitional states between isomers. However, more 
experiments were necessary to test this hypothesis, as well as the possible contribution of one or both 
of the Pro residues. 
 
 
 
Figure 29: Schematic representation of cis-trans 
isomerization of a peptide bond. 
Rotation around the dihedral angle  of the partial 
double bond allows the isomerization. A) cis-trans 
isomerization of a non-Pro peptide bond and B) a Pro 
peptide bond. 
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Figure 30: Chromatographic profile of folded purified TRTX-Pre1a and reinjection of 
major peak.  
rpHPLC analysis of folded TRTX-Pre1a on an analytical C18 column with a 1 mL/min flow 
rate and linear gradient (0.25%/min, 25-35 %B) depicted by the dotted line. The grey bars 
indicate the fractions collected after initial injection. Inserts show rpHPLC analysis of the 
two reinjected fractions using the exact same parameters for analysis. 
 
3.3 TRTX-Pre1a homology model 
More information was required to explain the possible conformational heterogeneity seen with the 
rpHPLC chromatogram. In the absence of a solution structure of TRTX-Pre1a, a homology model was 
created based on the template of a previously isolated spider venom peptide with high sequence and 
structural homology. A sequence comparison of β-TRTX-Ps1a with TRTX-Pre1a shows strong 
homology between many of the loop regions, with some variation occurring over a four residue stretch 
of Loop 1 (Table 3). Isolated from the Chilean spider Paraphysa scrofa, β-TRTX-Ps1a is a non-
selective inhibitor of NaV channels that inhibits current through the mechanism of voltage sensor 
trapping[251]. The NMR solution structure of a β-TRTX-Ps1a has been solved by our close 
collaborator Professor Glenn King, although not yet in the public domain. The structure of β-TRTX-
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Ps1a was consequently used with permission as a template to create a homology model of TRTX-Pre1a 
(Figure 31). 
 
The model of TRTX-Pre1a revealed a hydrophobic face composed of five aromatic residues, W7, F8, 
Y22, W30 and Y32. Both W7 and F8 appeared to be towards the center of the hydrophobic stack on 
adjacent residues and may therefore result in steric clashes leading to energetically strained structural 
arrangement. Further, their sequence position followed directly after the G6 residue. Gly is known to 
contribute to a loss of structural rigidity due to its lack of a sterically hindering carbon side chain, 
resulting in increased flexibility and rotational capacity around this region[527, 528]. Interestingly, the 
highly homologous β-TRTX-Ps1a contains a Gly in a comparable position, but is structurally stable 
while maintaining nanomolar activity[251]. This stability could be attributed to the F5 and W7 residues 
of β-TRTX-Ps1a being separated by a non-aromatic Leu, resulting in a more stable arrangement of the 
F5, L6, W30, and Y33, while W7 is oriented towards the opposite face (Figure 31). The features described 
for Loop 1 of TRTX-rPre1a and its possible contribution to conformational heterogeneity will be 
explained in more detail in the discussion. 
 
Figure 31: Homology model of TRTX-rPre1a compared to β-TRTX-Ps1a. 
A) TRTX-Pre1a, with hydrophobic face residues highlighted in red, disulfide bonds in yellow. B) β-
TRTX-Ps1a solution structure with comparative features highlighted. 
A) B) 
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The homology model resolved structural features of note, specifically involving the close interactions 
between aromatic residues that make up the hydrophobic face and could contribute to aromatic 
stacking. However, as the actual structure of TRTX-Pre1a is likely to differ from the model, 
unanswered questions remain regarding the conformational stability of Loop 1. Therefore, a NMR 
solution structure of 13C/15N-labeled recombinantly expressed TRTX-rPre1a was solved and will be 
discussed in this chapter. 
 
3.4 Bacterial recombinant expression 
Further studies required the production of TRTX-Pre1a for pharmacological characterization as well as 
isotopic labeling for heteronuclear NMR experiments. In order to quickly and efficiently produce 
labeled and properly folded 
disulfide rich protein a method of 
recombinant expression developed 
in-house[529]. TRTX-Pre1a was 
successfully expressed 
recombinantly in E. coli as an MBP 
fusion protein. Before scale-up 
expression to 2 L LB, a 100 mL test 
expression was carried out with two 
temperature conditions with 
multiple time points. No observable 
difference in the level of inducible 
expression was seen between 
temperatures or time points tested 
when assessed by SDS-PAGE 
(Figure 32). The optimal growing 
temperature for E. coli is 37°C, 
which results in a shorter window 
for logarithmic growth and 
therefore faster induced expression 
of the peptide product[530].  
 
 
Figure 32: SDS-PAGE Coomassie stain of test expression 
for rPre1a. 
Time 0 refers to before addition of IPTG. All other times are 
hours after induction. Induction was observed to be 
equivalent for all time points measured. Fusion protein mass 
= MW of [MBP (~42 kDa) + His6 (~600 Da) + peptide (~4.3 
kDa)] = ~47 kDa, indicated by arrow. 
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These results prompted an initial 2 L expression at 37°C for 3 h. After IMAC and rpHPLC purification, 
multiple peaks of equivalent size were seen in the region of expected mature toxin elution (~40% 
solvent B, minute 25) with no clear dominant peak (Figure 33). These results could be indicative of 
either disulfide shuffling due to exposure of glutathione during TEV protease cleavage or improper 
folding occurring in vivo. The latter hypothesis could be tested by optimizing the expression protocol. 
Reducing the temperature of induced expression to 16°C has been proven effective for enhancing the 
expression of soluble protein, limiting protein aggregation, and ensuring proper folding[531]. 
Therefore, a second 2 L expression was carried out with an overnight induction period of 16°C. 
 
Equivalent protocols for IMAC purification and cleavage by TEV protease were performed as 
described previously (Figure 34). The entire cleavage reaction was separated by rpHPLC and a single 
 
Figure 33: rpHPLC trace of rPre1a 2L expression at 37°C post TEV 
cleavage. 
Cleaved MBP can be seen at minute 34. 
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dominant peak was observed (Figure 35A). This result was indicative of proper in vivo folding. The 
peak was identified by MALDI-TOF MS as containing the correct mass for recombinant (r)Pre1a, 
4314.5. The theoretical mass of rPre1a was determined by adding the molecular weight of native Pre1a 
to that of Ser, equating to 4314.93 (Figure 35B). Despite the addition of an N-terminal Ser residue, 
recombinant Pre1a also eluted at the same retention time as the synthetic, properly folded Pre1a (Figure 
36). The fraction was lyophilized and resuspended in pure H2O for further analysis and functional 
testing. 10 µM stocks of purified TRTX-rPre1a were made and stored individually at -20°C to limit 
freeze-thawing of primary stock.  
 
 
Figure 34: SDS-PAGE Coomassie stain of NiNTA purification of rPre1a lysate. 
A) Purification of lysate by NiNTA IMAC. WC=whole cell lysate; Sol=Soluble lysate; 
FT=initial flow through; W=15 mM imidazole wash; E=250 mM imidazole elution; 
1M=1 M final imidazole wash; L= molecular weight marker. B) Before (1) and after (2) 
TEV cleavage of fusion protein. 
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Figure 35: rpHPLC purification of rPre1a. 
A) rpHPLC trace of rPre1a 2L expression at 16°C post TEV cleavage. A dominant peak is visible at 
minute 25-27, suggesting one dominant fold. B) MALDI-TOF MS confirmed a M+H+ of 4314.5. 
 
3.5 NaV channel activity of TRTX-rPre1a 
TRTX-rPre1a was tested on X. laevis oocytes 
injected with rat (r) or human (h) NaV channel 
RNA and measured with two-electrode voltage 
clamp (TEVC) methods. Initial testing with 1 
µM concentrations across all available 
isoforms of NaV channels was performed to 
obtain a general selectivity profile, followed 
by concentration response curves for the more 
active isoforms. All available NaV channel 
constructs were tested, which included the 
centrally expressed neuronal rNaV1.2, the 
peripherally expressed neuronal rNaV1.3 and 
hNaV1.7, the skeletal muscle rNaV1.4, and the 
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Figure 36: Comparison of elution time of rPre1a 
with native Pre1a 
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cardiac hNaV1.5. 
 
The observed effect of TRTX-rPre1a on rNaV1.3 expressed in oocytes was consistent with previous 
results indicating inhibition of inactivation  (Figure 37). Inhibition of fast inactivation can be viewed as 
a prolongation of late current, or a failure of the channel to conform to the inactivated state during a 
depolarizing stimulus. A slight potentiation of peak current was also detectable at 1 µM concentrations. 
 
For all other NaV channels tested, TRTX-rPre1a exhibited either inhibition of current or resulted in no 
significant activity (Figure 38). TRTX-rPre1a had the greatest effect on the neuronally expressed 
rNaV1.2 and hNaV1.7, with 1 µM resulting in an approximate 70% reduction in peak current. 
Concentrations of 1 µM TRTX-rPre1a also inhibited rNaV1.4 to a lesser extent, resulting in 
approximately 15% reduction in peak current. The functional effect of TRTX-rPre1a on hNaV1.5 was 
negligible at a concentration of 1 µM. It is of interest to note that these initial results suggested 
neuronal selectivity over both skeletal and cardiac isoforms. 
 
 
Figure 37: TEVC rPre1a inhibition of inactivation on NaV1.3. 
A) Inhibition of fast inactivation of rNaV1.3 expressed in oocytes with 1 µM rPre1a, as measured by 
TEVC; n=5. Baseline inactivated current is equivalent to 0. Sample current trace for NaV1.3 (B) shows 
inhibition of fast inactivation of late current with 1 µM rPre1a (red) after depolarization to 0 mV from 
a holding potential of -80 mV. Control current is shown in black. 
B) 
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Figure 38: TEVC rPre1a inhibitory effects on NaV channels. 
A) Inhibition of NaV peak current with 1 µM rPre1a against four separate rat or human NaV isoforms 
expressed in oocytes, as measured by TEVC; n ≥ 3 for each. The dotted line represents baseline 
current. Significant inhibition of the neuronal rNaV1.2 and hNaV1.7 is observed (p < 0.001). rNaV1.4 is 
significantly inhibited to a lesser extent (p < 0.05). Example current traces for rNaV1.2 (B) and 
hNaV1.7 (C) showing inhibition of peak current with 1 µM rPre1a (red) after depolarization to 0 mV 
from a holding potential of -80 mV. Control currents are shown in black. 
 
TRTX-rPre1a demonstrated an equipotent concentration-dependent effect when tested on both rNaV1.2 
and hNaV1.7 using TEVC methods (Figure 39). The IC50 of TRTX-rPre1a is sub-micromolar a both 
channels: rNaV1.2 with 290 nM and hNaV1.7 with 340 nM. Concentration-response curves were also 
attempted on the FLIPRTetra platform using the Membrane Potential fluorescence kit with stably 
transfected, single NaV channel expressing cell lines. As each cell line was unique to the channel it 
expressed, each required a separate assay. Aside from the cells used all variables were kept consistent 
with the exception of rNaV1.3, where the concentration of veratridine used for depolarization was 
decreased to a submaximal concentration of 5 µM to allow for the observation of a potentiating 
A) B) 
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response. Assays were limited to available cell lines. Both rNaV1.6 (IC50 = 6.4 µM) and rNaV1.7 (IC50 = 
7.5 µM) exhibited a concentration-dependent response to TRTX-rPre1a (Figure 40). Comparing the 
NaV1.7 response between TEVC and FLIPR methods reveals a 22-fold difference in potency for the 
latter method. A range of TRTX-rPre1a concentrations were also tested on both rNaV1.3 and hNaV1.4 
stably expressing cell lines using the same FLIPR methods. No effect of the peptide was observed in 
hNaV1.4 in this assay up to 30 µM rPre1a. In the case of rNaV1.3, analysis of the raw data for each well 
indicated an “all-or-nothing” maximal response with no concentration dependence, rendering an assay 
measuring an agonist response impractical.  
 
 
 
 
 
Figure 39: TEVC concentration response of rPre1a. 
A) Equipotent inhibition of current for both rNaV1.2 (IC50 = 0.29 µM) and hNaV1.7 (IC50 = 0.34 
µM); n ≥ 3 for each data point. Example IV-curves for both B) rNaV1.2 and C) hNaV1.7 after 
addition of 1 µM rPre1a. 
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Figure 40: FLIPR membrane potential concentration response of rPre1a. 
rPre1a tested on stably transfected cell lines A) expressing either rNaV1.6 (IC50 = 6.4 µM) or rNaV1.7 
(IC50 = 7.5 µM. B) Neither rNaV1.3 nor hNaV1.4 resulted in a measurable fluorescent response after 
addition of rPre1a. 
 
3.6 Structure of rPre1a 
The development of an efficient bacterial expression system allowed the production of uniformly 
13C/15N-labelled TRTX-rPre1a for structure determination using heteronuclear NMR. The NMR data 
clearly indicated the presence of multiple stable conformations. Here we have chosen to characterize 
the most abundant form. Backbone assignments were fully completed using the 1HN, 15N, 13Cα, 13Cβ, 
13C resonance assignments for the toxin obtained from analysis of amide proton strips in 3D HNCACB, 
CBCA(CO)NH, and HNCO spectra. Full peak assignment lists can be found in Appendix E. 
Unfortunately, backbone RMSD values did not converge sufficiently to obtain a high resolution 
structure. Side chain 1H and 13C chemical shifts were obtained primarily from 3D H(CC)(CO)NH-
TOCSY and (H)CC(CO)NH-TOCSY spectra, respectively. However, this pair of triple resonance 
experiments did not provide enough resolution for complete assignment of side chain 1H-13C 
connectivities, so some of the side chain 1H resonances could not be unambiguously assigned. 
Therefore, a high resolution solution structure showing side chain positions could not be determined 
due to insufficient constraints. However, some secondary structure could be determined using the data 
available.  
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Secondary structure prediction analysis was run using TALOS software using the chemical shifts of 
backbone atoms (Figure 41). Two β-sheet formations were predicted for residues C4-L5 and Y22-K23. 
Analysis of the 13C-NOESY strips confirmed the common ICK-motif disulfide folding pattern typical 
of many NaV channel modulating spider venoms (Figure 42). Typical ICK connectivity involves six 
cysteine residues bound in a I-IV, II-V, III-VI pattern. 13Cα and 13Cβ carbons of connecting cysteine 
residues can be visualized in corresponding strips, denoting a close proximity in 3-dimensional space 
consistent with disulfide bonds between the Cys side chains.  
 
 
Figure 41: Secondary structure predictions of rPre1a as calculated by 
TALOS.  β-sheet predictions are denoted by red arrows. 
 
The 15N-HSQC NMR data collected for TRTX-rPre1a also aided in the further characterization of its 
conformational heterogeneity. The 15N-HSQC spectrum revealed one major and two minor conformers 
in solution as demonstrated by a series of smaller peaks (chemical shift perturbations of certain 
residues) (Figure 43). It was possible to assign the backbone of the two minor isoforms thus identifying 
which residues are moving in the minor isoforms (See Appendix F for figure showing the 
CBCA(CO)NH strips). It was previously discussed that the possibility for the observed heterogeneity 
was due to cis-trans isomerization around or near proline residues, of which there are two in TRTX-
Pre1a. However, the residues in close sequence proximity to either P12 (S11, K13) and P19 (C18, N20) did 
not appear to exhibit chemical shift perturbations related to conformational heterogeneity. It should be 
noted that Pro is not visible on the 15N-HSQC spectra due to its lack of amide protons. 
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Figure 42: CBCA(CO)NH strips of the cysteine residues paired up as disulfide partners. 
The connectivity of Cys residues corresponds to a typical ICK arrangement.  
 
The residues that demonstrated the greatest chemical shift perturbations were C4, L5, G6, W7, F8 and 
R10, all of which occur in the Loop 1 region. G6 represents an excellent visual example of relative 
conformational populations as directly related to peak intensity in the 15N-HSQC. As seen in the insert 
of Figure 43, the major peak represents the major conformation in solution, while the two minor peaks 
represent 45% and 20% of the major form, respectively. This information coupled with the homology 
model strongly implicates the Loop 1 regions involvement with the apparent conformational 
heterogeneity of TRTX-Pre1a. 
 
Finally, the homology model of TRTX-Pre1a was aligned with the backbone of the solution structure to 
determine the models quality (Figure 44). The solution structure appears quite similar to the homology 
model. However, deviations do occur with the positioning of the C-terminal tail. 
106 
 
 
Figure 43: TRTX-rPre1a 15N-HSQC. Multiple conformational states are visible through peak 
shifting of a few residues, with Gly6 highlighted as an example. The peak height intensities of Gly6 
reflect the relative proportions of each form of the peptide in solution (A:B:C/1:0.45:0.2). Peak shifts 
of other residues are traced by blue line. Asp15 and Asp21 side chain groups are labeled. 
 
Figure 44: A backbone comparison of the TRTX-rPre1a solution structure and homology model. 
A) The dominant solution structure is represented in a single backbone structure. B) A comparison to 
the TRTX-rPre1a homology model. 
A) B) 
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4. Discussion 
 
Spider venoms have been instrumental in defining novel modes of action of and sites of functional 
regulation on NaV channels, demonstrating an ability to target extracellular loops around the S1-S4 
voltage sensor region and act as gating modifier toxins[34, 78, 532]. The discovery of TRTX-Pre1a 
highlights the very interesting functional modulatory capabilities of spider venom peptides and, 
potentially, many other classes of venom peptides that share the structural conformation of the ICK 
motif. Although the inhibitory mode of action was not fully determined through functional studies, 
evidence suggests that TRTX-Pre1a could work as a gating modifier toxin. The mode of action can be 
inferred from i) structural aspects such as the amphipathic hydrophobic face common among gating 
modifier toxins, ii) a high sequence similarity to related ICK-motif peptides with voltage-gated ion 
channel gating modifier properties (Table 3)[533], and most importantly iii) the functional role this 
peptide has on NaV1.3 through inhibiting inactivation, which in and of itself has been defined as a 
mechanism of voltage sensor trapping [215, 248]. In order to conclusively determine the mode of 
action as a gating modifier, one or more experiments can be conducted. Displacement of a 
radiolabelled ligand known to bind the NaV voltage sensor by titration of TRTX-Pre1a would suggest 
equivalent or overlapping binding sites. Mutagenesis of voltage sensor or loop regions of the NaV1.2 or 
NaV1.7 channels known to bind gating modifier toxins, with a subsequent drop in activity for TRTX-
Pre1a, would be a similar method of determination through active site association[34, 215]. An 
electrophysiological assessment could also be carried out that measures the voltage-dependence of 
activation, with a positive shift indicating gating modifier activity. However, experimental data remains 
to be completed in order to confirm this hypothesis.  
 
4.1 Recombinant expression 
Bacterial recombinant expression has been seen as a cost-effective and reliable alternative to producing 
peptides synthetically, potentially yielding milligrams of soluble, folded, mature peptide in a few liters 
of liquid medium[289]. The method used in this thesis for expressing recombinant TRTX-Pre1a was 
successful in producing high yields, with approximately 5 mg of mature, properly folded toxin 
produced per liter of LB medium. Recombinant expression also allowed the efficient production of 
uniform 13C/15N labeled peptide for NMR structural elucidation. The pLIC vector was chosen as a 
suitable candidate because of its production of a N-terminally fused maltose binding protein (MBP) and 
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periplasmic localization sequence[511]. The MBP protein acts as a solubility chaperone, limiting the 
occurrence of inclusion bodies that form from insoluble product. MBP has been show to be 
“uncommonly effective” at promoting peptide solubility when compared to other commonly used 
fusion proteins, such as glutathione S-transferase, and thioredoxin[534]. The exact mechanism of how 
and why MBP is so effective is not entirely known, although the periplasmic localization is known to 
aid folding. MBP itself is thought to have an “intrinsic” property of solubility, but endogenous 
chaperones within E. coli have also recently been demonstrated to mediate proper folding of the mature 
peptide[535].  
 
The cytoplasm of both eukaryotic and prokaryotic organisms is known be a reducing environment, not 
conducive to proper disulfide bond formation[536]. Eukaryotic organisms create an environment to 
properly fold peptides within an organelle called the endoplasmic reticulum (ER). Prokaryotic 
organisms lack an ER. However, gram-negative bacteria such as E. coli have a periplasmic space that 
exists between the inner and outer membrane. Not only is this space considered non-reducing, multiple 
disulfide bond isomerases and other chaperones have been found within the periplasm, making it a 
specialized region within the cell for post-translational folding[537]. The MalE periplasmic localization 
sequence on the pLIC vector promotes the fusion protein to be shuttled to the bacterial periplasm post-
production, where environmental conditions are more conducive to native folding [538]. 
 
The pLIC vector is completed with the addition of a TEV recognition site for cleavage of mature toxin 
from the fusion construct and an N-terminal His6 tag for immobilized-metal affinity chromatography 
(IMAC) with NiNTA resin. The TEV cleavage recognition site requires an optimal signal sequence of 
ENLYFQ/S. Although TEV cleavage has been shown to work effectively when the C-terminal Ser is 
replaced by multiple other residues[539], it was our observation that Ser was necessary to induce 
repeatable, full cleavage of the mature toxin from the MBP fusion protein. However, cleavage between 
the Gln and Ser leaves a N-terminal Ser residue as an artifact of cleavage on the mature toxin. This did 
not appear to have an effect on the function of this peptide as compared with the native peptide of the 
synthesized native sequence. 
 
In summary, the recombinant expression system efficiently produced milligrams of soluble, properly 
folded peptide in a reproducible, cost-effective manner.  
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4.2 Activity 
Many of the NaV modulating spider venoms toxins so far discovered conform to an ICK motif and act 
as gating modifier toxins, targeting extracellular loops around the S1-S4 voltage sensor region in DI-
DIV[34, 78, 532]. As discussed in Chapter 1, these regions have been segmented into neurotoxin 
receptor site 3 and site 4 as originally defined by α-scorpion toxin and β-scorpion toxin binding, 
respectively. Site 3 toxins are voltage-dependent inhibitors of inactivation that bind in a state-
dependent manner, trapping the voltage sensor in an open, hyperexcitability conformation[231]. 
Likewise, site 4 modulating peptides produce hyperexcitability by shifting the voltage-dependence of 
activation to a hyperpolarized potential, resulting in activation at sub-threshold potentials[188, 254, 
540]. A few spider venom peptides have been found to bind to the same loop regions comprising site 4 
but result in inhibition of current, or in some cases may occupy an undescribed binding region 
altogether. 
 
One of those venom peptides that may define a new site for gating modifier peptides is β/ω-TRTX-
Tp2a (ProTx-II)[251, 541]. Initial results using point mutations of specific extracellular loop amino 
acids of hNaV1.5 concluded that Tp2a does not bind to any extracellular region, but instead binds to a 
transmembrane helical region[542]. The amphipathic structure of Tp2a, caused by its hydrophobic face 
composed of Loop 1 residues, was shown to contribute to lipid binding[542]. This functional property 
was seen previously with other spider toxins and presented as a hypothesis of a lipid submerged 
binding site[532]. An exploration of NaV specificity found Tp2a to be 100-fold more selective to 
NaV1.7 than other isoforms, which is interesting because NaV1.7 possesses a unique residue on the C-
terminal portion of DIIS3[541]. Position 813 is a Phe, whereas all other NaV subtypes have a Gly or Ser 
(NaV1.6). Mutation of Phe813 to a Gly or Ser resulted in 100-fold reduced Tp2a sensitivity relative to 
other NaV subtype activity[541]. However, mutating the equivalent Gly839 residue in NaV1.2 to Phe 
did not significantly increase sensitivity to Tp2a, suggesting that the interaction of Tp2a is more 
complex and the Phe in this position is the only residue necessary to confer high affinity of Tp2a[541] 
[34]. Results focusing on larger regions of the voltage sensor domain further support the S3-S4 
segments as targets for Tp2a high affinity binding, and suggest that Tp2a may actually bind (at least 
partially) to extracellular S3-S4 loop regions[34]. Using chimeric expression of the rNaV1.2 voltage 
sensor “paddle” regions – composed of the C-terminal S3, N-terminal S4 regions, and the S3-S4 
extracellular linker –  spliced into KV2.1 domains, Tp2a was shown to inhibit activation by interacting 
with DI, DII, and DIV[34]. This finding was somewhat surprising given the presumed role of DIV in 
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inactivation as suggested by the authors. Based on the findings of this research, Bosmans et al. 
proposed that for a toxin to alter inactivation it must exclusively interact with the voltage sensor paddle 
of DIV and “any additional interactions with the other paddles will alter channel opening”[34]. This is 
an interesting finding that may give clues as to how Pre1a is able to alter the pharmacology of different 
NaV isoforms in two distinct ways. If this hypothesis is followed, the interaction of Pre1a with the 
individual domains of NaV1.3 should be explored, specifically whether it binds DIV without interacting 
with the other three domains of this isoform. However, the authors comment that there is high 
variability when dealing with specific toxins and receptor interfaces, and there is no “general lock-and-
key mechanism” to define a standard[34]. 
 
As stated previously in Chapter 1, µ-TRTX-Hh2a (huwentoxin-IV) has been shown to interact with 
neurotoxin receptor site 4 and because of its high affinity for NaV1.7, has become a popular candidate 
for intensive toxin profiling and NaV selectivity characterization through directed mutagenesis and 
functional studies[243, 256, 543-545]. Both Tp2a and Hh2a have been demonstrated to inhibit 
activation by trapping the DII voltage sensor in the resting configuration, although HWTX-IV may 
selectively bind to neurotoxin site 4[243, 546].   Both of these toxins were the highlight of an extensive 
study to define their voltage sensor activity on hNaV1.7[543]. The results of this study defined a new 
mode of action for Tp2a, where at concentrations above 1 µM the toxin was found to induce sustained 
currents through inhibition of fast inactivation in a mechanism similar to neurotoxin receptor site 3 α-
scorpion toxins, as well as reflecting activity seen with Pre1a on NaV1.3. This activity was found to be 
preferential to DIV of NaV1.7 and fully independent to inhibition of activation, which like Hh2a 
requires the DIIS3-S4 paddle region. Unlike Pre1a, Tp2a exerts its mode of action simultaneously and 
is unable to fully inhibit NaV current. These results suggest that Tp2a can bind to two different sites of 
the NaV channel simultaneously. This not only calls into question the previous proposal that DIV 
requires an exclusive interaction to inhibit NaV inactivation, but may also help redefine the roles of the 
classical view of NaV neurotoxin receptor sites[34, 543]. 
 
Data gathered from experiments with Hh2a and Tp2a not only demonstrate unique functional 
promiscuity, but also give much needed insight into the mechanism of interaction with NaV channels. 
Through the work described, the extracellular loops of the voltage sensor region of DII and DIV have 
been shown to be critical for the function of these two peptides’ specific mode of action. This insight 
can give us ideas on how to determine the functional role of Pre1a for future studies, as Pre1a exhibits 
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both inhibition of activation and inhibition of fast inactivation. Hh2a has been further characterized 
through Ala scanning and directed mutagenesis, demonstrating the functional necessity of hydrophobic 
residues on Loop 1 and the C-terminal region of the toxin[547]. Residues contributing to the 
hydrophobic face of Pre1a exist in similar Loop 1 and C-terminal regions, suggesting that this region of 
Pre1a is likely to be important for its activity at NaV channels. 
 
As with Tp2a, a significant structural feature of gating modifier peptides is their amphipathicity, with 
one face composed of hydrophobic residues surrounded by polar, mostly basic residues[254, 255, 548, 
549]. This structural composition is thought to aid in their observed ability to partially partition within 
the cellular membrane and interact with the transmembrane voltage sensor region[532]. This 
amphipathicity could also function to mediate interactions across different regions on the surface of the 
target receptor simultaneously, resulting in multi-domain binding[550]. Membrane partitioning should 
be included in future experiments to assess this ability in TRTX-Pre1a. Lipid model systems using 1-
palmitoyl-2-oleoyl-sn-3-phosphatidylcholine (POPC) or of a mixture of POPC and 1-palmitoyl-2-
oleoyl-sn-3-phosphatidylglycerol (POPG) to mimic the negative surface potential of the lipid leaflet 
facing the cytoplasm have been successfully tested and can be reproduced to determine if Pre1a 
exhibits membrane partitioning[551-553]. 
 
The functional profile of TRTX-Pre1a proved to be unique in that it not only inhibited NaV1.2 and 
NaV1.7 at sub-micromolar concentrations, but inhibited fast inactivation of NaV1.3 as well. As 
discussed, this inhibition of inactivation has been previously noted with Tp2a [543]. However, this 
effect was caused simultaneously with inhibition of activation. Sequence similarity to known peptides 
of similar class and known mechanisms of action give hints to the possible mechanism of Pre1a 
activity. The observed inhibition of fast inactivation of NaV1.3suggest that TRTX-Pre1a interacts with 
the voltage sensor as a gating modifier. A small depolarizing shift in the V1/2 max of NaV1.7 and 
NaV1.2 was observed for Pre1a (See Appendix C for normalized I-V plots), although more experiments 
are needed to confirm the results and decrease the standard error.. The inhibitory effect on NaV1.2 and 
NaV1.7 still remains to be determined. If NaV1.3 activity is due to a voltage sensor interaction, 
inhibition of activation could be via a mode of action similar to that of site 4 spider venom peptides, 
requiring the DIIS3-S4 paddle region. This mechanism involves voltage sensor trapping in the closed 
state, resulting in inhibition of current during a standard depolarization.  
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As to the binding sites through which it inhibits activation of NaV1.3, there are several possibilities: i) it 
binds to site 3 in a mechanism similar to Tp2a or α-scorpion toxins ii) it binds to site 4 of NaV1.3 but 
inhibits inactivation, not activation, or iii) it interacts with a completely novel binding site, around the 
voltage sensor domain or otherwise, to inhibit inactivation. As shown with Tp2a, these macromolecules 
are able to bind across sites, affecting multiple regions at once. Understanding the basis of the dual 
pharmacological action of Pre1a is an important step which requires further experimentation. Future 
studies to elucidate this activity could include using NaV channels with mutations of binding sites in 
combination with Pre1a mutants, the development of NaV channel chimeras similar to Bosmans 
referenced work, where a single domain of the NaV channel is substituted with a KV domain[79], and 
competitive binding experiments with known site 3 and site 4 toxins. Finally, the inhibitory effects of 
site 4 inhibitors can be reversed by strong, long-lasting positive voltage pulses, which drive the voltage 
sensor back into its activated conformation[246]. This experiment could be attempted as justification 
for site 4 interaction, although it is possible that an undefined interaction site in the voltage sensor 
region could be involved in the inhibitory activity of TRTX-Pre1a. More detailed examples of 
electrophysiology experiments are given in the final discussion. Regardless, defining the mode of 
action of Pre1a and its site of NaV channel interaction across the various isoforms remains as critical 
steps. If TRTX-Pre1a is shown to be a gating modifier and not a pore blocker, it is proposed that it be 
given the prefix “β/δ” to indicate the dual activity at NaV channels; β to indicate that it shifts the 
voltage-dependence of activation of NaV1.2 and NaV1.7, and δ to indicate inhibition of fast inactivation 
of NaV1.3, as per King et al. [353]. 
 
4.2.1 FLIPR and TEVC discrepancy 
An adaptation of the FLIPR assay developed in Chapter II was attempted using single NaV channel 
expressing cell lines against TRTX-rPre1a. For the initial cell lines tested, all showed a significant 
decrease in potency as compared to TEVC methods tested. A direct comparison could be made with 
NaV1.7, which has a 22-fold higher IC50 value while using the FLIPR platform. It is important to 
mention that different NaV1.7 channels were used between platforms, with the human homologue of 
NaV1.7 used for TEVC experiments and the rat homologue of NaV1.7 expressed in the cell lines used 
for FLIPR assay. It is unlikely that such a large discrepancy would be apparent when both channels 
share a 92.7% sequence homology, but the possibility cannot be completely discounted[554]. Another 
likely scenario involves cross-platform variability due to different endpoint responses being measured 
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and different host cells tested (oocytes versus mammalian cells) to name a few, all contributing to the 
apparent discrepancy in sensitivity. As TEVC was used for initial discovery purposes, the data obtained 
set a precedent for activity. The FLIPR assay resulted in much lower potencies overall and TEVC was 
pursued as the primary means of functional characterization for further studies. 
 
4.3 Structure 
Structural heterogeneity has been observed among a few tarantula toxins affecting the voltage sensor 
domain on voltage-gated ion channels[524, 555, 556]. VSTX3 is a toxin affecting the voltage-gated 
potassium channel from archeabacteria Aeropyrum pernix and showed a broad rpHPLC 
chromatographic profile[555]. Likewise, κ-TRTX-Gr1a (hanatoxin 1) has been shown to elute as two 
chromatographically separated peaks in equilibrium[524, 556]. In the case of κ-TRTX-Gr1a the authors 
concluded that the two peaks were a chromatographic phenomenon [524]. However, for VSTX3 it was 
proposed that some tarantula toxins affecting the voltage sensor domain of voltage-gated ion channels 
might exhibit a degree of conformational heterogeneity. As mentioned previously, κ-TRTX-Gr1a 
exhibits the ability to interact with multiple regions of the KV channel simultaneously. Perhaps the 
structural flexibility of these peptides allows them to occupy multiple binding domains and is necessary 
for their promiscuous function. This would be an extremely interesting phenomenon to explore, with 
relevant implications for rational drug design. Unfortunately, in the case of VSTX3, this phenomenon 
was not explored in more detail[555].  
 
The chromatography of κ-TRTX-Gr1a appears very much like the chromatographic behavior observed 
for TRTX-Pre1a, as can be seen in Figure 30 and the inset of Figure 28. Therefore an experiment 
similar to the one conducted by Swartz and Mackinnon was carried out [524]. Purified, folded TRTX-
Pre1a was injected and fractions of the dominant peak were collected. The fractions collected from the 
major peak were reinjected and a similar chromatographic profile with the two peaks was evident, as 
visualized in the inserts in Figure 30. This could be partially due to the multiple structural 
conformations that appear to be present in solution at room temperature. The possibility that the two 
visible peaks within the inset of Figure 28 originate from at least two conformational isomers of 
TRTX-Pre1a in solution was supported by information gained from making a homology model of the 
peptide and confirmed using NMR data collected to determine the solution structure of TRTX-rPre1a. 
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In order to gain a better understanding about the possible causes of the apparent conformational 
heterogeneity, a homology model of TRTX-Pre1a was made using the solution structure of β-TRTX-
Ps1a. The model revealed key structural features, such as a hydrophobic face made up of five residues, 
W7, F8, Y22, W30 and Y32. This structural feature is common with many NaV modulating, ICK motif, 
spider venom peptides[245] and has been hypothesized to contribute to the voltage sensor trapping 
mechanism of site 3 and site 4 gating modifier toxins[532]. The hydrophobic face has been theorized to 
allow the peptide to partition within the outer cell membrane, exposing a larger surface of interaction 
within the voltage sensor region[557]. The model revealed possible structural tension within the 
between the large aromatic residues of the hydrophobic face, hypothesized to be a product of aromatic 
stacking which will be discussed in detail later. To confirm the constraints and provide more evidence 
against the argument that this could be an artifact of the template used for modeling TRTX-Pre1a, a 
solution structure was attempted.  
 
The solution structure of TRTX-rPre1a was partially solved using heteronuclear NMR methods 
previously described. The peptide was uniformly 13C- and 15N-labeled through recombinant methods, 
which allows for high resolution chemical shift mapping of resonances [558]. However, the backbone 
RMSD values did not converge sufficiently to determine a high resolution structure, nor was the 
assignment of the aliphatic and aromatic side chain 1H and 13C atoms possible to complete using the 
acquired TOCSY spectra. Regardless, the information available was enough to assign secondary 
structure. Through analysis of the Cys residues through the 13C-NOESY strips, it was possible to 
identify disulfide bond connectivity through interproton nuclear Overhauser effect (NOE), which 
indicated the pairs of protons that are close to one another in space by around 6 Å. This was achieved 
by identifying NOEs between paired Cys residues, due to their proximity through space. The 
connectivity seen through this method was consistent with the standard ICK motif connectivity of I-IV, 
II-V, III-VI. Secondary structure of TRTX-rPre1a was predicted using TALOS software, which 
identified residues C4-L5 and Y22-K23 as potential contributors to β-sheet formation. The standard ICK 
fold as mapped in Figure 5 in the introduction identifies the typical antiparallel β-sheets found in many 
NaV modulating spider venom peptides. Residues C4-L5 represent a region on the ICK map that 
typically does not conform to a β-sheet on other peptides of similar class derived from spider 
venom[309]. Analysis of the backbone structure of TRTX-rPre1a suggests that a β-sheet in this 
position would not align in an antiparallel fashion (Figure 44). TALOS also did not predict a more 
common anti-parallel β-sheet that is known to occur in proximity to the 6th Cys residue. Relying on the 
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homology model, a β-sheet around the 6th Cys residue would likely align in an antiparallel fashion to 
the Y22-K23 β-sheets. 
 
Although it was not possible to determine a high resolution structure, important evidence for the cause 
of structural heterogeneity in TRTX-Pre1a was found upon examination of the 15N-HSQC spectrum. 
The hypothesis of cis-trans isomerization around the Pro amide bond was discounted a due to a lack of 
chemical shift perturbation in the vicinity of these residues. Perturbations were seen in residues 
associated with the Loop 1 region, confirming that the non-symmetrical peak observed on rpHPLC is 
due to structural heterogeneity under the chromatographic conditions. Furthermore, the NMR data 
indicates that the hydrophobic residues in this region – particularly W7 and F8 – are involved in the 
structural heterogeneity as hypothesized above. Analysis of the G6 chemical shift perturbations 
indicated a presence of at least three forms of the toxin in solution. 
 
These findings brought us back to the homology model in Figure 31 to study the Loop 1 region. 
Directly adjacent to the G6 residue are two aromatic residues contributing to the hydrophobic face, W7 
and F8. It is highly plausible that the five aromatic residues composing the hydrophobic face associate 
in a process known as aromatic stacking. Aromatic stacking involves non-covalent, weak interactions 
of ring centroids separated by a preferential distance of between 4.5-7 Å and typically results in 
structural stabilization, with multiple electrostatically favorable geometries possible [559]. The 
electrostatic component has been proposed to arise from interactions of the quadrupole moments of the 
aromatic rings. Two confirmations are found commonly in peptides i) π-interactions, which are side to 
face interactions of the ring centroid, and ii) offset stacking, which exhibits similar geometry to that of 
DNA base pairs [560]. Whereas β-TRTX-Ps1a and other similar toxins appear to form an ordered 
aromatic stack with two to three contributing residues, the association of five offset aromatic residues 
of TRTX-rPre1a may contribute to the shuffling of the aromatic stacks between multiple energetically 
favorable positions. In TRTX-Pre1a, the W7 residue is sandwiched between a F8 and W30 residue on 
one side and a Y22 and Y32 on the other, within 7 Å to each. This positioning is hypothesized to cause 
conformational fluctuations of W7 between multiple possible aromatic stacking interactions. 
Complicating the issue further, both W7 and F8 appear directly adjacent to each other, constrained by 
their proximity and the structural rigidity of disulfide bonding. The strong forces of disulfide bonds 
associated with the ICK motif secondary structure would work in opposition to weaker, non-covalent 
aromatic side chain interactions [561]. It is a hypothesis of this chapter that the aromatic stacking of 
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TRTX-Pre1a contributes to the structural instability, with one dominant form stabilized by the peptides 
structural motif. The W7A residue appears critical for this mode of action. 
 
4.4 Summary 
TRTX-Pre1a demonstrated a unique and interesting set of qualities, not yet seen with venom peptides 
characterized to date. Not only did Pre1a selectively inhibit neuronal NaV peak current – including the 
novel pain target NaV1.7 – but inhibited fast inactivation of the neuronal NaV1.3 channel at sub 
micromolar concentrations. Further, the appearance of conformational heterogeneity was demonstrated 
over multiple experiments. Data suggested the Loop 1 region of Pre1a contributes to this observed 
structural heterogeneity. This could likely be related to opposing forces due to favorable aromatic 
stacking interactions, steric clashes, and structural constraints due to the covalent disulfide bonds. The 
contribution of Gly6 to Loop 1 flexibility could also play a part. The role of this conformational 
flexibility, if any, is unknown, but it may be that it could play a role in the ability of Pre1a to exhibit 
two mechanisms of action at different channels.  
 
In order to test this hypothesis, as well as examine the functional effects of Pre1a in greater detail, a 
mutagenesis study was undertaken and will be discussed in detail in the next chapter. 
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Chapter IV: Guided mutagenesis and SAR of TRTX-rPre1a 
 
1. Introduction 
 
The previous chapter highlighted the unique, characteristics of /-TRTX-Pre1a and demonstrated an 
efficient method of production for this peptide that can be used as a platform to carry out structure-
activity relationship studies. The ability of TRTX-Pre1a to modulate different isoforms of the NaV 
receptor family with two distinct mechanisms of action can give helpful insight about how subtle 
changes in amino acid sequence can result in pronounced selectivity and functional changes. Not only 
did TRTX-Pre1a demonstrate functional characteristics not yet seen with other venom peptides, but it 
also exhibited conformational heterogeneity 
 
TRTX-Pre1a shares close sequence homology to many other spider venom peptides discovered over 
the last decade, specifically the NaV spider toxin Family 1[239] (Table 4). Many of these peptides 
already have pharmacological profiles of varying scope (from very basic nerve fiber function to in 
depth selectivity) that can be drawn upon to begin to understand which regions of Pre1a might 
contribute to its activity and subtype selectivity. Additionally, the inhibitory cysteine knot (ICK) motif 
apparent among these NaV modulating peptides imparts a further commonality. The structural rigidity 
of the ICK motif makes these peptides of interest for therapeutic development as it imparts high levels 
of thermal and biological stability. In combination, these similarities can be exploited in order to learn 
more of how structural and sequence characteristics impart functional differences. The close structural 
motif of all these peptides allows a close comparison of minor amino acid differences between them.  
  
In essence, using available data regarding known peptides of similar classes can help determine 
potential residues of functional importance. This chapter describes the directed mutagenesis of TRTX-
rPre1a and the resulting pharmacologic and structural changes imparted by these selected mutations. 
Using a combination of results obtained in the last chapter coupled with information collected from 
various sources describing studies on homologous venom peptides, five mutants were designed and 
produced. These mutations focused on points of interest regarding either i) the observed structural 
heterogeneity of TRTX-Pre1a, hypothesized to be a result of aromatic interactions within the Loop 1 
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region; or ii) the observed functional necessity of individual residues found through the alignment of 
characterized peptides with high sequence similarity yet differing selectivity.  
 
Table 4: NaV modulating spider toxin alignment.  
Comparative amino acid sequences of spider toxin family members with known NaV selectivity profiles. 
Green equates an IC50 <1 µM. Red is inactive up to 10 µM. Yellow is activity >1 µM. Blue represents 
<1 µM agonist activity. White is no data available. Data accessed through Arachnoserver[509]. 
 
 
Alanine (Ala) scanning is a commonly adopted method used to determine the functional significance of 
individual residues on both the structure and activity of a peptide[562, 563]. Out of the twenty standard 
amino acids, Ala is used because it contains a non-bulky, chemically inert methyl functional group that 
maintains the secondary structure preferences of many of the other amino acids while eliminating the 
side chain interactions. While Gly eliminates the functional side chain group completely, the 
replacement of the methyl group with a hydrogen atom creates added conformational flexibility that 
can distort a peptide’s secondary structure, hence its lack of use for a residue replacement[564]. This 
chapter incorporates both Ala substitutions as well as substituting residues based on functional 
properties, in this case charge. Recombinant methods of production optimized for TRTX-rPre1a in the 
previous chapter were used in lieu of solid phase synthesis. 
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The primary aims of this chapter were as follows:  
 
1) Identify the residue(s) responsible for the observed structural heterogeneity apparent in native 
TRTX-Pre1a and determine the functional effect of their mutation to alanine.  
 
2) Focus on functional mutations of a single C-terminal residue known to impart specific NaV1.3 
isoform selectivity and attempt to engineer in/out higher NaV1.7 selectivity for rPre1a. 
 
3) Solve the solution structure of a single mutant affecting the conformational heterogeneity seen with 
the native and recombinant Pre1a and compare both structural and functional characteristics. 
 
2. Methods 
 
2.1 Selection of rPre1a mutants 
TRTX-Pre1a has high sequence similarity to a variety of previously discovered ICK motif spider 
venom peptides across a range of genetic families, each with slightly differing NaV isoform selectivity 
profiles (Table 3/Table 4)[251]. The close sequence homologies coupled with associated changes in 
activity have the potential to indicate which residues of TRTX-Pre1a contribute to selectivity and 
general NaV activity. The first step was to access all known, published, and publicly available spider 
venom peptides on Arachnoserver [509]. Peptides were initially sorted for known biological activity 
towards mammalian NaV channels. Next, peptides were sorted for structural similarity, primarily being 
the six cysteine framework defining the ICK motif. Peptides exhibiting an ICK secondary structure but 
with more than six disulfide bonds were excluded [565]. The resulting Table 4 was used to determine 
residues that could be targeted for mutagenesis of rPre1a.  
 
There were two primary aims for the selection of residues for mutation. Residues were either chosen 
for their proximity to regions of conformational instability or for their known contribution to NaV 
channel function and selectivity. The first two mutations were decided based on structural aspects of 
rPre1a highlighted in the previous chapter, elucidated using a combination of homology modeling 
based on Ps1a and NMR data. The homology model revealed the dense clustering of aromatic side 
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chain residues in Pre1a that form the hydrophobic face common to this peptide family. In particular, it 
showed that the Loop 1 residues W7 and F8 are positioned in between several other aromatic residues – 
Y22, W30, and Y33 – in a potentially conformationally unstable position. The hydrophobic face of Pre1a 
differs from other known spider venom peptides of the same family in that all five contributing residues 
are aromatic. With Ps1a there is a significant contribution of Leu in the center of the hydrophobic 
face[251], while Tp2a has a Met[566], both of which are less bulky, non-aromatic residues. Neither 
toxin shows structural heterogeneity.  
 
A hypothesis regarding the close proximity of the hydrophobic stack of W7 and F8 of Pre1a as 
compared to F5 and L6 of Ps1a was explained in detail in the previous chapter. Based on this 
hypothesis, in this study W7 and F8 were independently mutated to Ala. The expected results of 
changing these residues to Ala would be to reduce the potential overcrowding of aromatic side chains, 
thereby decreasing or eliminating structural heterogeneity (Table 6). However, Trp is known to be a 
common protein-protein interaction “hotspot” residue, greatly contributing to receptor-ligand 
interactions [567]. It is therefore possible that these mutations may modify the rPre1a structure in such 
a way as to critically change the pharmacologic profile. It is therefore important to also assess whether 
these mutations affect NaV function in any way, including the dual mechanism of action.  
 
To address Pre1a function specifically, Table 4 was used to compare characterized peptides with high 
sequence similarity and known NaV activity profiles. After careful analysis of Table 4, an interesting 
sequence deviation was noted, which is highlighted in Table 5. The spider venom peptides Cm1a and 
Cm1b differ by only a single residue at position 32. Changing the aromatic Y32 residue of Cm1b to a 
negatively charged D32 of Cm1a abolishes the inhibitory activity at NaV1.3 while maintaining activity 
for all other NaV channels tested [251]. The equivalent residue position in Pre1a is the positively 
charged K34. Ps1a retains inhibitory activity to NaV1.3 and contains a polar, uncharged Q34 (Table 5). 
With this information, it was decided to focus on three functional charge mutations of the K34 residue 
for rPre1a, substituting it for i) a hydrophobic, but less sterically hindered Ala (A) to potentially 
remove side chain interactions, ii) a negatively charged Asp (D) as pre the NaV1.3 inactive Cm1b, and 
iii) a polar, uncharged Gln (Q) as per the NaV1.3 inhibitor Ps1a (Table 6). 
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Table 5: Sequence alignment of key peptides with summary.  
Spider toxin family alignment broken down to represent three structurally related peptides to Pre1a 
with the most interesting available functional information. Highlighted regions on the sequence 
correlate with Table 5. 
 
 
Table 6: Summary of TRTX-rPre1a mutations 
 
 
2.2 Production and purification of TRTX-Pre1a mutants 
Recombinant expression of all mutants and the resulting purification by IMAC and rpHPLC within this 
chapter followed methods described in Chapter III, section 2.1-2.6. 
 
2.3 Assessment of structural heterogeneity by rpHPLC 
rpHPLC experiments at increasing temperatures to observe the effect on isomerization were carried out 
using a CTO-20A column oven attached to a Shimadzu LC-20AT Prominence system equipped with a 
SIL-20AHT autosampler and a SPD-20A dual wavelength UV/VIS detector. The instrument was 
equipped with a Zorbax 300SB-C18 column (Agilent; 4.6 × 150 mm; 3.5 µm particle diameter) and run 
on a 10-50% linear gradient buffer exchange of solvent A (H20, 0.1% TFA) to B (90% ACN, 10% H20, 
0.1% TFA) over 20 min with a flow rate of 0.5 mL/min. 
 
Mutation
W7A
F8A
K34A Hydrophobic, occupies less space than Tyr of Cm1b
K34D Cm1a mimic, knocks down Nav1.3 activity (+) to (‐) charge
K34Q Ps1a mimic ‐ switched residue to polar, uncharged
Reasoning
Based on homology model of Ps1a. Area on Loop 1 in close 
proximity to Gly
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2.4 TEVC methods 
Handling of oocytes, buffers used, and all recording and analysis methods were completed as 
previously described in Chapter III, section 2.8 and analyzed according to methods in Chapter III, 
section 2.10. 
 
2.5 Structure determination by heteronuclear NMR 
Lyophilized 13C/15N-labeled recombinant rPre1a[W7A] was resuspended at a final concentration of 300 
µM in 300 µl 10 mM sodium phosphate buffer, pH 6.0, constituted in 95% H2O / 5% D2O. 
Subsequently sample was added to a susceptibility-matched 5 mm outer diameter microtube (Shigemi 
Inc., Japan). 
 
Data were acquired at 298 K using a 900 MHz NMR spectrometer (Bruker BioSpin GmbH, 
Rheinstetten, Germany) equipped with a cryogenically cooled triple resonance probe. Sequence 
specific backbone resonance assignments were obtained using 3D CBCA(CO)NH, 3D HNCACB, 3D 
HNCO, 2D 1H-15N HSQC, 3D HBHA(CO)NH, and 4D HCC(CO)NH-TOCSY spectra, which were all 
acquired using non-uniform sampling and transformed using maximum entropy reconstruction with the 
Rowland NMR Toolkit (http://www.rowland.org/rnmrtk/toolkit.html) as described previously [515].  
 
HSQC-NOESY (15N-, 13C aliphatic-, 13C aromatic-) spectra were obtained using uniform sampling and 
processed using standard Fourier transform methods, then used for extraction of inter proton distance 
restraints, with a mixing time of 220 ms. Dihedral-angles were derived from TALOS chemical shift 
analysis [516], and the restraints range for structure calculations were set to twice the estimated S.D. 
NOESY spectra were manually peak picked and integrated using Sparky NMR analysis software [517]. 
The peak lists were then automatically assigned, distance restraints extracted, and an ensemble of 
structures calculated using the torsion angle dynamics package CYANA[518]. During the automated 
NOESY assignment/structure calculation process, CYANA assigned 95.4% of all NOESY cross-peaks 
(1277 out of 1338). The final structure was calculated using 450 unique distance restraints (142 intra 
residue NOEs, 139 sequential NOEs, 63 medium range NOEs – to residues closer than 5 amino acids 
away in the sequence, and 106 long range NOEs – to residues further than 5 amino acids away in the 
sequence). The backbone root-mean-square deviation (RMSD) was calculated to be 0.65 Å and the 
side-chain RMSD was 1.79 Å. Dihedral-angles (26 φ, 27 ψ) were derived from TALOS chemical shift 
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analysis[516], and the restraint range for structure calculations was set to twice the estimated S.D. All 
X-Pro peptide bonds were identified as trans on the basis of characteristic NOEs and the Cα and 
Cβ chemical shifts of the Pro residues.  
 
Table 7: Statistical analysis of rPre1a[W7A] structures1 
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3. Results 
 
3.1 Purified TRTX-rPre1a mutants 
All five mutants of TRTX-rPre1a were successfully cleaved from their fusion protein and purified in 
milligram yields. Mass was confirmed by MALDI-TOF MS and purity was confirmed using analytical 
rpHPLC methods previously described. In reversed-phase chromatography, retention time of a peptide 
is directly related to its hydrophobicity [568]. A comparison of rpHPLC traces for each mutant showed 
shifts in retention times that reflect 
changes in hydrophobic surface 
properties (Figure 45). Both W7A and 
F8A resulted in a leftward shift of 
retention time as compared to native 
rPre1a, signifying a decrease in 
hydrophobic properties. This would 
be expected for each case, as a large 
hydrophobic side chain was 
substituted for one much smaller and 
presumably less surface exposed. Of 
the two mutations, W7A showed the 
greatest shift from the native peptide. 
In contrast, all three Lys mutations 
resulted in only a slight right-shift in 
retention time as compared to TRTX-
rPre1a, signifying a slight increase in hydrophobicity. All three Lys mutations co-eluted at the same 
retention time.  
 
An interesting point to note is the minor peak visible with TRTX-Pre1a is also apparent in an 
equivalent position on both the K34D and K34Q mutations (Figure 45). The W7A mutation also exhibits 
a minor peak, however the position of the major and minor peaks is reversed as compared to TRTX-
rPre1a such that the minor peak is now eluting at a later retention time (i.e. more hydrophobic). The 
most interesting point to note is the lack of a minor peak with F8A. Apparently, this mutation was 
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Figure 45: rpHPLC comparison of retention times of 
rPre1a with mutants. 
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successful in eliminating the structural heterogeneity apparent with the native TRTX-Pre1a. However, 
additional experiments are necessary to confirm this result.  
 
3.2  Conformational flexibility of rPre1a mutations 
It was clearly demonstrated within Chapter III that TRTX-Pre1a exhibits conformational heterogeneity. 
This property was observed first by rpHPLC in the form of a minor peak shown to by a conformer and 
then confirmed by analysis of the 15N-HSQC of rPre1a. Similar to TRTX-Pre1a, the K34D, W7A, and to 
a lesser extent K34Q mutations exhibited minor peaks suggestive of multiple structural conformations. 
The minor peak and leading tail for each was assessed using MALDI-TOF MS, with all regions yielded 
equivalent mass to the major peak, confirming they are structural isoforms rather than impurities. As a 
secondary test, an experiment was set up to study how the equilibrium between the two peaks from 
TRTX-Pre1a would be influenced by elevated temperatures.  
 
The rotational energy barrier between cis- and trans-isomers, cis-trans isomerization has been proven 
to be a slow process at room temperature [523]. Bearing this in mind, elevating the temperature speeds 
up the cis-trans isomerization of a peptide and shifts the equilibrium towards a single form. Although 
cis-trans isomerization has been discounted as an explanation for the structural heterogeneity of 
TRTX-Pre1a, the same concept of temperature dependence can be applied to other modes of 
conformational heterogeneity proposed for this peptide. For example, movement of aromatic residues 
has been proposed in Chapter III to be the primary force contributing to the conformational 
heterogeneity of TRTX-Pre1a. Therefore rpHPLC analysis of TRTX-Pre1a and mutations were carried 
out a room temperature (25°C) and 55°C to monitor the changes in peak shape (Figure 46). 
 
TRTX-Pre1a was tested alongside K34D and W7A. F8A was included to confirm its apparent 
conformational homogeneity using differing temperature conditions. Retention time is known to 
decrease with an increase in temperature, which was seen for each peptide tested[569]. Further, for 
each sample tested at 55°C a single peak was resolved. As expected, this result indicates that the slow 
interconversion between multiple conformational species that is evident from the retention data at 25°C 
occurred at a faster rate than the chromatographic separation time, converging into a single species. 
This data provides additional evidence for conformational heterogeneity apparent even in the K34 and 
W7 mutations. The results seen for F8A demonstrate that this mutation has eliminated the structural 
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heterogeneity seen with TRTX-Pre1a and the other mutations. The next step was to determine whether 
the mutations have affected functional activity at NaV channels and answer the question of whether 
structural heterogeneity is necessary for any of the functional effects of TRTX-Pre1a.  
 
 
 
Figure 46: rpHPLC experiment using heated column. 
An increase in temperature to 55°C (red) demonstrated that rPre1a and mutations present 
a single peak, suggesting the multiple peaks visible at 25°C (blue) are due to multiple 
conformational states. F8A appears to be an exception, exhibiting one visible, sharp peak 
state at both temperatures tested. 
 
3.3 Functional activity as measured by TEVC methods 
 Once purified, each of the five mutations were tested on X. laevis oocytes injected with rat (r) or 
human (h) NaV channel RNA and measured with two-electrode voltage clamp (TEVC) methods. 1 µM 
concentrations of each mutant were tested against all available NaV channel isoforms, including 
rNaV1.2, rNaV1.3, rNaV1.4, hNaV1.5 and hNaV1.7 (Figure 47/Figure 48). Mutations either increased or 
decreased the activity as compared to the wild-type, but did not result in an apparent change in the 
mechanism of action (e.g., inhibition of peak current versus inhibition of fast inactivation), nor did the 
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kinetics of activation change at the concentration used. No mutations tested had any effect on either 
rNaV1.4 or hNaV1.5 up to 1 µM. The only mutation that appeared to have no effect on activity 
compared to wild type rPre1a was F8A (Figure 49). This is a significant result, as F8A was also the only 
mutation to exhibit a single conformation as tested on rpHPLC (Figure 46). On the contrary, 1 µM 
W7A resulted in an almost complete loss of rNaV1.2 and hNaV1.7 inhibitory activity and rNaV1.3 
inhibition of fast inactivation (Figure 49). 
 
The three K34 mutations resulted in activity profiles that revealed how charged residues can greatly 
impact the efficacy of a peptide ligand, as well as which NaV channels may be more susceptible to 
ionic interactions. K34A replaced the positively charged long carbon side chain of Lys with a 
hydrophobic Ala, greatly reducing the side chain chemical space while abolishing the charge. This 
resulted in no significant change in rPre1a activity as tested on rNaV1.3 and hNaV1.7, but did result in a 
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Figure 47: Inhibition of rNaV1.2 and hNaV1.7 by rPre1a mutants. 
Comparison of rNaV1.2 and hNaV1.7 inhibition from baseline (dotted line) across 1 µM 
rPre1a mutants as tested by TEVC methods. n ≥ 3 for all experiments. Example I-T plots can 
be found in Appendix B. Significance was determined by ANOVA, denoted with * for >0.05 
or ** for >0.001. 
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reasonable (~2-fold) loss of activity at rNaV1.2 (Figure 47). K34Q replaced the Lys with an uncharged, 
polar side chain occupying a similar chemical space. This resulted in a slight decrease in activity for 
rNaV1.3 (Figure 48). However, there was an almost a 2-fold increase in activity for hNaV1.7. This was 
the only mutation that significantly increased activity for hNaV1.7.  
 
As mentioned in section 2.1 of this chapter, K34D was designed as a mimic of β-Cm1a – which has no 
activity at NaV1.3 – resulting in a single residue charge shift from positive to negative. As was hoped, 
this single mutation essentially abolished activity against rNaV1.3 at 1 µM, demonstrating the 
importance of this reside position for interaction with this NaV isoform. The K34D mutation 
unfortunately also dramatically decreased the activity of Pre1a at hNaV1.7 using a 1 µM concentration, 
 
Figure 48: TEVC rPre1a inhibition of inactivation on NaV1.3. 
Comparison of rNaV1.3 inhibition of fast inactivation across 1 µM rPre1a mutants as 
tested by TEVC methods. The results are expressed as fold increase in magnitude of the 
late current, calculated by dividing the late current amplitude in the presence of peptide 
by the control late current. n ≥ 3 for all experiments. Example I-T plots can be found in 
Appendix B. Control response = 1 (dotted line). Significance was determined by ANOVA, 
denoted with a * for >0.05 or ** for >0.001. 
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resulting in approximately 10% inhibition rather than 80%, as was seen with the wild-type. 
Surprisingly, the rNaV1.2 activity of K34D was increased 2-fold over native rPre1a. With these results 
combined with the inactivity at rNaV1.4 and hNaV1.5, it suggests that rPre1a[K34D] could be a highly 
selective inhibitor of NaV1.2. However, its activity at NaV1.1, NaV1.6, and NaV1.8 remain to be tested.  
 
3.4 Solution structure of rPre1a[W7A] 
The W7A mutation of rPre1a was selected for NMR structural elucidation due to its central position 
among the hydrophobic face, seen in Figure 31 of the previous chapter. Despite the appearance of a 
minor peak in the rpHPLC trace indicating a second structural isoform, the 15N-HSQC of rPre1a[W7A] 
showed only a single conformation in aqueous solution. The appearance of a minor, more hydrophobic 
isoform in the rpHPLC trace could be due to the more hydrophobic conditions used with rpHPLC (i.e. 
25-30% organic solvent when the peptide elutes), which would allow the appearance of the 
hydrophobic minor form. As there is no organic solvent in the aqueous buffer used with NMR, it seems 
the conditions are less favorable for the minor isoform seen in rpHPLC. Coupled with the high yields 
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Figure 49: Percent change in activity as compared to rPre1a[wt]. 
Normalized averaged results for each mutation were compared to their respective 
rPre1a results, repeated for three NaV subtypes. Negative values represent a 
decrease in activity. Positive values represent an increase in activity. 
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of rPre1a[W7A] from recombinant expression, it was decided to focus on solving the solution structure 
for this peptide. At the time, only limited pharmacology data was available to influence the decision.  
The solution structure for the rPre1a[W7A] 
was successfully solved using heteronuclear 
NMR experiments on recombinantly 
expressed 13C/15N-labelled peptide (Figure 
50). Backbone assignments were fully 
completed using the 1HN, 15N, 13Cα, 13Cβ, 13C 
resonance assignments for the toxin obtained 
from analysis of amide proton strips in 3D 
HNCACB, CBCA(CO)NH, and HNCO 
spectra. The full peak lists can be found in 
Appendix E. Side chain 1H and 13C chemical 
shifts were obtained primarily from using a 
4D HCC(CO)NH-TOCSY experiment, which 
has the advantage of providing side chain 1H-
13C connectivities[570]. Additional aliphatic 
side chain assignments as well as aromatic 
side chain assignments were derived from 3D 
15N- and 13C-edited NOESY-HSQC spectra. 
The NMR data indicated a single stable fold in 
solution and the rPre1a[W7A] structure was therefore more precisely determined than the original 
rPre1a solution structure (backbone RMSD of 0.34 ± 0.08 Å for C4-K34) (summarized in Table 7). 
CYANA[518] was used for automated NOESY assignment and structure calculation. 200 structures 
were calculated from random starting conformations, then the 20 conformers with highest 
stereochemical quality as judged by MolProbity[571] were selected to represent the solution structure 
of rPre1a[W7A]. 
 
As demonstrated previously with rPre1a, the structure of rPre1a[W7A] exhibits a standard ICK motif, 
with four inter-cysteine loops bounded by N- and C-terminal “tails” (Figure 50). The dominant 
secondary structural features are two β-sheets involving residues Y22-C24 and C31-Y33 (Figure 51). 
Previous prediction by TALOS for rPre1a secondary structure resulted in slight differences, although 
 
Figure 50: Overlay of 20 backbone structures 
for rPre1a[W7A]. 
The structure of the W7A mutant was well defined, 
even in the tail regions. Disulfide bonds in typical 
ICK motif arrangement are highlighted in yellow. 
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positively predicting the β-sheet at Y22. A β-sheet at C4 was predicted, while the C31 β-sheet was not. 
However, the two β-sheets typically seen with ICK peptides were clearly defined in the final structure 
(Figure 51). 
 
The position of the W7A mutation can clearly be seen as a central position between aromatic residues 
composing the hydrophobic face (Figure 52). The space-filling model highlights the gap, or cleft, left 
by the absence of the large aromatic Trp.  
 
 
 
 
 
Figure 51: Cartoon representation of 
rPre1a[W7A].  
W7A mutation is highlighted in red. 
Disulphide bonds are in yellow. β-sheets are 
in blue 
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3.4.1 Comparison of rPre1a[W7A]to rPre1a[wt] 
In order to determine the effects of the W7A mutation on structure, the changes in 15N and 1H chemical 
shifts of the 15N-HSQC were compared between rPre1a[wt] and rPre1a[W7A]. The 15N-HSQC of W7A 
does not exhibit the peak shifting associated with conformational heterogeneity as seen with the HSQC 
of rPre1a[wt] (Figure 53). Major chemical shift changes between rPre1a and W7A can be seen to occur 
at residues F8 and Y33. To quantitatively express changes in the chemical shifts of the individual amide 
pairs, a compound chemical shift change (in ppm) was defined as the weighted change in the δ-value, 
using the equation below:  
߂ߜweighted ൌ ඥሺ0.154 ൈ ∆ߜܰሻଶ ൅ ሺ∆ߜܪሻଶ 
 
Figure 52: Space filling model of rPre1a[W7A].  
Aromatic residues contributing to the hydrophobic face are in red. 
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The chemical shift scaling factor, Rscale, was determined from the ratio of the average variances to be 
0.154[572]. The results of the quantitative measurements of the change in weighted chemical shifts 
were plotted in Figure 54. The plot confirms that the largest changes occurred around residues F8 and 
Y33, both of which contribute to the hydrophobic face and aromatic stack, while the vast majority of the 
peaks overlay with the wild type peptide, confirming that the rPre1a[W7A] is correctly folded. 
 
 
Figure 53:  Overlay 15N-HSQC of rPre1a[wt] (blue) with rPre1a[W7A] (red).  Chemical shifts are 
traced by black lines. Asp15 and Asp21 side chain groups are also labeled. 
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Figure 54: Weighted 15N-HSQC chemical shift difference of 1H and 15N of rPre1a[wt] and 
rPre1a[W7A]. Large deviations are seen at F8 and Y33, which is consistent with the 15N-HSQC overlay. 
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This same 15N-HSQC comparison was completed for each mutation to confirm proper folding and 
check for major structural distortions. Each peptide was 15N-labeled through recombinant expression 
methods and the resulting 15N-HSQC was compared to that of rPre1a[wt]. A collection of the K34 
mutant 15N-HSQC plots overlaid with rPre1a[wt] can be found in Appendix D. Retention times of 
newly expressed mutants were checked against confirmed 15N-labeled retention times and 
corresponding peaks were isolated for pharmacologic testing.  
 
The 15N-HSQC of W7A was compared to that of F8A to identify regions of structural deviations caused 
by these mutations (Figure 55). Although F8A peaks were not picked and assigned, some inferences 
can be made using the rPre1a[wt] 15N-HSQC, due to their similarities. The spectrum of F8A appears 
more similar to that of rPre1a[wt] than W7A, without exhibiting the structural heterogeneity identified 
by peak shifts as  seen with rPre1a[wt] (Figure 56). There was also no major deviation of peaks from 
that of rPre1a[wt], indicating correct folding and minimal structural perturbation experienced by this 
mutation. 
.  
 
Figure 55: Overlay 15N-HSQC of rPre1a[W7A] (red) with rPre1a[F8A] (black).  Only rPre1a[W7A] 
peaks are labeled as peaks were not picked for rPre1a[F8A]. 
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Figure 56: Overlay 15N-HSQC of rPre1a[F8A] (black) with rPre1a[wt] (blue). Only rPre1a[wt] 
peaks are labeled as peaks were not picked for rPre1a[F8A], peaks can be inferred from the 
rPre1a[wt]. Peak shifting and structural heterogeneity is not seen with rPre1a[F8A]. 
 
4. Discussion  
This chapter described the directed mutagenesis of β/δ-TRTX-rPre1a and resulting structure-function 
changes, as well as elucidated the solution structure of a single mutant, rPre1a[W7A]. Mutations were 
chosen based on a combination of structural information gained from experiments conducted in 
Chapter III and identification of a critical C-terminal Lys residue after comparison of sequence 
similarity to spider venom peptides with known NaV subtype selectivity. In this chapter, we have 
successfully engineered rPre1a for enhanced NaV selectivity to NaV1.2 and NaV1.7. We have also 
solved the solution structure of a mutant version of the rPre1a with reduced activity, which will give 
valuable insights into structural aspects contributing to activity. 
 
Despite the relatively large number of NaV modulating spider venom peptides so far discovered and the 
high interest in discovering and developing subtype selective modulators there have been few SAR 
studies reported, with only one focusing on NaV1.7. The majority of research in the public domain 
involves full Ala scans of a peptide with a focus on activity at a single NaV isoform, such as the case of 
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β/ω-TRTX-Tp2a (protoxin-II) and β-TRTX-Cj1a (jingzhaotoxin-III) tested on NaV1.5 [245, 542]. 
Another example is β-hexatoxin-Mg1a (Magi-5), tested for potency changes at NaV1.2 [254]. Of these, 
only Tp2a exhibits a slight sequence similarity to the Family 1 NaV spider venom peptides, which 
includes β/δ-TRTX-Pre1a (Table 4). The most detailed SAR study is also the most recently published. 
This study involved not only a full Ala scan of µ-TRTX-Hhn2a (huwentoxin 4), but also followed up 
with directed mutagenesis of individual residues shown to be important form the scan [547]. This study 
focused solely on engineering the peptide’s potency on NaV1.7. However, as Hhn2a shares a high 
sequence similarity to Pre1a (Table 4), the results presented are directly relevant to the results observed 
with rPre1a mutations, as will be explained below. Taken together, this collection of published work 
demonstrates the novelty and scope of the work presented within this chapter, as it is to date the only 
directed engineering of a spider venom peptide in terms of both its potency and selectivity at different 
NaV channel isoforms as well as identifying the molecular basis of its structural stability. 
 
4.1 Functional aspects of K34 mutagenesis 
Mutations of the single K34 residue – based on both side chain length and charge – resulted in 
significant pharmacologic changes from the native rPre1a, with the two non-alanine mutations resulting 
in an increase in selectivity to different NaV isoforms. All mutations retained rPre1a’s relative 
inactivity against rNaV1.4 and hNav1.5. Changing the positively charged, long carbon chain Lys to a 
small hydrophobic Ala residue (K34A) does not appear to substantially alter NaV channel activity or 
selectivity as compared to rPre1a[wt]. The replacement of a positive charge at this position with a 
polar, neutral Gln (K34Q) resulted in an approximate 30% decrease in rNaV1.3 inhibition of fast 
inactivation compared to rPre1a[wt]. However, this same mutation increased hNaV1.7 inhibition of 
peak current by over 2-fold as compared to rPre1a[wt] resulting in favorable net improvement of 
hNaV1.7 to rNaV1.3 selectivity. However, activity at rNaV1.2 did not significantly change from that of 
rPre1a[wt], thus limiting its potential as a NaV1.7 selective therapeutic lead. It is important to note that 
the highly homologous Hh2a and Ps1a both have a Gln (Q) at this position and are potent Nav1.7 
inhibitors [543]. In the recent SAR study for Hh2a mentioned above, a change of Q34A also resulted in 
no change of potency for hNaV1.7, further supporting the lack of effect of an Ala mutation in this 
position on Pre1a. However, the results of the Hh2a study demonstrate the limitations with Ala 
scanning, as this residue was not followed up with further mutations due the observed lack of effect, 
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even though this chapter has demonstrated the importance of K34 for both function and selectivity to 
NaV channels. 
 
A shift from a positive to negative charge with the K34D mutation also resulted in an increase of 
selectivity for a single NaV channel. The natural single mutation from Y to D at this position in Cm1b 
and Cm1a, respectively, is sufficient to ablate the potent NaV1.3 activity of Cm1b. This impressive 
effect was the inspiration for making the K34D mutation of Pre1a. As was hoped the rPre1a[K34D] 
mutation eliminated rNaV1.3 activity. Unfortunately, inhibition of peak hNaV1.7 current was also 
dramatically decreased by this mutation. However, rNaV1.2 inhibitory activity increased 2-fold as 
compared to rPre1a. These two mutations highlight the ability to manipulate selectivity towards one 
NaV isoforms through a single residue change and give promise that more potent and selective NaV 
modulators can be rationally designed.   
 
An interesting observation to note is that the affinity to the NaV isoforms tested can be dictated by a 
single residue on the C-terminal tail. Considering K34D, this substitution of a negatively charged 
residue at the K34 position eliminates all functional activity for both NaV1.3 and NaV1.7. Although we 
had hoped to tailor activity to NaV1.7 with this mutation, it was equally exciting to reveal the 
impressive NaV1.2 selectivity imparted by this mutation. Future studies should include determining the 
full selectivity profile for rPre1a[K34D]. If it is found to be inactive at NaV1.1, NaV1.6 and NaV1.8 this 
would represent the first known highly selective inhibitor of NaV1.2. As such, rPre1a[K34D] could be 
an efficient research tool to determine the physiological and/or pathophysiological role of NaV1.2 using 
acute pharmacologic intervention, thus avoiding possible confounding results due to in vivo receptor 
compensation as can occur with genetic knock-out of a channel. Further, as NaV1.2 has been implicated 
in a wide variety of epilepsy disorders – many of which exhibit gain-of-function, excitatory phenotypes 
– it is reasonable to  assume a selective NaV1.2 inhibitor could undergo further development for use as 
a therapeutic for relevant epileptic conditions [175, 573]. Recently, some of the SCN2A mutations 
leading to epileptic conditions have even been linked to the development of autism [574]. 
 
While K34Q did not demonstrate the dramatic effects of K34D, it did increase the functional inhibition 
of NaV1.7 peak current. The structure for rPre1a[W7A] reveals another Lys residue in close association 
with K34, at position 22 on Loop 3. It would be of interest for future work to perform a similar 
mutagenesis experiment on this mutant – as well as create double-mutants of these Lys residues – in 
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order to further explore the effects of residue charge and size within this region. In combination with 
the recent work to improve the NaV1.7 potency of Hh2a by Revell et al., this mutation sets a 
precedence for engineering in selectivity to a specific NaV channel [547]. 
 
4.2 Function and structure of W7 and F8 mutations 
The mutations of W7A and F8A were chosen primarily because they represented two large, 
hydrophobic residues, directly adjacent on the rPre1a sequence on the Loop 1 region. In Chapter III of 
this thesis, the 15N-HSQC spectra of rPre1a revealed that residues of the Loop 1 region experienced 
three noticeable chemical shifts within the same spectra. The noticeable movement of residues within 
this region was therefore hypothesized to contribute to the conformational heterogeneity of rPre1a. 
Further, the central position of W7 on the hydrophobic face is typically occupied by a non-aromatic, 
hydrophobic residue, such as a Met for Tp2a, a Lys for Ps1a, and an Ile for Hh2a. It was our hypothesis 
that the presence of two large aromatic residues in Loop 1, as seen with Pre1a, creates tension between 
the five bulky aromatic residues of the hydrophobic face. 
 
The W7A mutation was chosen for NMR structural elucidation due to its central position within the 
hydrophobic face, high yields of correctly folded peptide from recombinant expression, and a 15N-
HSQC spectrum that exhibited a single conformation in aqueous solution. It was only after structural 
elucidation that the functional data was obtained, demonstrating an almost complete loss of function for 
all NaV isoforms tested. Despite this, solving the structure of an inactive mutant gives insight into the 
function of the specific mutated residue, as was demonstrated in an SAR experiment with µ-TRTX-
Hhn1b [575]. As suggested by Li et. al., if the mutation causes major structural perturbations, it can be 
inferred that the structural deformity is contributing to the loss of function. However, if the structure 
remains relatively intact – as was the case for W7A – then it is likely that the residue directly 
contributes to receptor interaction [575]. The loss of activity observed with W7A could be attributed to 
the contribution of the Trp to protein-protein interaction “hotspots”, which was mentioned previously 
[567]. However, an more in-depth publication that intricately detailed the development and use of 
hotspot prediction software suggests that Trp is only a low level contributor as a hotspot residue [576]. 
Although this data was based primarily on macro-proteins, it was recently confirmed to be the case in 
peptide-protein interactions, as well [577]. However, these results do not discount that W7 could 
contribute to a binding face, such as the highly conserved hydrophobic face. Further experiments are 
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needed to confirm the role of W7 towards function at this position. As the precise role of the 
hydrophobic face is yet to be determined, experiments could include mutagenesis of other residues 
within the hydrophobic stack, functional mutations of W7, identifying the precise binding site of rPre1a 
on NaV channels, and determining if W7 is involved in pairwise interactions with the NaV channel 
protein.. 
 
In contrast to W7A, the F8A mutation resulted in no change of activity for any NaV isoform tested, as 
compared to rPre1a[wt], yet resulted in the abolition of any detectable conformational heterogeneity. 
The solvophobic environment inherent with rpHPLC experiments at room temperature and 55°C 
resolved a single, sharp peak. Likewise, the 15N-HSQC overlaid closely with that of rPre1a[wt], 
suggesting proper folding, no structural perturbation, and a single conformational isomer. These results 
suggest that conformational heterogeneity is not necessary for the activity of rPre1a[wt]. However, it 
does not discount the possibility that rPre1a could occupy multiple interaction sites on the NaV channel, 
as is the case with κ-Gr1a [578]. 
 
The hypothesis regarding aromatic stacking in the hydrophobic face was proposed within Chapter III. 
Aromatic residues within 4.5-7 Ǻ have a tendency to form aromatic stacks, with multiple 
electrostatically favorable geometries possible in peptides [560]. The higher precision of the 
rPre1a[W7A] ensemble allows additional structural features to be recognized. This is especially 
apparent with the positioning of residues involved with the hydrophobic face. A 9 Ǻ spacing can be 
viewed between the F8-W30 residue pairs and the two Y22 -Y33 residue pairs in Figure 52 [579]. This 
large space creates an unfavorable conformation for aromatic interactions between these two pairs of 
aromatic residues [561]. However, each of the pairs mentioned would still be able to form aromatic 
interactions between each other, creating localized stability. With the addition of the W7 residue, it can 
be hypothesized that the aromatic ring of Trp might “flip” between energetically favorable positions in 
the offset aromatic pairs. With the F8A mutation, the removal of one of the external forces on W7 
strengthens the formation of a single aromatic position, resulting in a single conformer. However, to 
confirm this hypothesis, further mutagenesis and the structural elucidation of these analogs – especially 
F8A – is required. 
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4.3 Summary and future prospects 
In lieu of determining the precise NaV binding domain through experiments involving NaV channel 
point mutations, NaV chimeras, or competitive binding with Pre1a, it is difficult to make assertions on 
the precise mechanism of ligand interaction. Regardless, the results presented in this chapter give 
positive insight into the functional role of individual key residues for Pre1a and related venom peptides, 
as well as demonstrating an ability to manipulate structural heterogeneity. The results also demonstrate 
a proof of concept for the engineering of selectivity towards specific NaV isoforms. This data can be 
used to guide future projects, such as guiding the selection of residues for a more complete mutagenesis 
or indentifying residues between the NaV channel isoforms involved in ionic ligand binding. 
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Chapter V: Conclusion 
 
The continual progression of new technologies expands our ability to discover and isolate new 
compounds from natural sources previously overlooked; such is the case for animal venoms. As the 
tools for novel ligand discovery progress they fill databases with new molecular scaffolds and their 
corresponding pharmacologic data. To realize the full potential of the knowledge base we are building, 
utilization of this data needs to progress as well. This thesis describes the successful development and 
functional application of cell-based assays for the purpose of discovering and isolating NaV modulating 
peptides from crude venom. It then goes on to describe the in depth characterization of a single NaV 
modulating spider venom peptide demonstrating unique functional characteristics. This included 
guided mutagenesis of key residues through utilization of available data regarding peptides of a similar 
family. The experiments presented here successfully demonstrated a proof-of-concept for engineering 
selectivity towards specific NaV isoforms, with implications for therapeutic design and development of 
venom peptides. 
 
Although multiple functional assays using whole cells in microtiter format were developed, one assay 
in particular was carried forward to be used as a general screen of crude venoms. The choice was based 
on a few relevant factors, regarding the throughput of the assay and the robustness of response. The 
FLIPRTetra instrument was critical in this decision, as it was able to measure a fluorescence response 
over all wells simultaneously, whereas the Envision instrument was a single-well reader. The 
FLIPRTetra is able to read multiple fluorescent dyes, of which two were used to monitor either NaV 
depolarization induced Ca2+ influx or changes in the membrane potential. Aside from cell plating and 
compound preparation, the assay itself was completed within a time course of minutes, with the 
instrument capable of compound addition while simultaneously measuring the response. This not only 
gave us the ability to test our cone snail crude venoms, but venoms available from multiple other 
organisms through collaborative work.  
 
Out of this crude venom screening, a very potent NaV excitatory peptide was discovered, isolated, and 
sequenced. Belonging to the poorly classified group of δ-conotoxins, the discovery of δ-MVIA gave us 
an opportunity to attempt to further characterize the NaV neurotoxin receptor site 6. However, the 
extreme hydrophobic properties exhibited by this peptide made the production unattainable with 
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methods attempted for both SPPS and recombinant expression. Unfortunately, as no more C. magus 
specimens were available, this project was left until better methods for handling highly hydrophobic 
peptides could be developed. Future directions should include attempting recombinant expression in 
different organisms, such as the eukaryotic yeast Pischia pastoris, which may possess a more favorable 
environment for the expression of hydrophobic, disulfide rich peptides [580]. Fusion protein 
technology is also advancing rapidly [581-583], as is the possibility of co-expression with enzyme 
catalysts and isomerases that can aid proper folding and expression [289]. 
 
The discovery of TRTX-Pre1a and resulting characterization was in stark contrast to the difficulties 
experienced with the production of δ-MVIA. Pre1a, originally isolated from P. reduncus crude spider 
venom by Dr. Lachlan Rash, was produced successfully using bacterial recombinant expression 
methods. These methods allowed the production of enough recombinant peptide for all pharmacology 
experiments as well as providing a means for efficient, uniform isotopic labeling for structural 
elucidation. Pre1a presented a unique pharmacologic profile unlike any venom peptide described to 
date. Sub-micromolar inhibition of peak current was recorded for both rNaV1.2 and hNaV1.7, while 
potent inhibition of fast inactivation was observed at rNaV1.3. A lack of activity at rNaV1.4 and 
hNaV1.5 demonstrated a preference for neuronal NaV subtypes, as well. Further, Pre1a exhibited 
structural heterogeneity with multiple conformational states in solution, observable with both rpHPLC 
and the 15N-HSQC spectrum from heteronuclear NMR. To date, this phenomenon has only been 
reported for two spider venom peptides, of which neither study had attempted to identify the cause. In 
this study, we have made progress in attempting to describe the structural heterogeneity for rPre1a, 
identifying the Loop 1 region as a zone of flexibility through analysis of the 15N-HSQC chemical shifts. 
A homology model revealed an atypically close interaction of five aromatic residues (W7, F8, Y22, W30, 
and Y33) composing a hydrophobic face, where most other similar peptides characterized have less 
aromatics spaced by less bulky hydrophobic residues, such as Leu or Met..  
 
Of the five residues identified to contribute to the hydrophobic face, F8 and W7 were chosen for Ala 
substitution due to their adjacent proximity in sequence and location on the flexible Loop 1. The F8A 
mutation eliminated observed structural heterogeneity while maintaining function equivalent to the 
wild type rPre1a. In contrast, the W7A mutation – directly adjacent to F8 but located more centrally on 
the hydrophobic face – successfully eliminated all tested NaV function while improving structural 
stability as compared to rPre1a[wt]. These results demonstrated the necessity of a single residue (W7) 
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for direct, non-selective NaV channel interaction and also revealed that the structural heterogeneity of 
Pre1a is not necessary for either of its observed modes of activity or isoform selectivity. 
 
Pre1a belongs to a relatively large family of NaV modulating spider venom peptides with varying 
subtype selectivity. Residues that may contribute to their selectivity could be postulated by comparing 
peptides with the highest sequence similarity yet different selectivity for NaV channel subtypes. Despite 
the large number of partially characterized spider venom peptides in the literature, and full alanine 
scans of several of these peptides, the experimental approach used here (rational design based on 
existing knowledge) had not yet been implemented for these peptides. A single residue at position 34 
on the C-terminal tail was identified for its potential role in NaV1.3 selectivity and was subjected to 
rational mutagenesis involving both standard Ala substitution and replacement of amino acids with 
specific functional side chains. Of the three K34 mutations, two resulted in increased NaV isoforms 
selectivity. K34Q increased the potency to NaV1.7 while slightly decreasing potency to NaV1.3 as 
compared to Pre1a[wt]. However, this mutation did not improve on global selectivity, as NaV1.2 
potency remained unchanged from the wild type. Even so, the information gained from this mutant 
forms a foundation for combining with other point mutations to further improve the selectivity of 
Pre1a. K34D significantly decreased activity at both NaV1.3 and NaV1.7, but increased the potency to 
NaV1.2 by 2-fold. The rational mutagenesis of K34 and the resulting enhanced selectivity profiles sets a 
precedence for the utilization of publicly available information for the purpose of identifying key 
residues contributing to selectivity and function on specific ion channels and their isoforms. 
 
This thesis does not represent a complete story of Pre1a, but presents initial findings of a story that is 
currently ongoing. Aspects of this peptide are still needed to better understand its unique functional 
role. This will aid in the understanding of NaV-ligand interactions and how these can be incorporated 
into the development of molecular tools and therapeutics. There is no shortage of experiments yet to be 
completed. Exploring the binding site of Pre1a is of particular importance. Classical competitive 
binding experiments can be completed using radiolabelled peptides with known binding sites. 
Identifying the NaV domains involved in Pre1a binding can be accomplished using chimeric KV 
channels with a single NaV domain substituted in. As Kv channels are homotetramers, any one of their 
domains can be substituted with any one of the domains of a NaV channel and remain functional. This 
method has been used to successfully determine the domain of Ps1a binding[34]. Once narrowed to a 
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specific binding region, these results can help infer what residues of the NaV channel itself can be 
mutated and functionally tested with Pre1a to observe a change in activity. 
 
Concerning function, voltage dependence of steady-state inactivation of Pre1a should be tested on 
NaV1.2 and NaV1.7 using a standard double-pulse protocol, in which a 20 ms depolarizing test potential 
of 0 mV follows a 500 ms prepulse at potentials that range from -130 to -10 mV with a 10 mV 
increment[243]. Another experiment of interest tests voltage-dependence of reversal of inhibition by 
using a very strong depolarized conditioning potential (+100 to +240 mV) of varying length of time, or 
of standard time and varying potential, before a standard test depolarization to 0 mV. The test peak 
current (Y-axis) is compared to conditioning duration (X-axis) and gives functional information on 
whether the toxin binds to the voltage sensor region. Strong depolarization before a test pulse is 
thought to inhibit binding to the voltage sensor region by “pushing off” the toxin, so a loss of activity 
would be apparent over greater lengths of time[243, 255]. To test the voltage dependence of late 
currents for NaV1.3, the voltage can be varied after a standard 0 mV depolarization. Subsequent step to 
voltages ranging from −100 to −30 mV are then applied for an equivalent length of time to monitor 
their effects on inactivation[584]. Recovery from inactivation can be tested by administering standard 
depolarizing pulse potentials separated by increasing time intervals. 
 
Depending on the results of Pre1a, these experiments may also be applied to the mutants to observe 
possible changes in their mode of action. In regards to the mutations of Pre1a, full concentration 
dependence curves of each active mutant on NaV1.2, NaV1.3, and NaV1.7 is still needed for EC50 and 
IC50 values. Shifts of peak current under varying concentrations will also be apparent. Further 
mutagenesis of Pre1a using the information gained within this thesis and from new research will yield 
more information about the structural aspects of Pre1a and how they contribute to function. 
Specifically, focusing on the Loop 1 region and the Lys residues that seem to form a cluster are of 
interest as these have been shown to contribute strongly to selectivity and potency. 
 
In conclusion, this thesis has produced an improved means of isolating NaV channel modulators and 
contributed significantly to our understanding of the precise molecular details governing the structure 
and function of β/δ-TRTX-Pre1a. Moreover, it has uncovered several important considerations not only 
for future experimentation but also for future drug design. It is hoped that this information provides a 
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useful starting point for the further rational design and engineering of β/δ-TRTX-Pre1a analogs with 
high value as research tools and possible therapeutic leads for a broad range of neurological conditions. 
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Appendix A: δ-MVIA recombinant expression 
1. Methods 
1.1 Vector design for recombinant expression 
Vector design was performed as previously described in Chapter III, section 2.1. However, the 
synthetic gene was codon optimized and ordered through EZBiolab (Carmel, IN, USA) due to 
regulation restraints with GeneArt in Germany.  
 
In addition, a change had to be made to the original construct. The TEV cleavage recognition site 
requires an optimal signal sequence (ENLYFQ/S) to separate the peptide toxin at its N-terminus from 
the associated tags. The initial construct was designed for cleavage to occur between a Gln and Ser 
residue, leaving a residual Ser at the N-terminus of the peptide. Cleavage can occur between a number 
of residues in place of Ser - such as Asp, as is found at the N-terminal of δ-MVIA - so the addition of a 
Ser was not deemed necessary in the initial construct design[539]. However, a post-optimization 
change in the TEV enzyme resulted in an inability to cleave at Asp. Therefore, a mutational insertion of 
Ser at the N-terminal of the δ-MVIA sequence was needed. Primers were designed using PrimerX 
software for regions flanking the δ-MVIA sequence within the pLIC vector (Figure 57).  
 
 
 
Figure 57: Primer set for N-terminal Ser addition to δ-MVIA gene on the pLIC construct. 
 
Mutagenesis was performed using a QuickChange II Site Directed Mutagenesis Kit (Agilent, CA, 
USA) and confirmed by sequencing with the designed primers as templates (Australian Genome 
Research Facility). The sequenced pLIC-δ-Ser-MVIA construct was transformed into Top10 
chemically competent E. coli (Invitrogen, CA) for large-scale vector preparation and BL21ΔE3 
(Invitrogen, CA) for recombinant expression. Both transformants were stored as glycerol stocks (25% 
glycerol / 75% LB medium) at -80°C. 
 
 Forward:  5' GAAAACCTGTACTTCCAAAGCGATGGCTGCTATAATGC  3'
 Reverse:  5' GCATTATAGCAGCCATCGCTTTGGAAGTACAGGTTTTC  3'
147 
 
A second vector encoding a lysozyme fusion protein was also designed in parallel. The lysozyme 
sequence used was derived from chicken egg-white lysozyme (PDB: 1LSG_A) and codon optimized 
for bacterial expression[585]. The crystallization of chicken egg-white lysozyme has been well 
characterized and has great potential for acting as a crystallization chaperone, as is the case with recent 
publications[586-588]. The purpose was to express δ-MVIA as a mature fusion protein and crystallize 
the entire product, yielding a new method for structural elucidation of venom peptides, as no venom 
toxin has been characterized by this method to date. A N-terminal His10 affinity tag and a TEV 
cleavage site between the lysozyme and mature toxin sequence was designed into the construct. The 
designed fusion protein gene was synthesized and cloned into a pET11a expression vector, then 
sequenced by the UQ Protein Expression Facility (Australia). The sequenced pET11a-Lys-MVIA 
construct was transformed into Top10 chemically competent E. coli (Invitrogen, CA) for large-scale 
vector preparation and BL21ΔE3 (Invitrogen, CA) for recombinant expression. Both transformants 
were stored as glycerol stocks (25% glycerol / 75% LB medium) at -80°C. 
 
1.2 Bacterial recombinant expression and purification 
Recombinant expression of δ-MVIA and the resulting purification by IMAC and rpHPLC followed 
methods developed in Chapter III, section 2.1-2.5. 
 
2. Recombinant expression results 
 
After multiple failed synthesis attempts by collaborators, δ-MVIA was successfully expressed as an 
inducible 47 kDa fusion protein using methods proven in both Chapters III and IV (Figure 58). The 
fusion protein was also able to be purified through IMAC methods, yielding a band detectable by 
Western blot using an anti-His antibody (Figure 59). Unfortunately, the purified sample was unable to 
be cleaved or stored for any period of time without crashing out of solution. Post-cleavage using 
standard TEV protease methods resulted in undetectable levels of mature toxin. Isolation of the entire 
fusion protein was attempted, as well. However, there was no way to check for proper folding as the 
MBP protein dominated the molecule. Storage at 4°C, -20°C, and -80°C all resulted in the sample 
becoming a precipitate upon thawing. Quick buffer exchange and immediate assay as a fusion protein 
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was attempted post purification with irreproducible results. It was the recommendation of the 
supervisory committee to move on from this project. 
 
 
 
 
 
 
Figure 58: SDS-PAGE of inducible expression of 
MBP-MVIA. Positive induction of 100 mL LB culture 
of pLIC-S-MVIA. U = uninduced; L = molecular weight 
ladder (BioRad); I = induced with 1 mM IPTG. 
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Figure 59: SDS-PAGE of δ-MVIA IMAC purification. A) Coomassie stain; B) Western of NiNTA 
purification from 2L LB expression of pLIC-S-MVIA, induced with 1 mM IPTG, 16°C, 20 h. Sol = 
soluble lysate; FT = NiNTA flowthrough; W = 15 mM immidazole wash; E = 250 mM immidazole 
elution; final column wash of 1 M immidazole to check for residual binding. 
 
The attempt was also made to express δ-MVIA with a custom designed lysozyme fusion construct for 
co-crystallization studies. Although expression occurred for all tested conditions, no soluble protein 
was detected (Figure 60).  
 
 
 
Figure 60: Western of MVIA-Lysozyme test expression. The 
mature fusion protein yields a 12 kDa band. 1) Uninduced cell 
pellet (Insoluble fraction); 2) Uninduced cell lysate (soluble 
fraction); 3) 16 °C pellet; 4) 16 °C lysate; 5) 25 °C pellet; 6) 25 °C 
lysate; 7) 37 °C pellet; 8) 37 °C lysate.  
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Appendix B: I-T plots of Pre1a and K34Q addition to rNaV1.2, rNaV1.3, 
and hNaV1.7 
 
 
Figure 61: I-T plots Pre1a inhibition of rNaV1.2 and hNaV1.7. Concentration dependent inhibition 
of Pre1a on A) rNaV1.2 and B) hNaV1.7 expressed in oocytes. 1 µM Pre1a addition resulted in 
inhibition of peak current for C) rNaV1.2 and D) hNaV1.7. n is representative of data obtained from 
separate oocytes.I-V plots were taken before the first addition and after reaching steady-state 
inhibition of final addition of peptide (Appendix C). 
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Figure 62: I-T plot of Pre1a inhibition of inactivation of rNaV1.3. A) Concentration  dependent and 
B) 1 µM additions of Pre1a to rNaV1.3 expressing oocytes. Data points represent late current (late 
current) values, C) highlighted in red. Pre1a activity was partially reversible with extended saline 
wash, as seen in B). I-V plots were taken before the first addition and after reaching steady-state 
activity of final addition of peptide (Appendix C). 
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Figure 63: I-T plots for Pre1a[K34Q] inhibition of rNaV1.2 and hNaV1.7 and washout.  
1 µM addition of Pre1a[K34Q] resulted in inhibition of peak current for both A) rNaV1.2 and B) 
hNaV1.7 expressed in oocytes. B) Partial reversal of hNaV1.7 inhibition can be seen with 
extended wash.  I-V plots were for taken for Pre1a[K34Q] and all other mutations before the first 
addition and after reaching steady-state inhibition of final addition of peptide (Appendix C). 
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Appendix C: I-V relationships and steady-state activation of NaV1.2 and 
NaV1.7 
 
 
Figure 64: rNav1.2 I-V relationship curves.  Pre1a and each 
mutant analyzed at 1 µM on rNaV1.2 expressed in oocytes. Data 
was normalized to peak current. n represents the number of 
individual oocytes tested. 
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Figure 65: Steady-state activation of rNaV1.2.  Steady-state activation of 
rNaV1.2 was analyzed using the equation G(V) = I/(V − Vrev), where I, V, 
and Vrev represent inward current elicited as described for the I-V plot in 
Figure 61, test potential, and reversal potential, respectively.  
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Figure 66: hNav1.7 IV-relationship curves.  Pre1a and each 
mutant analyzed at 1 µM on hNaV1.7 expressed in oocytes. Data 
was normalized to peak current. n represents the number of oocytes 
tested. 
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Figure 67: Steady-state activation of hNaV1.7.  Steady-state activation of 
rNaV1.2 was analyzed using the equation G(V) = I/(V − Vrev), where I, V, 
and Vrev represent inward current elicited as described for the IV plot in Figure 
63, test potential, and reversal potential, respectively.  
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Appendix D: 15N-HSQC comparisons of rPre1a[wt] vs K34 mutants 
 
Each representation shows the 15N-HSQC of each mutant overlaid with the 15N-HSQC of wild-type 
rPre1a. No major deviations with Cys residues could be seen, suggesting proper folding of each 
peptide. Peaks were not assigned for any of the following mutants, so all labeling is specific to the 
rPre1a[wt] HSQC. 
 
 
Figure 68: Overlay 15N-HSQC of rPre1a[wt] (blue) and rPre1a[K34Q] (green).  
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Figure 69: Overlay 15N-HSQC of rPre1a[wt] (blue) and rPre1a[K34D] (purple).  
 
 
Figure 70: Overlay 15N-HSQC of rPre1a[wt] (blue) and rPre1a[K34A] (yellow).  
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Appendix E: Chemical shift lists for rPre1a[wt] and rPre1a[W7A] 
rPre1a[wt]     rPre1a[W7A] 
Residue  Atom  Nuc  Shift  SDev     Residue  Atom  Nuc  Shift  SDev 
S1  C  13C  170.659  0     S1  C  13C  169.892  0 
S1  CA  13C  57.432  0     S1  CA  13C  57.511  0.005 
S1  CB  13C  63.241  0     S1  CB  13C  63.161  0.015 
S1  HA  1H  4.093  0.001     S1  HA  1H  4.138  0.003 
S1  QB  1H  3.964  0     S1  QB  1H  3.977  0.002 
E2  C  13C  175.719  0     E2  C  13C  174.885  0 
E2  CA  13C  56.318  0.011     E2  CA  13C  56.301  0 
E2  CB  13C  30.565  0.019     E2  CB  13C  30.518  0.071 
E2  CG  13C  36.266  0     E2  CG  13C  36.205  0.029 
E2  H  1H  8.809  0.004     E2  H  1H  8.793  0.002 
E2  HA  1H  4.434  0.004     E2  HA  1H  4.417  0.006 
E2  HB2  1H  2.142  0.003     E2  HB2  1H  2.121  0.004 
E2  HB3  1H  1.966  0.002     E2  HB3  1H  1.935  0.004 
E2  MG  1H  2.296  0.001     E2  N  15N  121.504  0.007 
E2  N  15N  121.215  0.042     E2  QG  1H  2.279  0.001 
D3  CA  13C  54.142  0.011     D3  C  13C  174.551  0 
D3  CB  13C  41.078  0.009     D3  CB  13C  41.017  0.03 
D3  H  1H  8.597  0.002     D3  H  1H  8.535  0.003 
D3  HA  1H  4.692  0.001     D3  HA  1H  4.667  0.004 
D3  HB2  1H  2.744  0.003     D3  HB2  1H  2.722  0.002 
D3  HB3  1H  2.603  0.002     D3  HB3  1H  2.577  0.006 
D3  N  15N  122.467  0     D3  N  15N  122.579  0.031 
C4  C  13C  173.068  0     C4  C  13C  171.993  0 
C4  CA  13C  54.145  0.013     C4  CA  13C  54.027  0 
C4  CB  13C  43.215  0.012     C4  CB  13C  43.58  0.045 
C4  H  1H  8.155  0.002     C4  H  1H  8.149  0.004 
C4  HA  1H  4.927  0.003     C4  HA  1H  4.869  0.009 
C4  MB  1H  3.252  0.001     C4  HB2  1H  3.244  0.003 
C4  N  15N  116.255  0.036     C4  HB3  1H  3.156  0.001 
L5  C  13C  174.976  0     C4  N  15N  116.298  0.023 
L5  CA  13C  54.209  0.017     L5  C  13C  173.719  0 
L5  CB  13C  43.312  0.071     L5  CA  13C  54.256  0.042 
L5  CD1  13C  21.915  0     L5  CB  13C  43.386  0.037 
L5  CD2  13C  26.24  0     L5  CD1  13C  26.337  0 
L5  CG  13C  26.436  0     L5  CD2  13C  21.992  0 
L5  H  1H  8.599  0.003     L5  CG  13C  25.945  0.002 
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L5  HA  1H  4.431  0.008     L5  H  1H  8.517  0.003 
L5  HB2  1H  1.793  0.002     L5  HA  1H  4.374  0.004 
L5  HB3  1H  1.501  0.002     L5  HB2  1H  1.739  0.003 
L5  HG  1H  1.613  0.001     L5  HB3  1H  1.43  0.003 
L5  MD1  1H  0.866  0     L5  HG  1H  1.576  0.002 
L5  MD2  1H  0.974  0.002     L5  MD1  1H  0.944  0.001 
L5  N  15N  120.984  0.007     L5  MD2  1H  0.847  0.008 
G6  C  13C  173.072  0     L5  N  15N  120.874  0.029 
G6  CA  13C  42.796  0.026     G6  C  13C  172.186  0 
G6  H  1H  8.239  0.005     G6  CA  13C  42.79  0.059 
G6  HA2  1H  3.881  0.011     G6  H  1H  8.214  0.004 
G6  HA3  1H  3.586  0.003     G6  HA2  1H  3.659  0.003 
G6  N  15N  108.991  0.023     G6  HA3  1H  3.443  0.006 
W7  C  13C  177.322  0     G6  N  15N  109.079  0.005 
W7  CA  13C  58.027  0.079     A7  C  13C  177.284  0 
W7  CB  13C  29.212  0.098     A7  CA  13C  53.541  0.042 
W7  H  1H  7.789  0.001     A7  CB  13C  18.983  0.009 
W7  HA  1H  3.548  0.011     A7  H  1H  7.609  0.004 
W7  HB2  1H  3.047  0.01     A7  HA  1H  3.045  0.002 
W7  HB3  1H  2.833  0.009     A7  MB  1H  0.971  0.001 
W7  N  15N  119.174  0.024     A7  N  15N  119.572  0.008 
F8  C  13C  175.082  0     F8  C  13C  173.69  0 
F8  CA  13C  60.151  0.048     F8  CA  13C  60.177  0.021 
F8  CB  13C  37.092  0.051     F8  CB  13C  35.692  0.042 
F8  H  1H  8.742  0.004     F8  CD1  13C  131.54  0 
F8  HA  1H  3.456  0.011     F8  CE1  13C  131.22  0 
F8  HB2  1H  2.728  0.006     F8  CZ  13C  129.487  0 
F8  HB3  1H  2.127  0.005     F8  H  1H  8.63  0.003 
F8  N  15N  121.912  0.021     F8  HA  1H  3.575  0.002 
S9  C  13C  174.323  0     F8  HB2  1H  3.092  0.004 
S9  CA  13C  59.482  0     F8  HB3  1H  2.845  0.005 
S9  CB  13C  64.442  0.062     F8  HZ  1H  7.281  0 
S9  H  1H  7.997  0.005     F8  N  15N  113.92  0.014 
S9  HA  1H  4.422  0.001     F8  QD  1H  6.303  0.001 
S9  HB2  1H  3.877  0.002     F8  QE  1H  7.232  0 
S9  HB3  1H  3.824  0     S9  C  13C  173.186  0 
S9  N  15N  115.915  0.027     S9  CA  13C  59.534  0.046 
R10  C  13C  175.927  0     S9  CB  13C  64.653  0.046 
R10  CA  13C  56.346  0.047     S9  H  1H  7.957  0.004 
R10  CB  13C  29.487  0.029     S9  HA  1H  4.473  0.005 
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R10  CD  13C  42.717  0     S9  N  15N  116.697  0.013 
R10  CG  13C  26.806  0.047     S9  QB  1H  3.826  0.008 
R10  H  1H  8.671  0.002     R10  C  13C  174.838  0 
R10  HA  1H  4.866  0.009     R10  CA  13C  56.625  0 
R10  HD2  1H  3.378  0     R10  CB  13C  29.607  0.017 
R10  HD3  1H  3.314  0.002     R10  CD  13C  42.837  0 
R10  HG2  1H  1.841  0.002     R10  CG  13C  27.029  0.051 
R10  HG3  1H  1.751  0     R10  H  1H  8.724  0.003 
R10  MB  1H  1.895  0.002     R10  HA  1H  4.929  0.004 
R10  N  15N  125.042  0.013     R10  HD2  1H  3.431  0.006 
C11  C  13C  171.682  0     R10  HD3  1H  3.398  0.01 
C11  CA  13C  53.69  0.066     R10  HG2  1H  1.897  0.006 
C11  CB  13C  45.599  0.07     R10  HG3  1H  1.787  0.007 
C11  H  1H  8.123  0.003     R10  N  15N  125.153  0.005 
C11  HA  1H  4.853  0.001     R10  QB  1H  1.925  0.004 
C11  HB2  1H  3.139  0.003     C11  C  13C  170.698  0 
C11  HB3  1H  2.924  0.003     C11  CA  13C  53.805  0 
C11  N  15N  119.683  0.009     C11  CB  13C  45.408  0.014 
S12  CA  13C  52.826  0     C11  H  1H  8.121  0.003 
S12  CB  13C  64.908  0.091     C11  HA  1H  4.867  0.006 
S12  H  1H  8.939  0.008     C11  HB2  1H  3.14  0.004 
S12  HA  1H  5.077  0.001     C11  HB3  1H  2.886  0.005 
S12  HB2  1H  3.829  0.001     C11  N  15N  119.632  0.014 
S12  HB3  1H  3.699  0.002     S12  CA  13C  52.964  0 
S12  N  15N  114.775  0.005     S12  CB  13C  65.096  0.018 
P13  C  13C  176.979  0     S12  H  1H  8.932  0.005 
P13  CA  13C  64.338  0     S12  HA  1H  5.069  0.001 
P13  CB  13C  32.093  0.084     S12  HB2  1H  3.827  0.004 
P13  CD  13C  51.262  0.074     S12  HB3  1H  3.696  0 
P13  CG  13C  27.81  0.029     S12  N  15N  114.79  0.009 
P13  HA  1H  4.017  0.003     P13  C  13C  175.993  0 
P13  HB2  1H  2.166  0.001     P13  CA  13C  64.432  0.053 
P13  HB3  1H  1.931  0.001     P13  CB  13C  32.137  0.025 
P13  HD2  1H  3.848  0.007     P13  CD  13C  51.272  0.061 
P13  HD3  1H  3.772  0.001     P13  CG  13C  27.908  0.048 
P13  HG2  1H  2  0.001     P13  HA  1H  4.006  0.006 
P13  HG3  1H  1.634  0.001     P13  HB2  1H  2.196  0.003 
K14  C  13C  176.134  0     P13  HB3  1H  1.909  0.002 
K14  CA  13C  56.935  0     P13  HD2  1H  3.846  0.005 
K14  CB  13C  32.322  0.053     P13  HD3  1H  3.776  0 
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K14  CD  13C  28.904  0.037     P13  HG2  1H  1.995  0.002 
K14  CE  13C  42.114  0     P13  HG3  1H  1.606  0.01 
K14  CG  13C  25.029  0.028     K14  C  13C  175.117  0 
K14  H  1H  7.545  0.003     K14  CA  13C  56.925  0.038 
K14  HA  1H  4.179  0.008     K14  CB  13C  32.534  0.044 
K14  HB2  1H  1.807  0     K14  CD  13C  28.923  0.067 
K14  HB3  1H  1.625  0     K14  CE  13C  41.788  0 
K14  HD2  1H  1.646  0.001     K14  CG  13C  25.001  0.052 
K14  HD3  1H  1.59  0.001     K14  H  1H  7.55  0.003 
K14  HG2  1H  1.405  0.009     K14  HA  1H  4.175  0 
K14  HG3  1H  1.329  0.001     K14  HB2  1H  1.796  0.006 
K14  ME  1H  2.956  0     K14  HB3  1H  1.617  0.002 
K14  N  15N  114.749  0.015     K14  N  15N  114.438  0.021 
N15  C  13C  173.59  0     K14  QD  1H  1.575  0 
N15  CA  13C  52.55  0.045     K14  QE  1H  2.948  0.001 
N15  CB  13C  38.115  0.086     K14  QG  1H  1.376  0.001 
N15  H  1H  7.169  0.002     N15  C  13C  172.586  0 
N15  HA  1H  4.714  0.008     N15  CA  13C  52.854  0 
N15  HB2  1H  2.692  0.005     N15  CB  13C  38.069  0.019 
N15  HB3  1H  2.58  0.003     N15  H  1H  7.196  0.004 
N15  HD21  1H  7.492  0.003     N15  HA  1H  4.696  0.006 
N15  HD22  1H  6.829  0     N15  HB2  1H  2.682  0.005 
N15  N  15N  118.224  0.027     N15  HB3  1H  2.558  0.007 
N15  ND2  15N  110.828  0.003     N15  HD21  1H  7.496  0.001 
D16  C  13C  177.379  0     N15  HD22  1H  6.83  0.002 
D16  CA  13C  55.376  0     N15  N  15N  118.352  0.011 
D16  CB  13C  41.359  0.089     N15  ND2  15N  110.835  0.03 
D16  H  1H  8.524  0.002     D16  C  13C  176.411  0 
D16  HA  1H  4.374  0.006     D16  CA  13C  55.531  0.01 
D16  HB2  1H  3.031  0.004     D16  CB  13C  41.48  0.041 
D16  HB3  1H  2.515  0.003     D16  H  1H  8.509  0.002 
D16  N  15N  124.217  0.031     D16  HA  1H  4.34  0.009 
K17  C  13C  177.146  0     D16  HB2  1H  3.022  0.009 
K17  CA  13C  54.251  0.021     D16  HB3  1H  2.505  0.002 
K17  CB  13C  31.224  0.025     D16  N  15N  124.183  0.013 
K17  CD  13C  28.589  0     K17  C  13C  176.038  0 
K17  CE  13C  42.238  0     K17  CA  13C  54.467  0.067 
K17  CG  13C  24.557  0.046     K17  CB  13C  31.338  0.036 
K17  H  1H  8.071  0.004     K17  CE  13C  42.125  0.041 
K17  HA  1H  4.659  0.005     K17  CG  13C  24.499  0.009 
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K17  HB2  1H  2.393  0.002     K17  H  1H  8.002  0.004 
K17  HB3  1H  1.613  0.002     K17  HA  1H  4.65  0.009 
K17  HE2  1H  2.971  0.001     K17  HB2  1H  2.371  0.003 
K17  HE3  1H  2.899  0.005     K17  HB3  1H  1.579  0.002 
K17  HG2  1H  1.511  0.005     K17  HE2  1H  2.956  0 
K17  HG3  1H  1.406  0.002     K17  HE3  1H  2.895  0.004 
K17  MD  1H  1.643  0     K17  HG2  1H  1.488  0.004 
K17  N  15N  128.048  0.023     K17  HG3  1H  1.386  0.002 
C18  C  13C  175.735  0     K17  N  15N  128.081  0.014 
C18  CA  13C  56.889  0     K17  QD  1H  1.628  0.005 
C18  CB  13C  39.257  0     C18  C  13C  174.582  0 
C18  H  1H  9.367  0.006     C18  CA  13C  57.024  0.027 
C18  HA  1H  5.041  0.001     C18  CB  13C  39.294  0.036 
C18  MB  1H  2.98  0.011     C18  H  1H  9.326  0.002 
C18  N  15N  121.582  0.015     C18  HA  1H  4.975  0.002 
C19  CA  13C  53.747  0     C18  HB2  1H  2.944  0.004 
C19  CB  13C  38.497  0.087     C18  HB3  1H  2.88  0.001 
C19  H  1H  9.818  0.013     C18  N  15N  121.544  0.027 
C19  HA  1H  4.819  0     C19  CB  13C  38.762  0.017 
C19  HB2  1H  3.585  0.004     C19  H  1H  9.515  0.003 
C19  HB3  1H  2.534  0.003     C19  HA  1H  4.742  0 
C19  N  15N  122.814  0.051     C19  HB2  1H  3.504  0.002 
P20  C  13C  176.69  0     C19  HB3  1H  2.375  0.002 
P20  CA  13C  65.457  0     C19  N  15N  122.064  0.007 
P20  CB  13C  31.833  0.017     P20  C  13C  175.723  0 
P20  CD  13C  50.816  0.022     P20  CA  13C  65.208  0.032 
P20  CG  13C  27.791  0.045     P20  CB  13C  31.901  0.037 
P20  HA  1H  4.269  0.001     P20  CD  13C  50.767  0.027 
P20  HB2  1H  2.34  0.002     P20  CG  13C  27.92  0.005 
P20  HB3  1H  1.821  0.001     P20  HA  1H  4.112  0.003 
P20  HD2  1H  4.002  0.001     P20  HB2  1H  2.274  0.002 
P20  HD3  1H  3.719  0.001     P20  HB3  1H  1.76  0.002 
P20  HG2  1H  2.13  0     P20  HD2  1H  3.973  0.011 
P20  HG3  1H  2.044  0.002     P20  HD3  1H  3.678  0.006 
N21  C  13C  173.28  0     P20  HG2  1H  2.125  0.001 
N21  CA  13C  55.141  0     P20  HG3  1H  2.008  0 
N21  CB  13C  37.132  0     N21  C  13C  171.514  0 
N21  H  1H  8.152  0.01     N21  CA  13C  55.699  0 
N21  HA  1H  4.302  0.003     N21  CB  13C  37.357  0 
N21  HD21  1H  7.293  0     N21  H  1H  8.096  0.004 
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N21  HD22  1H  6.836  0.001     N21  HA  1H  4.119  0.003 
N21  MB  1H  2.474  0.005     N21  N  15N  113.149  0.018 
N21  N  15N  113.209  0.005     N21  QB  1H  2.537  0.005 
N21  ND2  15N  112.113  0.001     Y22  C  13C  172.996  0 
Y22  C  13C  173.825  0     Y22  CA  13C  56.673  0.085 
Y22  CA  13C  55.985  0.057     Y22  CB  13C  42.008  0.025 
Y22  CB  13C  42.015  0.049     Y22  CD1  13C  132.485  0 
Y22  H  1H  8.788  0.006     Y22  CE1  13C  117.919  0 
Y22  HA  1H  5.245  0.004     Y22  H  1H  8.697  0.003 
Y22  HB2  1H  3.142  0.001     Y22  HA  1H  4.947  0.007 
Y22  HB3  1H  2.784  0.003     Y22  HB2  1H  3.258  0.004 
Y22  N  15N  118.434  0.018     Y22  HB3  1H  2.46  0.008 
K23  C  13C  176.021  0     Y22  N  15N  117.389  0.009 
K23  CA  13C  54.775  0     Y22  QD  1H  6.657  0.002 
K23  CB  13C  37.046  0.008     Y22  QE  1H  6.662  0.002 
K23  CD  13C  29.249  0     K23  C  13C  175.088  0 
K23  CE  13C  42.205  0     K23  CB  13C  37.089  0.072 
K23  CG  13C  24.756  0.001     K23  CD  13C  28.994  0.008 
K23  H  1H  9.074  0.004     K23  CE  13C  42.36  0 
K23  HA  1H  4.611  0     K23  CG  13C  24.982  0.025 
K23  HG2  1H  1.403  0.001     K23  H  1H  8.96  0.002 
K23  HG3  1H  1.329  0     K23  HA  1H  4.66  0.007 
K23  MB  1H  1.628  0.004     K23  HB2  1H  1.651  0.002 
K23  MD  1H  1.676  0.001     K23  HB3  1H  1.591  0.002 
K23  ME  1H  2.991  0.002     K23  HD2  1H  1.652  0.002 
K23  N  15N  118.371  0.002     K23  HD3  1H  1.629  0 
C24  C  13C  174.447  0     K23  HG2  1H  1.402  0.002 
C24  CA  13C  56.71  0.012     K23  HG3  1H  1.31  0.003 
C24  CB  13C  38.427  0.096     K23  N  15N  118.693  0.005 
C24  H  1H  10.418  0.009     K23  QE  1H  2.962  0.004 
C24  HA  1H  4.457  0.005     C24  C  13C  173.357  0 
C24  HB2  1H  3.144  0.006     C24  CA  13C  56.627  0.054 
C24  HB3  1H  2.53  0.002     C24  CB  13C  38.442  0.063 
C24  N  15N  129.565  0.004     C24  H  1H  10.45  0.003 
S25  C  13C  176.005  0     C24  HA  1H  4.455  0.004 
S25  CA  13C  57.186  0     C24  HB2  1H  3.067  0.004 
S25  CB  13C  63.639  0.006     C24  HB3  1H  2.526  0.008 
S25  H  1H  7.94  0.004     C24  N  15N  129.112  0.011 
S25  HA  1H  4.487  0.007     S25  C  13C  175.099  0 
S25  HB2  1H  4.003  0.003     S25  CA  13C  57.147  0.042 
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S25  HB3  1H  3.835  0     S25  CB  13C  63.765  0.081 
S25  N  15N  124.487  0.025     S25  H  1H  8.056  0.002 
S26  C  13C  174.233  0     S25  HA  1H  4.519  0.002 
S26  CA  13C  61.049  0     S25  HB2  1H  4.092  0.009 
S26  CB  13C  62.567  0     S25  HB3  1H  3.891  0.008 
S26  H  1H  8.943  0.003     S25  N  15N  124.651  0.014 
S26  HA  1H  4.005  0.007     S26  C  13C  173.225  0 
S26  HB2  1H  3.942  0     S26  CA  13C  61.323  0 
S26  HB3  1H  3.856  0     S26  CB  13C  62.563  0.013 
S26  N  15N  125.324  0.024     S26  H  1H  8.976  0.003 
K27  C  13C  176.834  0     S26  HA  1H  4.009  0.005 
K27  CA  13C  57.225  0     S26  HB2  1H  3.942  0.003 
K27  CB  13C  33.369  0.025     S26  HB3  1H  3.855  0.002 
K27  CG  13C  24.524  0     S26  N  15N  125.423  0.073 
K27  H  1H  7.661  0.003     K27  C  13C  175.77  0 
K27  HA  1H  4.189  0.003     K27  CA  13C  57.612  0.11 
K27  HB2  1H  1.684  0.002     K27  CB  13C  33.45  0.031 
K27  HB3  1H  1.527  0.001     K27  CG  13C  24.501  0.014 
K27  HG2  1H  1.341  0.001     K27  H  1H  7.665  0.003 
K27  HG3  1H  1.268  0.002     K27  HA  1H  4.179  0.004 
K27  ME  1H  2.961  0.001     K27  HB2  1H  1.677  0.004 
K27  N  15N  119.27  0.016     K27  HB3  1H  1.521  0.004 
D28  C  13C  174.317  0     K27  HD2  1H  1.607  0 
D28  CA  13C  54.686  0     K27  HD3  1H  1.358  0 
D28  CB  13C  41.494  0.028     K27  HG2  1H  1.321  0.002 
D28  H  1H  7.28  0.003     K27  HG3  1H  1.243  0.003 
D28  HA  1H  4.304  0     K27  N  15N  119.394  0.03 
D28  HB2  1H  1.358  0     K27  QE  1H  2.953  0.001 
D28  HB3  1H  1.326  0     D28  C  13C  173.321  0 
D28  N  15N  114.442  0.017     D28  CA  13C  54.651  0.026 
L29  C  13C  176.066  0     D28  CB  13C  41.522  0.011 
L29  CA  13C  55.864  0.127     D28  H  1H  7.238  0.003 
L29  CB  13C  37.223  0.063     D28  HA  1H  4.234  0.007 
L29  CD1  13C  25.477  0.086     D28  HB2  1H  1.263  0.003 
L29  CD2  13C  23.464  0     D28  HB3  1H  1.022  0.001 
L29  CG  13C  27.237  0.053     D28  N  15N  114.542  0.04 
L29  H  1H  8.006  0.002     L29  C  13C  175.112  0 
L29  HA  1H  3.871  0.013     L29  CA  13C  55.61  0.046 
L29  HB2  1H  2.029  0.003     L29  CB  13C  37.504  0.007 
L29  HB3  1H  1.899  0.006     L29  CD1  13C  25.467  0 
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L29  HG  1H  1.316  0.007     L29  CD2  13C  23.493  0 
L29  MD1  1H  0.889  0.008     L29  CG  13C  26.827  0.128 
L29  MD2  1H  0.88  0.001     L29  H  1H  8.039  0.002 
L29  N  15N  113.436  0.028     L29  HA  1H  3.909  0.002 
W30  C  13C  178.068  0     L29  HB2  1H  2.034  0.009 
W30  CA  13C  55.363  0.025     L29  HB3  1H  1.893  0.005 
W30  CB  13C  31.864  0.032     L29  HG  1H  1.343  0.007 
W30  H  1H  6.72  0.002     L29  MD1  1H  0.899  0.008 
W30  HA  1H  5.686  0.004     L29  MD2  1H  0.881  0.005 
W30  HB2  1H  2.882  0.003     L29  N  15N  113.903  0.013 
W30  HB3  1H  2.486  0.003     W30  C  13C  177.328  0 
W30  N  15N  110.838  0.002     W30  CA  13C  55.009  0 
C31  C  13C  174.33  0     W30  CB  13C  31.66  0 
C31  CA  13C  54.847  0     W30  CD1  13C  125.402  0 
C31  CB  13C  39.176  0.023     W30  CE3  13C  121.466  0 
C31  H  1H  8.386  0.002     W30  CH2  13C  124.934  0 
C31  HA  1H  4.718  0     W30  CZ2  13C  114.181  0 
C31  HB2  1H  3.171  0.002     W30  CZ3  13C  122.009  0 
C31  HB3  1H  2.561  0.006     W30  H  1H  6.84  0.003 
C31  N  15N  118.497  0.013     W30  HA  1H  5.802  0.002 
K32  C  13C  175.228  0     W30  HB2  1H  3.147  0 
K32  CA  13C  55.081  0.035     W30  HB3  1H  2.702  0.002 
K32  CB  13C  35.787  0.038     W30  HD1  1H  6.917  0.002 
K32  CD  13C  29.567  0.017     W30  HE1  1H  10.28  0.003 
K32  CG  13C  25.486  0.016     W30  HE3  1H  7.525  0 
K32  H  1H  8.708  0.002     W30  HH2  1H  7.229  0.004 
K32  HA  1H  4.927  0.002     W30  HZ2  1H  7.521  0.001 
K32  HB2  1H  2.109  0.004     W30  HZ3  1H  7.163  0.002 
K32  HB3  1H  1.903  0.005     W30  N  15N  110.597  0.035 
K32  HD2  1H  1.744  0.002     W30  NE1  15N  128.965  0 
K32  HD3  1H  1.698  0.001     C31  C  13C  173.546  0 
K32  HG2  1H  1.548  0.002     C31  CB  13C  38.953  0.025 
K32  HG3  1H  1.432  0.002     C31  H  1H  8.397  0.003 
K32  N  15N  124.965  0.002     C31  HA  1H  4.691  0.004 
Y33  C  13C  176.539  0     C31  HB2  1H  3.009  0.002 
Y33  CA  13C  59.636  0     C31  HB3  1H  2.505  0.005 
Y33  CB  13C  38.402  0.069     C31  N  15N  118.911  0.021 
Y33  H  1H  8.16  0.01     K32  C  13C  174.473  0 
Y33  HA  1H  4.258  0     K32  CB  13C  29.666  0.048 
Y33  HB2  1H  2.948  0.005     K32  CE  13C  42.098  0.018 
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Y33  HB3  1H  2.637  0.005     K32  CG  13C  25.408  0.053 
Y33  N  15N  121.663  0.006     K32  H  1H  8.998  0.003 
K34  C  13C  174.818  0     K32  HA  1H  4.817  0.003 
K34  CA  13C  57.193  0     K32  HB2  1H  2.055  0.001 
K34  CB  13C  32.856  0.002     K32  HB3  1H  1.808  0.004 
K34  CD  13C  29.413  0.07     K32  HD2  1H  1.801  0.002 
K34  CE  13C  41.585  0.05     K32  HD3  1H  1.62  0.001 
K34  CG  13C  25.1  0     K32  HE2  1H  3.069  0.008 
K34  H  1H  8.17  0.004     K32  HE3  1H  2.979  0.004 
K34  HA  1H  3.899  0.001     K32  HG2  1H  1.662  0.002 
K34  HB2  1H  1.422  0.001     K32  HG3  1H  1.593  0.001 
K34  HB3  1H  1.352  0.002     K32  N  15N  126.63  0.007 
K34  HD2  1H  1.437  0.001     Y33  C  13C  175.057  0 
K34  HD3  1H  1.383  0.001     Y33  CA  13C  59.1  0.03 
K34  HE2  1H  2.725  0.001     Y33  CB  13C  38.389  0.015 
K34  HE3  1H  2.622  0.001     Y33  CD1  13C  132.998  0 
K34  MG  1H  0.915  0.001     Y33  CE1  13C  117.923  0 
K34  N  15N  125.608  0     Y33  H  1H  8.639  0.004 
I35  C  13C  175.036  0     Y33  HA  1H  3.861  0.001 
I35  CA  13C  60.845  0.033     Y33  N  15N  126.24  0.008 
I35  CB  13C  38.686  0.084     Y33  QB  1H  2.748  0.003 
I35  CD1  13C  12.809  0     Y33  QD  1H  6.659  0.002 
I35  CG1  13C  26.984  0.046     Y33  QE  1H  6.659  0.002 
I35  CG2  13C  17.457  0     K34  C  13C  173.383  0 
I35  H  1H  7.643  0.003     K34  CA  13C  56.979  0.019 
I35  HA  1H  4.07  0.004     K34  CB  13C  32.985  0 
I35  HB  1H  1.763  0.007     K34  CD  13C  29.331  0.095 
I35  HG12  1H  1.337  0.007     K34  CE  13C  41.913  0 
I35  HG13  1H  1.055  0.004     K34  CG  13C  24.783  0.056 
I35  MD1  1H  0.827  0     K34  H  1H  8.015  0.003 
I35  MG2  1H  0.826  0.005     K34  HA  1H  3.87  0.004 
I35  N  15N  121.316  0.023     K34  HB2  1H  1.339  0.003 
W36  CA  13C  58.461  0     K34  HB3  1H  1.309  0.001 
W36  CB  13C  30.149  0.049     K34  HD2  1H  1.396  0.008 
W36  H  1H  7.716  0.011     K34  HD3  1H  1.32  0.002 
W36  HA  1H  4.48  0.006     K34  HE2  1H  2.616  0 
W36  HB2  1H  3.324  0.001     K34  HE3  1H  2.672  0.003 
W36  HB3  1H  3.164  0.001     K34  HG2  1H  0.899  0.003 
W36  N  15N  129.657  0     K34  HG3  1H  0.832  0.004 
   K34  N  15N  127.575  0.089 
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   I35  C  13C  174.074  0 
   I35  CA  13C  61.104  0.024 
   I35  CB  13C  38.605  0.035 
   I35  CD1  13C  12.916  0.083 
   I35  CG1  13C  27.126  0.071 
   I35  CG2  13C  17.503  0.007 
   I35  H  1H  7.412  0.004 
   I35  HA  1H  3.983  0.009 
   I35  HB  1H  1.721  0.006 
   I35  HG12  1H  1.298  0.011 
   I35  HG13  1H  1.01  0.003 
   I35  MD1  1H  0.815  0.005 
   I35  MG2  1H  0.781  0.007 
   I35  N  15N  121.321  0.02 
   W36  CA  13C  58.548  0.034 
   W36  CB  13C  30.181  0.042 
   W36  CD1  13C  126.784  0 
   W36  CE3  13C  122.075  0 
   W36  CH2  13C  124.507  0 
   W36  CZ2  13C  114.827  0 
   W36  CZ3  13C  122.028  0 
   W36  H  1H  7.634  0.003 
   W36  HA  1H  4.473  0.004 
   W36  HB2  1H  3.289  0.002 
   W36  HB3  1H  3.156  0.002 
   W36  HD1  1H  7.21  0 
   W36  HE1  1H  10.092  0.001 
   W36  HE3  1H  7.66  0.001 
   W36  HH2  1H  7.21  0.002 
   W36  HZ2  1H  7.484  0.002 
   W36  HZ3  1H  7.129  0.002 
   W36  N  15N  129.671  0.014 
   W36  NE1  15N  128.851  0 
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Appendix F: Revealing minor isoforms of Pre1a 
 
 
Figure 71: CBCA(CO)NH strips for rPre1a structure. Two minor isoforms could be partially 
assigned using the CBCA(CO)NH strips pulled from the 15N-HSQC for rPre1a. 
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